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Th is PhD dissertation camprises generally four ma in parts, subdivided in 7 0 chapters. A first 
part wil/ guide the reader through a series of princip/es and methodo/ogies related to 
(environmenta/) sustainability and its evafution in time within processing industries. Next, 
environmental sustainability is applied to the pharmaceutical sector. The economie 
relevanee of this Added Va/ue manufacturing industry is c/early illustrated according to 
various sourees such as the R&D investment scoreboard ofthe Europeon Commission (up to 
40% of all revenue is reinvested in R&D applications). Th is while R&D intensity con be linked 
with the willingness to include environmental performance in prospective technologies and 
new compounds. 
A second part deals with some very specific and timely technologica I impravement strategies 
in pharmaceutica/ manufacturing and the environmental performance of that compared to 
the alternatives through resource based Life Cycle Assessment. Potentially the breakthrough 
of this decade is continuous manufacturing in pharmaceutical manufacturing. In case of the 
continuous wet granulation (ConsiGma) compared to batch processing one does not only 
reduce lead times, enables pull production, one a lso red u ces the cumulative natura/ resource 
footprint with 34.0%. Another very Jively and fa st moving field in providing medicines is the 
introduetion of the so-ca/led Large Molecules or biologica Is. The conventional very fossil 
intensive chemistry needed to produce a pharmaceutical compound consumes up to 70 to 
80% of fossil resources (in relative terms of the toto/ resource footprint). The outhor 
investigated the difference in resource extraction patterns between these so-ca/led Smal/ 





Su m mary I Abstract 
strains). In relative contributions, it was proven that the production of biologics is a/most as 
fossil intensive as the production of Smal/ Molecules, in contrast to what was expected. Th is 
is mainly due to the long termentotion processes and the u se of buffer media for downstream 
separation techniques of the proteins. While on a compound basis the production of 
biologieals proved to be a bout 4 times more resource intensive, on a yearly treatment basis 
though, the opposite was found. Due to the very unique characteristics of the monoc/onat 
antibodles (proteins) as long acting platforms, Smal/ Molecules scored about 250 times 
worse than biologica Is, revealing the need for system expansion from compound level to the 
complete healthcare pathway. 
Part three of this dissertation constructs a set of methodologies that can be used by 
business es toen ha nee the value of Life Cyc/e Assessment within the organisation. Part three 
focusses primarily on: 
xvi 
(7) Revealing the needs, bottlenecks and upcoming chal/enges in order to advance the 
state of the art. Th is work was done at the Joint Research Centre of the Europeon 
Commission including more than 300 stakeholders. The main outcomes were to be 
found in the field of Life Cyc/e lnventory rnadelling and goal and scope definition 
(system expansion, functionalities, etc.). Some of these identified bottlenecks are dealt 
with in the next chopters of part three. 
(2) The derivation of technology experience curves (in this dissertation for Wet 
Granulation) in order to inc/ude environmental performance indicators in early R&D 
decision trees. This enables a proactive way of dealing with environmental 
sustainability in Quafity by Design. 
(3) The establishment of a set of forecasting equations with 7-5 readily avai/able predietor 
variables as a streamlined Life Cycle Assessment methad to calculate the cumulative 
resource consumption of Active Pharmaceuticallngredients in fu/1 sca/e production. 
 
Summary/ Abstract 
(4) A framework on how integration of resource based environmental sustainability 
assessment can be implemented in operational management systems within 
businesses. 
To end with, part four provides in chopter 70 overall conclusions ofthis dissertation tagether 
with an outlook on (1) implemen totion of the methodo/ogies deve/oped in this work and (2) 
future methodological challenges to be addressed on the micro level, macro leveland within 






Dit doctoraat bestaat hoofdzakelijk uit 4 delen, onderverdeeld in 10 hoofdstukken. Een eerste 
deel geeft een aanzet voor de lezer over (milieu)duurzaamheid, methodologieën om 
(milieu)duurzaamheid in kaart te brengen en de evolutie ervan in de maakindustrie. Het 
tweede hoofdstuk van deel één geeft een toegepaste benadering van grondstoffen-
gebaseerde (milieu)duurzaamheid in de farmaceutische sector. Oe economische relevantie 
van de waardecreatie in deze sector is van onmiskenbaar belang, zo blijkt o.a. uit het 'R&D 
Scoreboard' van de Europese Commissie. Tot 40% van de totale omzet in de sector wordt 
opnieuw geïnjecteerd in innovatiegerichte R&O-toepassingen. Daarnaast is er een duidelijke 
link tussen R&O-intensiteit in de maakindustrie (meer specifiek de farmaceutische industrie) 
en de toepassing van grondstoffen-gebaseerde (milieu)duurzaamheids-indicatoren in 
beslissingsbomen in de ontwikkeling van nieuwe technologieën en actieve farmaceutische 
stoffen. 
Deel twee behandelt een aantal zeer specifieke en actuele technologische ontwikkelingen die 
de jongste jaren hun implementatie kennen (of zullen kennen) in de farmaceutische 
industrie. Wellicht is de meest belangrijke doorbraak van dit decennium de introductie van 
continue productietechnologieën (flow productie) die geoptimaliseerd werden ter 
implementatie in de farmaceutische industrie. In het geval van tablettering aan de hand van 
natte granulatie en directe compressie bewijst de continue productietechnologie 
(ConsiGma) een reductie van de grondstoffenvoetafdruk van 34.0%. Een ander zeer actief en 
innovatief domein is dat van de zogenaamde biologische medicijnen (niet te verwarren met 




productieroute maar de primaire grondstof is biologisch van aard (bv. dierlijke cellen, DNA-
materiaal van virussen, etc.). Terwijl bij de conventionele chemische synthese typisch 70-80% 
van de grondstoffenvoetafdruk te wijten is aan het gebruik van fossiele grondstoffen 
doorheen de verschillende fasen van de levenscyclus werd verwacht dat voor biologische 
geneesmiddelen de voetafdruk bepaald zou worden door landgebruik, biomassa en water. 
Niets blijkt echter minder waar. Niettegenstaande de biologische aard van de celcultuur blijft 
het maken van biologische medicijnen een energie-intensief proces, in dit geval door 
fermentatie en het gebruik van bufferoplossingen tijdens de opzuivering van de proteïnen. 
De relatieve contributie tot de voetafdruk verandert slechts in heel beperkte mate t.o.v. 
chemische synthese. Wel blijkt dat op product-niveau ongeveer 4 keer zoveel grondstoffen 
nodig zijn in de productie van biologische medicijnen versus chemisch gesynthetiseerde. Op 
een jaarlijkse behandelingsbasis echter blijkt net het omgekeerde: ongeveer 250 keer meer 
grondstoffen zijn vereist in de productie van chemisch gesynthetiseerde medicijnen omwille 
van de typische karakteristieken van monoklonale antilichamen als biologische proteïnen, 
namelijk hun 'long acting' platform. Uit deze vaststelling blijkt duidelijk dat men binnen 
levenscyclusanalyse een herziening (uitbreiding) dient te doen van de systeemgrenzen om 
de juiste functionaliteiten te behelzen die effectief waarde bevatten. 
Het derde luik van deze thesis brengt een set methodologieën samen die gebruikt kunnen 
worden door bedrijven/organisaties om de waarde van grondstoffen-gebaseerde 
levenscyclusanalyse optimaal te valoriseren. Deel drie focust hoofdzakelijk op: 
XX 
(1) De identificatie van de noden tekortkomingen en toekomstige uitdagingen binnen 
de nieuwste ontwikkelingen met als doel grensverleggend tot deze laatste bij te 
dragen. Deze studie is uitgevoerd aan het Joint Research Centre van de Europese 
Commissie te /spra (Italië) van waaruit meer dan 300 stakeholders betrokken werden. 
De belangrijkste bevindingen positioneerden zich in het domein van levenscyclus 
inventory modellering en het bepalen van de scope van de studie (systeemexpansie, 
functionaliteiten, enz.). Aan een aantal van deze tekortkomingen worden in de 
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Probably the very first man to openly question the earth’s limits by introducing the 
concept of sustainability was the German miner Hans Carl von Carlowitz. In his 
‘Sylvicultura oeconomica’ (1713), he stated timber was only meant to be cut in the 
amount it was regrown, with forestry having to ensure that soil fertility was maintained 
(García-Serna et al., 2007). It took several ages for mankind to approximately quantify 
consumption patterns and their consequences on the environment. The American 
Geophysicist M. King Hubbert (1956) is assumed to be the first scientist who was able 
to create a method of modelling the consequences of the industrial activity after the 
second World War. Bearing in mind his assumption that the reserves for all different 
commodities do not increase, the peak of maximum mineral extraction from the earth 
would be reached by 2020, exceeding 12 Gtoe/year. Regarding oil though, the maximum 
consumption would be reached by 2008, leading to a shift in energetic resource 
consumption from oil and natural gas to coal (Delgado, 2008). In the second half of the 
20th century, several alarming publications were made by for instance Rachel Carson. In 
her ‘Silent Spring’ (1962), she denounces the environmental problems caused by 
synthetic pesticides (García-Serna et al., 2007). This work was found to be part of the 
base to the establishment of the US Environmental Protection Agency (US EPA). 
Nevertheless, it took until the publication of the Brundtland report ‘Our Common future’ 
(1987) to formulate a comprehensive definition of the sustainability concept. Since then, 
the awareness has been growing in the international scientific community. Sustainable 
development was often quoted as ‘development that meets the needs of the present 
without compromising the ability of future generations to meet their own needs’ 
(García-Serna et al., 2007). Since world’s famous report on ‘The Limits to Growth’ 
(1972, Club of Rome), the limitation to resource availability became more and more a 
true reason for concern. A shift in attitude of mind from a more prominent point of view 
on sustainability to a necessity resulted in a worldwide demand for sustainable products 
and services. Although Meadows and Meadows were not the first to question the earth’s 
physical limits, the report was conceived in a rather sceptical way (Meadows and 
Meadows, 2007). The report claimed the population to grow in an exponential way, 
while the ability of technology to increase availability of resources seemed to be a linear 
process. Aurelio Peccei, founder of the Club of Rome agreed to promote the report as 
being official in the spring of 1971, despite of the anxious reactions of his fellow 
colleagues, which would foreshadow the world’s reaction (Meadows and Meadows, 
2007; Girod et al., 2009). Recent reports on sustainability include the Special Report on 
Emissions Scenarios (SRES), made by the Intergovernmental Panel on Climate Change 
(IPCC) in 2000. These SRES scenarios were used to produce the IPCC Third 
Assessment Report (TAR) (2001) and the IPCC Fourth Assessment Report (AR4), 
published in 2007. The main outcome of the report was that warming of the climate 
system would be unequivocal and that it was very likely due to the observed increase in 
anthropogenic greenhouse gas emissions (Girod et al., 2009). The IPCC Fifth 
Assessment Report (AR5) focused a lot on uncertainties due to evaluation and 
assessment methods in the scenario analysis (Mastrandrea et al., 2011). Few of its main 
projections were further warming with likelihood to exceed 2.0°C for many scenarios, 
change of global water cycles affecting ecosystems even in the first trophic levels, etc. 
(Kavvada et al., 2013). 
Figure 1: World population: estimates, 1950-2015, medium-variant projection and 80 and 
95 per cent confidence intervals, 2015-2100. Adopted by United Nations, 2015. 
At the end of the 18th century, the earth’s population was only one billion. By the next 
century, the world’s population approached six billion people (Figure 1). In November 
2011, human population exceeded seven billion. According to the United Nations (UN), 
the world population continues to grow more slowly than in the recent past. Today, it is 
growing by 1.18 (compared to 1.24 ten years ago) per cent per year, or approximately 
an additional 83 million people annually. The world population is projected to increase 
by more than one billion people within the next 15 years, reaching 8.5 billion in 2030, 
and to increase further to 9.7 billion in 2050 and 11.2 billion by 2100 (United Nations, 
2015). It is obvious that, following this trend, there will be an increased need for food 
and fuel resources. Moreover, human consumption patterns are far from sustainable and 
have a heavy environmental burden. The relationship between sustainable development 
and the use of resources, fuel, food, land and water is very significant (Apaiah et al., 
2006).  
 
Figure 2: The three pillars of sustainability 'People, Planet, Profit’. The centre of the chart 
is the area of sustainable production. 
As already mentioned, a shift in attitude of mind from a more prominent point of view 
on sustainability to a necessity resulted in a worldwide demand for sustainable products 
and services. The three pillars of sustainability ‘people, planet, profit’ (Figure 2) are 
helpful to understand the concept of an integrated socio-economic and environmental 
policy. When it comes to determining whether or not a company can claim her products 
or services to be sustainable, these definitions seem to be inadequate. No human actions 
are one hundred per cent sustainable. It is a matter of being more sustainable than the 
alternative. 
 
Approaching sustainability from a more technological point of view, one can represent 
the latter by assuming the technosphere interacts with the ecosphere in two ways 
(Dewulf et al., 2000). First of all, the technosphere extracts material and energy 
resources from the ecosphere (resource point of view). Subsequently, waste (or low 
quality products as represented in Figure 3) is generated and emitted from the 
technosphere into the ecosphere (emission point of view). As for the definition of the 
Brundtland report, the future needs of mankind would be endangered if the consumption 
rate of the resources is higher than the rate of resource production. Otherwise, if waste 
is to be emitted to a higher extend, damage of the ecological mechanisms in the 
ecosphere can occur. In its turn, it will affect the resource production rate of the 
ecosphere (Dewulf et al., 2000). These two boundary conditions can be represented by 
the solar driven closed cycle of materials (Figure 3). 
 
Figure 3: Solar driven closed cycle of materials. High quality products (e.g. wood) are 
delivered by the ecosphere whereas low quality products (CO2, H2O) are returned by the 
technosphere back into the ecosphere (together with a certain degree of heat production 
or dissipation) (Dewulf et al., 2000).  
The first law of thermodynamics states that energy can never be lost nor created, so 
fossil resources could theoretically be used without any consequences. While energy 
cannot be lost, the quality of energy certainly can and will. The quality of the energy 
formed in the combustion of fossil fuels (heat), is much less than the quality of the initial 
energy in the fuel. As cited in the second law of thermodynamics (regarding isolated 
systems), the ability to do work will always decrease until equilibrium has been reached. 
For example, the energy (heat) in hot water is of lower quality than electrical energy. A 
conventional energy analysis fails to distinguish these gradations in energy quality. 
More detailed information about sustainability assessments and Life Cycle Assessment 
(LCA) will be given in Chapter 1.3 and 1.4 (Apaiah et al., 2006). As a result of the 
second law of thermodynamics, a certain amount of heat will be produced in an 
irreversible technological process. High quality products (e.g. wood) are delivered by 
the ecosphere whereas low quality products (CO2, H2O) are returned by the 
technosphere back into the ecosphere (according to a certain degree of heat production 
or dissipation) (Figure 3).  
 
Figure 4: Rationale behind the content of Chapter 1 and its connection to other chapters 
and topics through this PhD thesis. 
 
These two basic boundary conditions are incorporated in a number of concepts: Clean 
Technology (CT), Industrial Ecology (IE) and Green Chemistry (GC). The principles 
CT and GC focus on the process (product) level, while IE aims at a broader perspective: 
the overall industrial environment (Dewulf and Van Langenhove, 2004). These 
concepts, along with a few other established principles and disciplines are shortly 
described in Chapter 1.2 below. The rationale of why these specific principles were 
chosen to be introduced here, together with the applicability of them through this PhD 
thesis is given in Figure 4. 
 
Due to the importance of environmental sustainability and sustainable development in 
general, especially in the processing and more specifically in the (fine) chemical and 
pharmaceutical industry, industries and academia started to work out several principles 
on how to define sustainability in production areas and how to reach this in 
manufacturing processes. Green Engineering (GE), being the idea that bundles all 
relevant, subsequent principles, should be continuously adapted. The 12 Principles of 
GE provide a framework for scientists and engineers to engage in when designing new 
materials, products, processes, and systems that are benign to human health and the 
environment. A design based on the 12 principles moves beyond baseline engineering 
quality and safety specifications to consider environmental, economic, and social factors 
(Anastas, 2003; Anastas and Zimmerman, 2003; McDonough et al., 2003; Anastas, 
2008). Since (environmental) sustainability is an important objective in developing new 
technologies, it is important always being one step ahead. This type of ‘Smart 
Engineering’ is a critical factor to consider when defining an integrated sustainable 
policy. As economic, ecological and sociological branches are continuously evolving, 
GE cannot be static (García-Serna et al., 2007). 
 
As one of those dynamic concepts under the GE umbrella Clean Technology (CT) has 
been represented as “a means of providing a human benefit which, overall, uses less 
resources and causes less environmental damage than alternative means with which it is 
economically competitive” (Dewulf et al., 2000). The focus does not rely on the 
materials provided, but on the human benefit obtained. With the idea of economic 
efficiency, it goes beyond concepts as Cleaner Production (CP). One should prefer the 
least economic costly alternative with the least environmental cost. This idea is certainly 
not implemented in Clean-up Technologies, where environmental burden is suppressed 
‘at all costs’, without changing the process in an integrated way to accomplish any 
financial profit. There are several ways of applying CT, however the largest share of 
improvement actions is to be subdivided in achieving Clean Technologies through (1) 
changing technology and (2) changing the feedstock, which is shortly explained below 
(Dewulf et al., 2010). 
 
While CT is aiming at the lowest environmental burden with the lowest economic cost, 
it seems logic that changing technologies through e.g. process intensification 
(integration of heat through heat exchangers, combined heat and power production in 
order to optimise the use of exhaust heat, etc.) is of high concern. These type of changes 
has been applied frequently in the processing industry to optimise resource consumption 
within factory boundaries. However, it remains challenging to integrate industrial zones 
such as industrial port areas etc. Waste for one producer can be a valuable feedstock for 
a neighbouring producer, thereby optimising the industrial metabolism. An example of 
how changing technology can strive towards CT is given in Chapter 4 with the 
introduction of continuous manufacturing technologies compared to batch processing.
 
While the environmental cost or burden of a process, product or service certainly is at 
least partly the result of the converting technology (see above), it is as much a 
characteristic of the used feedstock for production. The environmental impact of a bio-
based plastic (e.g. polymerised monomers from a crop feedstock) compared to a fossil 
based plastic (through the use of crude oil) can be significantly different. The very same 
is true in the fine chemical and pharmaceutical sector. Chapter 5 will elaborate on the 
use of a biological feedstock (cell culture) versus the commonly very fossil based 
chemical synthesis steps used in pharmaceutical manufacturing.
 
In natural ecological systems, one assumes the presence of three theoretical types of 
systems: (1) linear flow through systems with energy input, unlimited resource input 
and unlimited waste generation; (2) quasicyclic systems with energy input, limited 
resource input and limited waste generation; (3) cyclic systems where energy is the only 
input considered and all material is being recycled (Figure 5) (Dewulf and Van 




Figure 5: Three types of natural ecological systems. (a) linear flow through systems with 
energy input, unlimited resource input and unlimited waste generation; (b) quasicyclic 
systems with energy input, limited resource input and limited waste generation; (c) cyclic 
systems where energy is the only input considered and all material is being recycled 
(Dewulf and Van Langenhove, 2004).  
In the concept of Industrial Ecology (IE) (1996), the overall industrial environment 
should be compared to a natural ecological system. The final theoretical objective is to 
maintain a cyclic system, where energy is the only input. To close the material loops, 
individual firms have to be connected into such industrial ecosystem. Therefore, reuse, 
recycling and waste valorisation are the basic principles of IE. 
 
Design for Environment (DfE), which can be considered as a methodology to obtain an 
IE should be performed on different levels in the production process of a product or 
service. Design for environmental processing and manufacturing (e.g. reducing the use 
of hazardous chemicals), as well as design for environmental packaging (e.g. 
eliminating unnecessary paper or cardboard use) and design for disposal or reuse 
(closing the loop) is to be considered (Allenby, 1999). In the end of this PhD thesis, 
Chapter 10.2 explains how DfE can be achieved using the results of this work while 
Chapter 10.4 elaborates in a potential research outlook what can be done beyond the 
micro level, touching base on the concept of IE.
 
The last few years, the whole concept of cyclic IE has become a top priority within 
European policy. In 2015, the European Commission (EC) and the Council drafted an 
EU action plan for the Circular Economy (CE) (European Commission, 2015a). The EC 
adopted the CE Package, which includes revised legislative proposals on waste to 
stimulate Europe's transition towards a circular economy which is designed to boost 
global competitiveness, foster sustainable economic growth and generate new jobs. The 
revised legislative proposals on waste include: the proposed Directive on Waste; the 
proposed Directive on Packaging Waste; the proposed Directive on Landfill; the 
proposed Directive on Electrical and Electronic Waste, on End-of-Life Vehicles, and 
Batteries and Accumulators and Waste Batteries and Accumulators. The CE Package 
consists of an EU Action Plan which establishes a concrete programme of action, with 
measures covering the whole life cycle: from production and consumption to waste 
management and the market for secondary raw materials (Gordeeva, 2016; Gu et al., 
2016). 
 
Once such an ecosystem has taken its shape (linear flow through, quasicyclic or cyclic), 
this chain of effects – what is called a Supply Chain (SC) in an industrial metabolism – 
has a certain degree of resilience.  
 
Integrated design of new technologies or products must be resilient rather than resistant. 
This way, systems are allowed to respond more correctly to unpredictable changes in 
variables (inputs/outputs). A material or product is called resilient if it has the capability 
to return to its original shape or position after stressing or deforming the latter, without 
exceeding its elastic limits. The very same is true for SCs. Rangeability in for instance 
process control indicates how far a given variable can deviate from its setpoint. More 
than 90% of processes in the chemical industry are based on static-stationary states, 
represented by energy and material balances. However, if one of the inputs has to be 
changed as a consequence of scarcity, the system will probably fail to adapt since it is 
not resilient. Resilience engineering embraces adaptation incorporated design and 
relates to Chapters 9.2.4 and 9.2.5 of this dissertation on Supply Chain (SC) 
transparency and reliability (García-Serna et al., 2007). Next, it is highly relevant in 
Chapter 10.5 where a multidisciplinary approach is being proposed in coupling 
Operational Excellence and Life Cycle Assessment (LCA) (Chapter 1.4.2). 
 
Zooming in on the chemical and pharmaceutical industry, Green Chemistry (GC) 
introduces a concept based on a set of 12 rules containing five main principles: (1) waste 
minimization, (2) the use of renewable resources other than biomass, (3) eco-efficiency, 
(4) degradation and (5) health and safety (Glavic and Lukman, 2007). Reducing the use 
and generation of hazardous substances should be incorporated into the design of 
chemical products or processes through the selection of feedstocks (more bio-based 
materials), reagents, alternative reaction pathways or alternative ‘green’ solvents. Mind 
the connection with Chapter 1.2.2 on DfE with GC more focusing on the process itself 
while IE embraces the whole (industrial) ecosystem (Horvath and Anastas, 2007).  
 
These overall Green Engineering (GE) concepts are all leading to a more sustainable 
development of technologies and processes without knowing the quantitative 
improvements towards preceding generations. Measuring methods including Life Cycle 
Assessment (LCA), Exergetic Life Cycle Analysis (ELCA) and emission-based 
methods will be indispensable in order to quantify sustainability (Chapter 1.3 and 1.4). 
 
 
Before arriving at measuring methods and known tools in industry, a set of quantitative 
measuring metrics are shortly introduced in this chapter. Since no technology can be 
one hundred per cent ‘green’, adequate assessment of the ‘greenness’ of a technology or 
process is an important aspect for decision makers (Dewulf et al., 2007b). Metrics, 
defined in a consistent way, are important tools to quantify and allow better 
communication with for instance the stakeholder community. Many different 
classifications of metrics exist depending on the system boundaries, impact 
classification and time horizon, the location of the impact within the cause and effect 
chain, etc. (what does one actually want to quantify?). When it comes to system 
boundaries or the level a certain assessment method acts on, metrics can be subdivided 
in process oriented metrics and life cycle oriented metrics. While the latter type of 
indicators or metrics are acting on the process itself (not taking into account the 
production system of any of the inputs, neither the downstream processing of products 
or waste), the former are taking into account the complete (cumulative) end to end Value 
Chain (VC) of a certain product or service in the industrial metabolism, starting at raw 
material extraction until the End-of-Life (EoL) phase (Dewulf et al., 2008; Lapkin and 
Constable, 2009). Earlier the concept ‘Supply Chain’ (SC) was introduced. Note that 
this is not necessarily the same as a ‘Value Chain’ (VC). The VC is that part of the SC 
that is used to create competitive advantages over similar VCs, while the SC is typically 
the set of operations performed to produce a product or service. In disciplines such as 
process engineering typically process oriented metrics are used. Note that all 12 
originally formulated Green Chemistry (GC) principles were process oriented and did 
not include any other aspect of the VC than the process inputs and outputs themselves, 
in contrast to the 12 Green Engineering (GE) principles. An example that is often used 
at process level to evaluate resource accounting and resource efficiency is the exergy 
content expressed in joules of exergy (further explained in Chapter 1.3.7). 
 
Next, metrics can be classified according to the type of environmental impact they 
quantify. According to the impact assessment method used, up to 18 different impact 
categories are to be distinguished (European Commission - Joint Research Centre - 
Institute for Environment and Sustainability, 2010). A typical example of a life cycle 
based metric within quantifying climate change is the Carbon Footprint (CF), expressed 
in CO2-eq. It is clear that this emission based indicator is restricted in use to the 
quantification of climate change. 
 
While the CF is a metric calculated based on the radiative forcing of the molecule of the 
environmental stressor compared to that of CO2 (and clearly acts as a midpoint indicator 
measured in the beginning of the cause effect chain upon emission), the other side of the 
spectrum of indicators is damage oriented. At the end of the cause and effect chain the 
impact of a certain environmental stressor (e.g. a pulse of emitted CO2) is aggregated in 
a way that several midpoint impact categories (e.g. climate change, acidification, marine 
eutrophication, etc.) will contribute to three commonly defined endpoints or Areas of 
Protection (AoPs). The consensus of today is to subdivide AoPs in (1) the natural 
environment or ecosystem, (2) human health and (3) natural resources, whereas quite 
some new approaches in this fast moving field aim at tackling the postulated 
incompleteness and potential overlap between these AoPs (PROSUITE, 2009; Dewulf 
et al., 2015). The following paragraphs go back to process oriented metrics and explain 
the concept and usability some of the most used indicators in chemical and 
pharmaceutical manufacturing, related to Chapter 2.2 and Chapter 6. 
 
 
The metric and terminology Atom Efficiency (AE) is incorporated in the second 
principle of Green Chemistry; “synthetic methods should be designed to maximize the 
incorporation of all materials used in the process into the final product” (Anastas and 
Warner, 1998; Lapkin and Constable, 2009; McGonagle et al., 2014).  
 𝐴𝐸 =
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡
𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠
 
 
Traditionally, the overall efficiency of a process has been expressed in calculating the 
percent mass yield but the AE is of a very different concern than yield, because a high-
yielding process could still result in a substantial amount of by-products. Poor atom 
economy or efficiency is common in the fine chemical and pharmaceutical industry (as 
is the Coefficient Of Performance (COP, introduced in Chapter 4.3.3).  
 
 
While AE focusses very much on the reactants incorporated in the final 
molecule/product and not on other inputs such as solvents, catalysts, etc., the Molar 




𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑠𝑚 + 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑎𝑑𝑑 + 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑐𝑎𝑡 + 𝑚𝑜𝑙𝑒𝑠 𝑜𝑓 𝑠𝑜𝑙𝑣
 
 
where 𝑠𝑚 stands for starting material or building blocks, 𝑎𝑑𝑑 for additives, 𝑐𝑎𝑡 for 
catalysts and 𝑠𝑜𝑙𝑣 for solvents respectively. The metric creates the ability of focusing 
on more than building blocks, opening the door to metrics for a circular economy in the 
quantification of waste as a resource (e.g. used solvents). 
 
Taking that thought one step further, there is the E-Factor which compares the mass of 
product to the mass of waste generated within a certain process. It accounts for all raw 
materials and waste associated with a unit operation. It should be noted that a variety of 
less inclusive E-Factor calculations (e.g., based solely on the solvent consumption) can 
also be used for a more convenient analysis, which leads to multiple E-Factors (Lapkin 
and Constable, 2009; McGonagle et al., 2014). This factor and others are evaluated for 
the fine chemical and pharmaceutical industry specifically in Chapter 2.2. The equation 
of the E-Factor is given below: 





Curzons and colleagues disclosed the Process Mass Intensity (PMI) and Reaction Mass 
Efficiency (RME) metrics, both of which relate the mass of constituents used in a 
particular reaction to the mass of product formed. The PMI compares masses of 
reactants to product but did originally not account for the solvent used in a reaction. 
However, just as is the case with the E-Factor, less inclusive, recent PMI calculations 
(e.g., based on solvent consumption levels) can also be used for a more convenient 
analysis, which leads to multiple PMIs (Lapkin and Constable, 2009; McGonagle et al., 
2014). These type of metrics have been broadly useful as quantitative measures with 
which to assay individual reactions and overall processes. Indeed, indices such as PMI 
have been instrumental in advancing the sustainability of pharmaceutical processes, with 
PMI highlighted as the preferred metric aimed to drive greater efficiencies in 
pharmaceutical syntheses which will be elaborated in Chapter 2.2 and Chapter 6. The 
calculation of the PMI is given below (Lapkin and Constable, 2009; McGonagle et al., 
2014): 
𝑃𝑀𝐼 =  
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑤𝑎𝑠𝑡𝑒
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡
= 𝐸 − 𝐹𝑎𝑐𝑡𝑜𝑟 + 1  
 
As stated in the previous paragraph, the Reaction Mass Efficiency (RME) relates the 
mass of constituents used in a particular reaction to the mass of product formed. More 
specifically, the RME compares the mass of the product to the total mass of reactants. It 
can mathematically be expressed as follows: 
 






Another resource oriented metric that will be more extensively elaborated in the work 
since it will be used in the more research related sections is exergy. Energy as such can 
never be lost nor created, nevertheless, the amount of useful energy or marketplace 
energy is not conserved. The concept of energy used in industrial settings, the ability to 
cause change, is in fact what is understood by the concept of exergy. The amount of 
exergy (Ex) can be defined as the amount of useful work that can be obtained from a 
system in equilibrium with its surroundings through reversible processes only (Dewulf 
et al., 2008). It has been justified (Gouy and Stodola, 1910) that the absolute value of 
exergy loss (𝐸𝑥𝑙𝑜𝑠𝑠) equals the product of entropy production (𝑆𝑔𝑒𝑛) and reference 
temperature (𝑇0) (Koroneos et al., 2003). 
𝐸𝑥𝑙𝑜𝑠𝑠 = 𝑇0 × 𝑆𝑔𝑒𝑛  
 
The total exergy of a system can be itemized into four different types of exergy: (1) 
‘physical exergy’ (related to the temperature and pressure differences of the system); (2) 
‘chemical exergy’ (due to the chemical composition of the system compared to that of 
the reference environment); (3) ‘kinetic exergy’ (proportional to the velocity difference 
between the system and its reference state); (4) ‘potential exergy’ (due to the relative 






The subscript ‘sys’ is used to demonstrate the association with the exergy of the system 
as a whole instead of a material stream (no subscript). 
 
The physical exergy of a system can be expressed as follows: 
𝐸𝑥𝑠𝑦𝑠
𝑃𝐻 = (𝑈 −  𝑈0) +  𝑝0 × (𝑉 − 𝑉0) − 𝑇0 × (𝑆 − 𝑆0)  
𝑈, 𝑈0, 𝑝0, 𝑉, 𝑉0, 𝑆 and 𝑆0 represent respectively the internal energy, the internal energy 
of the reference state in thermodynamic equilibrium, the pressure of the reference state 
in thermodynamic equilibrium, the volume, the volume of the reference state in 
thermodynamic equilibrium, the entropy and the entropy of the reference state in 
thermodynamic equilibrium. 
 
According to the two contributions to the physical exergy of a system, the latter consists 
of ‘mechanical exergy’ (associated with system pressure along the isothermal line at 𝑇0) 





While for a material stream, the total exergy can be described as 





× 𝑚 × ?̅?2  
and 𝐸𝑥𝑃𝑇: 
𝐸𝑥𝑃𝑇 = 𝑚 × 𝑔 × 𝑧  
𝑚, ?̅?, 𝑔 and 𝑧 denote respectively the mass of the material stream, the velocity of the 
matter relative to the environment, the gravitational acceleration and the elevation height 
relative to the reference environment. 
 
The physical exergy of a material stream can be expressed as follows: 
𝐸𝑥𝑃𝐻 = (𝐻 − 𝐻0) − 𝑇0 × (𝑆 − 𝑆0)  
With 
𝐻 = 𝑈 + 𝑝 × 𝑉  
𝑑𝐻 = 𝑑𝑈 + 𝑑(𝑝 × 𝑉) =  𝑑𝑈 + 𝑝 × 𝑑𝑉 + 𝑉 × 𝑑𝑝  
 
𝑑𝑈 = 𝑇 × 𝑑𝑆 − 𝑝 × 𝑑𝑉  
𝐻, 𝐻0, 𝑝 and 𝑇 are the enthalpy, the enthalpy of the reference state in thermodynamic 
equilibrium, the pressure and the temperature of the material stream respectively. 
 
The physical exergy can also be expressed as the sum of the mechanical and thermal 
exergy of a stream of matter: 
𝐸𝑥𝑃𝐻 = 𝐸𝑥𝑇 + 𝐸𝑥𝑀  
The chemical exergy of a material stream can be denoted as follows (Bilgen et al., 2007): 




where 𝑛 is the number of moles, µ the chemical potential, µ0 the chemical potential of 
the reference state (in equilibrium with its surroundings), 𝑅 the gas constant, 𝐶 the 
concentration and 𝐶0 the concentration of the reference state in thermodynamic 
equilibrium. When the material stream consists of several, different substances, one 
obtains (Bösch et al., 2006): 
𝐸𝑥𝐶𝐻 = ∑ 𝑛𝑗 × 𝑒𝑥𝑗
𝐶𝐻  
𝑒𝑥°𝑗




with 𝑛𝑗 the mole fraction of substance 𝑗 in the material stream, 𝑒𝑥𝑗
𝐶𝐻 the molar chemical 
exergy of substance 𝑗 (approximated by 𝑒𝑥°𝑗
𝐶𝐻, the standard molar chemical exergy of 
substance 𝑗), 𝛥𝑓𝐺°𝑗 the standard Gibbs free energy of formation of substance 𝑗, 𝑛𝑒𝑙 the 
number of molecular elements of substance 𝑗 and 𝑒𝑥°𝑒𝑙
𝐶𝐻 the standard partial molar 
chemical exergy of molecules of substance 𝑗. 
 
‘Thermal exergy’ (concept used to quantify the exergetic content of energy carriers) is 
represented by a Carnot cycle (Bösch et al., 2006): 




with 𝑄ℎ the energy of the heat source, 𝑇ℎ the temperature of the heat source and 𝑇0 the 
temperature of its surroundings, being the reference state.
 
 
Amini et al. (2007) presented the main purpose of Exergy Analysis (EA) as to detect 
and evaluate the causes of thermodynamic imperfection of a process in a quantitative 
way (see Figure 6). Knowing its imperfections, one can improve the thermodynamic 
performance of a process by choosing the right alternative (Amini et al., 2007). As 
mentioned earlier (Chapter 1.3.1), the concept of exergy brings about an excellent tool 
to quantify both material resource consumption and energy requirement in one single 
unit, based on the principles of thermodynamics. Not only is EA an important tool to 
assess the environmental impact of a product or service, it is also useful in providing 
optimum designs and operation conditions (Bilgen et al., 2007). Given the triple bottom 
line of sustainability, the purpose of EA in improving cost effectiveness is highly 
discernible. All resources are, to some degree, finite, illustrating the connection between 
economical scarcity and resource depletion (environmental burden) (Bilgen et al., 2007). 
 
 
Figure 6: Second Law analysis of a real process: the entropy of an isolated system always 
increases over time, or remains constant in the ideal cases where the system is in a steady 
state or is undergoing a reversible process (Dewulf et al., 2008). 
 
 
While EA is an example of a process oriented assessment method, Life Cycle 
Assessment (LCA) is an analysis of the cumulative environmental impact of a product 
or service taking into account its complete life cycle in the industrial metabolism (from 
the extraction of raw materials to the very End of Life, EoL phase). A complete Life 
Cycle Assessment consists of four coherent and iterative stages: (1) definition of the 
goal and scope; (2) Life Cycle Inventory (LCI); (3) Life Cycle Impact Assessment 
(LCIA); (4) interpretation of the obtained results. The first step to accomplish is to define 
the goal and scope (among others system boundaries and functional unit). Subsequently 
an LCI is performed, aiming at describing the environmentally relevant physical and 
energetic flows or environmental stressors to and from the technosphere (Russell et al., 
2005). This data collection is the most time-consuming part and is at least equally 
important as the assessment itself. A relatively modest part of the industrial processes 
and involved chemicals have been registered into life cycle databases (e.g. ecoinvent) 
(Jiménez-González, 2000). One of the most prominent shortcomings to current LCA 
methodologies is the balancing of different environmental stressors in different impact 
assessment categories, which may all be quantified in a different way. Being one of the 
main tools in sustainability assessments of industrial processes or products, LCA takes 
into account most of the known ecological effects on the ecosystem (interacting with the 
overall industrial environment or technosphere) and the population endangering the 
possibilities of current and future generations (after Brundlandt’s sustainability 
definition) (Dewulf and Van Langenhove, 2002). In order to quantify the impact on the 
ecosphere, one has to consider the whole life cycle of a product. This typically leads to 
a cradle-to-grave (or in a more circular economy line of thought cradle-to-cradle, see 
the cyclic ecosystem in Chapter 1.2.2) approach. All stages of an LCA can possibly be 
performed by different operators with different interpretations, leading to rather 
subjective results. Many initiatives have been taken in order to harmonise LCA 
methodologies and make it a more objective tool (Russell et al., 2005). In LCA, the 
calculation of depletion of natural resources is rather debatable. Usually, a distinction is 
made between the use of minerals and metals and the use of fossil resources. The fact 
that depletion of minerals actually cannot take place because of the mass conservation 
law raised several questions about this concept. On the other hand, according to the 
second law of thermodynamics the quality of rich ores of different minerals or metals 
can be and will be lost during its life cycle. This loss can be measured by introducing 
the exergy concept into LCA (Cornelissen and Hirs, 2002; Finnveden et al., 2009; 
Valero and Martinez, 2010; Drielsma et al., 2016; Finnveden et al., 2016; van Oers and 
Guinee, 2016). 
 
In an Exergetic Life Cycle Analysis (ELCA), the localization and identification of losses 
of natural resources through the life cycle of a product or service takes place. It is a more 
protruding way of design, since better proposals for reducing the loss of natural 
resources can be obtained. Examples of ELCA methods are the Cumulative Exergy 
Demand (CExD) (Bösch et al., 2006) and the Cumulative Exergy Extraction from the 
Natural Environment (CEENE) (Dewulf et al., 2007a; Zhong et al., 2016). An ELCA is 
a clear example of a resource based LCA that aims at avoiding losses through the Supply 
Chain (SC), optimising production efficiencies and turning residual waste into resources 
in striving towards a circular economy. 
 
Before touching upon applied sustainability assessment in the pharmaceutical sector, 
some environmental sustainability assessment tools, developed in industry are shortly 
introduced below. According to the SAMT (Sustainability Assessment Methods and 
Tools to support decision-making in the process industries) Horizon 2020 project, 52 
methodologies and 38 tools were designed in the processing industry until today (Pajula, 
2016). Four tools, developed at BASF, SOLVAY, UMICORE and the American 
Chemical Society (ACS) are exemplified underneath. 
 
BASF created the tool of eco-efficiency analysis to address not only strategic issues, but 
also issues posed by the marketplace, politics and research. It serves as an enabling 
decision-making tool for processing industries visualising in a transparent way life cycle 
costs and ecological results in order to establish an eco-efficiency portfolio. This concept 
is very much related to the Clean Technology (CT) concept that has been elaborated in 
Chapter 1.2.1. The results within the tool are summarised through weighting factors 
evaluating alternatives of a customer defined benefit over the whole life cycle (Saling 
et al., 2002). The tool is a helpful, analytical tool in R&D as well as in continuous 
improvement to eventually obtain more sustainable processes and products (Saling et 
al., 2002). 
 
Two tools have been developed at Solvay: (1) the Sustainable Portfolio Management 
(SPM) and (2) the Solvay Sustainability Screening Sites (S3S). The necessity to both 
minimize the potential negative impact and enable appropriate allocation of resources 
to capture opportunities at the marketplace drove the development of SPM at Solvay. 
Business opportunities and investment strategies include a sustainability challenge that 
encompasses an exhaustive SPM analysis (Bande and Debecker, 2012). All business 
units are carefully consulted with in-house experts from strategy, product stewardship, 
marketing, technical services, etc. Solvay has developed a unified methodology called 
S3S (Solvay Sustainability Screening Sites) to help making decisions about future 
industrial sites. 43 indicators covering all aspects of industrial sustainability are 
measured (Bande and Debecker, 2012). In the end the tool and generated reports 
contribute to the evaluation of the sustainability of the industrial sites of Solvay.
 
Umicore’s believe to have a full understanding of the impact of its products from an 
ecological, societal and economic viewpoint resulted in investments aiming at a better 
understanding of life cycles of products depending on the competitive advantage of 
certain applications. The tool that was developed making these efforts is called 
Assessment of Product (and services) Sustainability (APS) of which its methodology 
consists of a set of qualitative indicators (through 58 preformatted questions) and 
quantitative weighting factors around eight themes. Based on a set of flagship products 
and services, the business provided input for the Horizon 2020 sustainability objectives 
of the enterprise, taking into account the understanding and knowledge on sustainability 
of its Value Chains (VCs) (Umicore, 2015). 
 
In contrast to the three aforementioned tools of BASF, Solvay and Umicore, the Fast 
Life Cycle Assessment of synthetic Chemistry tool (FLASC™) was developed by a 
sector federation rather than a single enterprise, though its development was heavily 
supported by GlaxoSmithKline (GSK) (Curzons et al., 2007). Leading members of the 
American Chemical Society (ACS) Pharmaceutical Roundtable (PR) such as GSK, 
DSM and BMS developed the tool (Curzons et al., 2007; Jiménez-González et al., 2013). 
Life cycle inventory (LCI) data for approximately 140 materials were generated and 
collated using the eight core GSK 'sustainability metrics' impact categories. In order to 
come to 14 unique material classes of impact profiles, principal component analysis was 
used. Using these Life Cycle Inventories (LCIs) typical batch profiles could be obtained 
for synthesising a GSK Active Pharmaceutical Ingredient (API). In the end, the 
development led to a series of formulas that enabled impact scoring for eight impact 
categories, averaged out into the FLASC™ score (Curzons et al., 2007; Jiménez-
González et al., 2013). 
 
As was the case for BASF, Solvay, Umicore and the pharmaceutical industry, 
minimising waste and optimising production efficiencies is key, but turning those Life 
Cycle Thinking (LCT) concepts in daily manufacturing business is all but obvious. Little 
process engineers will look from a life cycle point of view at their production line. It is 
on the manufacturing floor that inefficiency starts and change is needed. In the 
processing industries – more specifically the Added Value Manufacturing (AVM) 
industries such as the pharmaceutical industry – continuous improvement is an 
important aspect of process engineering. One of the toolboxes used to improve 
efficiencies, reduce waste and strive towards Operational Excellence (OE) is Lean 
manufacturing. Lean found its roots in the Japanese Toyota Production System (TPS) 
during the late eighties and is essentially an operational management technique to create 
value for customers and therefore reducing all Non Value Adding processes (NVA) or 
waste in industry. It is a set of tools such as Value Stream Mapping (VSM), Just in Time 
(JIT), pull production (introduction of flow or continuous operations), visual 
management, etc. to essentially reduce ‘the three Ms’ Muri, Muda and Mura or 
overburden, waste and unevenness (Crabtree, 2010). Overburden can lead to failures in 
production and is to be avoided. In its broader sense, waste comprises overproduction, 
overprocessing, transport, movement, waiting, reprocessing, stock and misuse of talent. 
All of these operations are NVA processes and will not add to the willingness to pay of 
any customer, hence the value of a product or service. Unevenness or variability in 
production through e.g. a production planning that is not meeting the demand or a series 
of unit operations with very different cycle times can lead to extra stock, waiting, 
movement and eventually higher lead times (Bicheno and Holweg, 2009). Essentially 
the goal of Lean and resource based LCA is (at least partly) the same: creating more 
value with less resources, doing more with less.
 
Partly redrafted from: 
De Soete, W., Jiménez-González, C. et al. (2016). "Challenges and 
Recommendations for Environmental Sustainability Assessments of Pharmaceutical 
Products in the Healthcare Sector." Green Chemistry submitted. 
 
 
Following a broad introduction in Chapter 1, this chapter zooms in on sustainability 
practices in the pharmaceutical industry specifically, starting with an introductory 
framework of the need for sustainable innovation in the sector. According to the WHO’s 
Global Health Observatory, the worldwide total expenditure on health was 10.0% of the 
Gross Domestic Product (GDP) in 2013 (World Health Organization, 2015). In Europe, 
overall healthcare expenditure expressed as percentage of the GDP increased from 8.2% 
in 2007 to 8.8% in 2012 (OECD/EU, 2014). Following the European Commission’s 
(EC) Directorate-General (DG) Health and Food Safety’s European Core Health 
Indicators (ECHI), public sector spending increased from 5.9% of the GDP to 6.6% in 
2012 (EC Directorate General for Health and Consumers (DG SANCO), 2013). These 
are revealing and significant findings since public expenditures have only been 
decreasing in relation to the GDP since the economic crisis of 2009 (EUROSTAT, 
2016). Furthermore, the statistics of the DG for Economic and Financial Affairs reveal 
that public expenditure on health will further increase on average by 1.0 to 2.0% of the 
GDP across EU up to 2060 (OECD/EU, 2014). When it comes to the private sector, the 
second most listed companies in the top R&D investing companies - for both EU and 
non-EU countries - are from the Pharmaceutical and Biotechnology sector (World 
Health Organization, 2015). In absolute numbers, the global pharmaceutical market 
almost tripled in the period 2001 to 2013, growing from around 390.2 billion US dollars 
in 2001 to 980.1 billion in 2013 (Statista, 2016). 
In the US as well, the healthcare sector is a driver of economic growth, with spending 
on healthcare in 2012 reaching $2.8 trillion, or 17% of the US GDP. However, the 
healthcare sector as any industrial activity is also a source of emissions that may 
adversely impact environmental and public health, some of them still in the process of 
being understood and quantified (e.g., pharmaceuticals in the environment) (Kümmerer, 
2008). The current state of the healthcare industry offers significant opportunities for 
environmental efficiency improvements, potentially leading to reductions in costs, 
resource use, and waste without compromising patient care. However, limited research 
exists that can provide quantitative, sustainable solutions (Thiel et al., 2015). 
The preceding paragraphs clearly show a continuing growth of the healthcare sector 
including the pharmaceutical industry. With an ever growing population and a growing 
share of elderly people, ‘healthy living’ and ‘active aging’ became priorities on several 
Strategic Agendas (SA) within the scientific research focus on health in e.g. the 
European Framework Programs FP7 and Horizon2020 and the Knowledge and 
Innovation Community (KIC) on Health from the European Institute for Innovation and 
Technology (EIT) (Meadows and Meadows, 2007). Not by accident, a parallel KIC was 
formed on Raw Materials (KIC RM), focusing on technology development, mining and 
extraction innovations and recycling in order to tackle our finite resource supply (EIT 
Raw Materials, 2015). As it was depicted by Thomas Malthus and later by Dennis 
Meadows, we are facing an ever growing population with a finite supply of resources or 
raw materials, and as it happened before, innovation is key to continued and sustainable 
growth (Malthus, 1798; Meadows and Meadows, 2007; Sfez et al., 2016). Bearing that 
in mind, it is not hard to see that the growth of the healthcare sector and pharmaceutical 
industry and the focus on research and technology development are emerging and of 
ultimate necessity. 
While Research & Development (R&D) and innovation is fostering growth, it should 
serve society in the decoupling of growth and raw materials extraction. Embracing 
sustainable development as development that meets the needs of mankind preserving 
the needs of our future generations, decoupling becomes an inherent characteristic of 
sustainable development (Meadows and Meadows, 2007). There is thus an emerging 
need to evaluate whether or not investments in R&D and innovation projects (up to 40% 
of total revenue) in the healthcare and pharmaceutical industry from both private and 
public investors are sustainable (OECD/EU, 2014; EFPIA, 2015; Sfez et al., 2016).
 
In the pharmaceutical sector, environmental metrics (e.g. Process Mass Intensity, Atom 
Efficiency, amongst others) have been developed over the last two decades to evaluate 
the environmental sustainability of chemical synthesis routes of Active Pharmaceutical 
Ingredients (APIs) (primary manufacturing), Dosage Form (DF) production (secondary 
manufacturing), packaging, distribution and logistics and the End-of-Life phase 
(pharmaceuticals in the environment). Metrics can roughly be subdivided between 
process-oriented metrics and life cycle oriented metrics (Lapkin and Constable, 2009; 
Sfez et al., 2016). Green chemistry principles started to create visibility within the sector 
with publications of Pfizer, GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) in 
the late nineties early 2000 (Jiménez-González, 2000; Constable et al., 2001; Constable 
et al., 2002; Dunn et al., 2004; Jiménez-González et al., 2004b; Jiménez-González et al., 
2004a; Constable et al., 2007; Curzons et al., 2007; Van der Vorst et al., 2009b; De 
Soete et al., 2013; Van der Vorst et al., 2013). In 2005, the formation of the American 
Chemical Society (ACS) Green Chemistry Initiative (GCI) Pharmaceutical Roundtable 
(PR) was accomplished, whilst integrating more and more life cycle driven indicators in 
evaluation methods (e.g. Carbon Footprint, CF) together with Green Chemistry Metrics 
(GCM). Life Cycle Assessment (LCA) has become a widely used method to assess the 
environmental impact of pharmaceutical products. The foundation of the UK’s National 
Health Service (NHS) Sustainable Development Unit (SDU) in 2008 and the subsequent 
focus on contribution of pharmaceuticals through the Coalition on Sustainable 
Pharmaceuticals and Medical Devices (CSPM) to the CF of NHS activities was 
recognised to be the next step towards elaborating different Life Cycle Impact 
Assessment Methods (LCIAMs). 
Not too many, but some very comprehensive reviews have been written on the state of 
the art in sustainability assessments for pharmaceutical products (APIs or dosage forms) 
by e.g. Constable et al. in 2007, Jimenez-Gonzalez et al. in 2014 and Kralisch et al. in 
2015. However, whilst perfectly shaping the written state of the art in sustainability 
assessments for pharmaceutical products, these reviews do not take into account several 
important aspects. First, the healthcare sector is an important contributor to take into 
consideration since pharmaceuticals only serve as a product within the complete 
healthcare pathway of a disease pattern. Many (especially chronic) treatment pathways 
do require quite some resources (e.g. General Practitioner, GP visits, therapy, 
hospitalization, etc.). Second, in a literature review, input data is commonly being 
processed from several published studies. Unfortunately, a considerable amount of 
efforts done towards improving environmental sustainability may not have been 
published and are used internally for optimization purposes only. Hence, broader 
stakeholder coverage to include the voice of the industry, academia, NGOs, policy 
makers, GPs, patients, etc. is emerging. Chapter 6 of this PhD dissertation takes the 
concept of reviewing and adding to the state of the art through identifying the needs, 
debottlenecking and defining perspectives from and to the sector one step further. 
A thorough literature review was performed of which a condensed version is presented 
in this chapter. For this, the Web of Science™ from Thomson Reuters™ was used. As 
time window, publications ranging from January 1997 until April 2016, were 
considered. Table 1 lists a complete, chronological list of relevant research papers. The 
detailed version including authors, publication year, years published, publication type, 
topic, Impact Assessment Method (IAM), applied system boundaries, citations, citations 
per year, journal (ISO abbreviations), journal ranking through Impact Factor (IF) and 
research field quartile is made available in Annex A1. The query search criteria are 
predefined topics related to sustainability assessment, Life Cycle Assessment (LCA), 
resource footprinting, carbon footprinting and Green Chemistry (GC) metrics in the 
pharmaceutical and healthcare sector. In a first stage, 125 articles were found over the 
different categories. Upon abstract reading, unrelated articles and double counted 
articles over the predefined categories were eliminated. 101 peer reviewed scientific 
articles were retained in the literature review. The extended list of literature is to be 
found in Annex A1, together with all categories (e.g. types of publication: case study, 
review, methodological framework, perspective, etc.). Six of the most cutting-edge and 
most cited articles as milestones within the field of sustainability assessments on 
pharmaceuticals and the healthcare sector were selected to be discussed below. Figure 
7 illustrates that reasoning for the selected articles within the category of Green 
Chemistry (GC) related to pharmaceutical production. Figure 7a shows for all categories 
that the Impact Factor (IF) per year is all but correlated with the amount of citations per 
year of a certain article. In Figure 7b, it becomes clear that the highest citations are 
obtained through the type of article: perspective or review article with 
recommendations, rather than with publishing in a journal with a high IF. In the field of 
GC, three of the most cited papers within IF range between 2.5 and 8.3 where selected, 
all of them being comprehensive reviews or perspective articles with recommendations. 
 
 
Figure 7: (a) Shows for all categories that the Impact Factor (IF) per year is all but 
correlated with the amount of citations per year of a certain articles. In (b), it becomes 
clear that the highest citations are obtained through the type of article: perspective or 
review article with recommendations, rather than with publishing in a journal with a high 
IF. In the field of Green Chemistry, three of the most cited papers within IF range between 
2.5 and 8.3 where selected, all of them being comprehensive reviews or perspective articles 
with recommendations. 
 
A short discussion follows below, highlighting the most cutting-edge and most cited 
articles as milestones within the field of sustainability assessments on pharmaceuticals 
within the healthcare sector. 
 
Table 1: References used for literature review per topical search criterion. 
Topic search criterion References 
Sustainability Assessment of 
Pharmaceuticals 
(Wernet et al., 2009) (Jiménez-González and Woodley, 
2010) (Schneider et al., 2010) (Jiménez-González et al., 
2011) (Jiménez-González et al., 2013) (De Soete et al., 
2013) (Woodley et al., 2013) (Szekely et al., 2014) 
Sustainability Assessment in 
Healthcare 
(Briggs, 2003) (Martin et al., 2009) (Boholm and 
Arvidsson, 2014) (Carmen Carnero, 2015) (Castro et al., 
2015a) (Castro et al., 2015b) (Debaveye et al., 2016) 
(Marsh et al., 2016) 
Life Cycle Assessment of 
Pharmaceuticals 
(Jiménez-González, 2000) (Jiménez-González et al., 
2004a) (Curzons et al., 2007) (Kim et al., 2009) (Wernet et 
al., 2010) (Igos et al., 2012) (Alfonsín et al., 2014) (De 
Soete et al., 2014b) (Jimenez-Gonzalez and Overcash, 
2014) (Perez-Lopez et al., 2014) (Brunet et al., 2014) (Ott 
et al., 2014) (Ramasamy et al., 2015) (Cespi et al., 2015) 
(Kralisch et al., 2015) (Ott et al., 2016)  
Life Cycle Assessment in 
Healthcare 
(Campion et al., 2012) (Thiel et al., 2015) 
Green Chemistry related to 
Pharmaceuticals 
(Curzons et al., 1999) (Curzons et al., 2001) (Constable et 
al., 2002) (Haswell and Watts, 2003) (Nisiwaki, 2003) 
(Thomas and Raja, 2005) (Koel and Kaljurand, 2006) 
(Tucker, 2006) (Constable et al., 2007) (Fortunak et al., 
2007) (Khetan and Collins, 2007) (Kuemmerer, 2007) 
(Alfonsi et al., 2008) (Cue and Zhang, 2009) (Fortunak, 
2009) (Garcia-Reyes et al., 2009) (Molina-Diaz et al., 2010) 
(Broxterman et al., 2011) (Hartman et al., 2011) (Wernet et 
al., 2011) (Jiménez-González et al., 2011) (Joshi et al., 
2011) (Soundarrajan et al., 2011) (Kaur et al., 2012) (Ley, 
2012) (Watson, 2012) (Ciriminna and Pagliaro, 2013) 
(Dunn, 2013) (Federsel, 2013) (Leahy et al., 2013) (Osorio 
et al., 2014) (Rastogi et al., 2014) (Banimostafa et al., 2015) 
(DeVito et al., 2015) (Gupta and Mahajan, 2015) 
(M'Hamed, 2015) (Roschangar et al., 2015) (Sullivan, 
2015) (Tucker, 2015) (Voorhees, 2015) (Gallou et al., 2016) 
(Borukhova et al., 2016) 
Resource Consumption 
related to Pharmaceuticals 
(Van der Vorst et al., 2009a) (Van der Vorst et al., 2009b) 
(Van der Vorst et al., 2010) (Van der Vorst et al., 2011) 
(Van der Vorst et al., 2013) (De Soete et al., 2014a) 
Resource Consumption 
related to Healthcare 
(Hatoum et al., 1998) (Optenberg et al., 2002) (Alvarez et 
al., 2004) (Daskalaki et al., 2007) (Manca et al., 2008) 
(Leekha et al., 2009) (Gonzalez-Cortes et al., 2011) 
(Gagliardino et al., 2012) (Polatli et al., 2012) (Roggeri et 
al., 2014) (Castro et al., 2015b) (Martyn et al., 2015) 
Carbon Footprinting of 
Pharmaceuticals 
(Connor et al., 2010) (Gatenby, 2011) (Lim et al., 2013)  
Carbon Footprinting in 
Healthcare 
(Connor et al., 2011) (Wormer et al., 2013) (Holmner et al., 
2014) (Pollard et al., 2014) 
 
Based on their number of citations and evaluation by experts (resulting from the expert 
interviews conducted in this PhD project and further elaborated in Chapter 6.3.1), six 
milestone papers were selected (represented in bold in Table 1 or in blue in Annex A1 
for the full details). These milestone papers follow the chronological development of 
Green Chemistry (GC), Life Cycle Assessment (LCA) and sustainable development in 
general in the pharmaceutical and healthcare sector for the past two decades. Following 
the parole of deductive sciences ‘scire est mensuare’ or ‘measuring is knowing’, the type 
of indicators used to measure the ‘greenness’ of fine chemicals and pharmaceuticals and 
their production routes and technologies has shifted from a process-oriented approach 
in the early nineties towards a life cycle or value chain approach with publications 
peaking as from 2010. In 2002, David Constable et al. published a review on the former 
current approaches towards metrics to Green Chemistry (Constable et al., 2002). In their 
review, four years after Paul Anastas and John Warner published their well-known 12 
principles of Green Chemistry, Constable et al. evaluated the effective mass yield, the 
E-factor and the atom economy indicators and explored the potential of newly developed 
indicators at GlaxoSmithKline (GSK), one of the first pharmaceutical companies to 
invest in Green Chemistry and member of the American Chemical Society (ACS) Green 
Chemistry Initiative Pharmaceutical Roundtable (GCIPR) (Anastas and Warner, 1998; 
Constable et al., 2002). GSK evaluated the Reaction Mass Efficiency (RME) (the ratio 
of the sum of the product masses and the sum of the reagent masses), mass intensity (the 
total mass of materials used per mass unit of product), mass efficiency (the inverse of 
mass intensity, expressed in percent) amongst others. In contrast with the effective mass 
yield and the E-Factor (mass of waste per mass of product), “RME appears to be a useful 
metric for focusing attention away from waste towards the use of materials.” As such, it 
was highlighted that it would be more likely to strive for technology innovation with 
sustainable best practices (Constable et al., 2002). The work of Constable et al. was 
included in the book of Alexei Lapkin in 2009, a piece that bundled the state of the art 
in Green Chemistry (GC) metrics for measuring and monitoring sustainable processes 
(Lapkin and Constable, 2009). GSK actually set a corporate target aimed to significantly 
increase the mass efficiency of new pharmaceuticals, which could potentially halve the 
waste generated. At the same time, GSK performed a company-wide carbon footprint 
setting the corresponding targets for global warming potential. By that time, it was 
generally accepted that focussing on RME was not the way forward, but mass efficiency 
provided a good sense of the productivity of pharmaceutical processes. Jiménez-
González et al. published the views of the GCIPR and its member companies in 2011 
(Jimenez-Gonzalez et al., 2011). The GCIPR submits that the Process Mass Intensity 
(PMI, the inverse of mass efficiency) as a key metric accounts for the total mass of 
materials (product and waste) per mass of product.  Although mathematically PMI is no 
more than the E-factor + 1, it does include the raw materials into the equation, which by 
far have a larger life cycle impact than the waste generated. In addition, by breaking 
down the PMI to subcategories water, reactants, solvents and other, a process-based 
hotspot analysis revealed the very high burden of solvents (up to 56%) in the production 
of Active Pharmaceutical Ingredients (APIs). The fairly simple process-oriented PMI 
metric showed linear correlations with the Global Warming Potential (GWP) (R² = 0.88) 
and the Aqueous Mass Intensity (AMI) (R² = 0.95), revealing part of the reasons for its 
popularity in the pharmaceutical sector: an easy to calculate metric correlating with 
societal impacts focussing on the process level (Jimenez-Gonzalez et al., 2011). Later, 
life cycle based metrics (carbon footprint, water footprint, acidification potential, 
photochemical ozone depletion etc.) were added to the PMI tool of the GCIPR to 
compute PMI, cumulative PMI and life cycle based metrics at ones in streamlined 
assessments (Jiménez-González et al., 2013; Cespi et al., 2015). Although there had 
been several LCA studies in pharmaceuticals and some streamlined LCA tools, a lot was 
to be learned from the earlier tools and techniques, such as the published Fast Life Cycle 
Assessment of Synthetic Chemistry (FLASC™) tool from GSK (Curzons et al., 2007). 
In April 2007, the GCIPR from the ACS published some key GC areas of which both 
research institutions and businesses acknowledged them as key priorities on the GC 
agenda. In terms of importance, the GCIPR ranked the following processes to be 
intensified (focusing on solvent themes) over the next coming years: (1) Amide 
formation avoiding poor atom economy reagents; (2) Hydroxyl activation for 
nucleophilic substitution; (3) Reduction of amides without hydride reagents; (4) 
Oxidation/Epoxidation methods without the use of chlorinated solvents and eventually 
(5) Safer and more environmentally friendly Mitsunobu reactions (Constable et al., 
2007). Obviously, all aforementioned priorities were very much focusing on the API 
production. Four years later, the GCIPR published their key green engineering research 
areas, which include more general sustainability priorities in the field of pharmaceutical 
manufacturing. It was agreed upon by the board of associated companies that focus on 
(1) Continuous Processing; (2) Bioprocesses; (3) Separation and Reaction 
Technologies; (4) Solvent Selection, Recycle and Optimization; (5) Process 
Intensification; (6) Integration of LCA; (7) Integration of Chemistry and Engineering; 
(8) Scale-up aspects; (9) PMI and (10) Mass and Energy Integration (Process 
Intensification). 
 
It was not until 2014 that two publications (a tutorial and review) were made in the field 
of LCA related methodological advances in the pharmaceutical sector. In 2014, 
Jiménez-González et al. published “The evolution of life cycle assessments in 
pharmaceutical and chemical applications – a perspective” (Jimenez-Gonzalez and 
Overcash, 2014). With a strong focus on the challenges faced with in order to generate 
the required Life Cycle Inventory (LCI) and using the resulting LCA output in decision 
making processes. Furthermore, it proposes series of emerging developments within 
LCAs used for decision making in the fine chemical and pharmaceutical sector. For the 
first time, compiled from a significant amount of literature, the issue of obtaining 
appropriate LCI data was prominently recognized as challenge number one. The second 
challenge that was identified is effectively applying LCIA insights (especially the way 
we translate them to Multi-Criteria Decision Making (MCDM)) (Jimenez-Gonzalez and 
Overcash, 2014). In the tutorial review by Kralisch et al. in 2015, more methodological 
aspects are touched upon (Kralisch et al., 2015). A very important one to add value in 
screening portfolios or development options on environmental sustainability is 
simplifying LCA and coupling LCA with other assessment methods (e.g. Life Cycle 
Costing – LCC - or risk assessment e.g. for nanomaterials) for MCDM in early stage 
development. Alternative energy sourcing, green solvents and introducing flow remain 
key within the principles of GC and process intensification (Kralisch et al., 2015).  
 
It has only been very recently that the scope of environmental sustainability assessments 
in the pharmaceutical industry was extended to the complete healthcare pathway, 
accounting for more unit operations (e.g. GP visits, hospitalisation, etc.) than just the 
production of the medicine. Depending on the targeted disease (chronic or acute) and 
the care pathway, the results may vary significantly (Debaveye et al., 2016). The work 
of the Sustainable Development Unit (SDU) of the British National Health Services 
(NHS) with its Coalition on Sustainable Pharmaceuticals and Medical Devices (CSPM) 
on “Care Pathways: Guidance on Appraising Sustainability” at the end of 2015 opened 
doors for a more complete assessment taking into account other services throughout the 
value chain of a certain care pathway, reaching out to the healthcare sector in general 
(Penny et al., 2015). 
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This PhD dissertation is essentially composed out of 4 main parts, subdivided in 10 
chapters as presented in Figure 8. PART 1 provides an introduction to the reader on a 
variety of related topics to environmental sustainability and pharmaceuticals. An overall 
introduction on sustainability, some of its principles and disciplines, metrics, assessment 
methodologies and Lean manufacturing are given in Chapter 1 (De Soete, 2012; De 
Soete et al., 2013). With a study that was performed at the European Commission’s Joint 
Research Centre (JRC), Institute of Environmental Sustainability, Ispra, Italy, Chapter 
2 illustrates the state of the art of sustainability assessment in the pharmaceutical 
industry through a comprehensive literature review (De Soete, 2016). Following this 
generic and applied introduction to part 2 and 3, Chapter 3 gives the overall outline and 
connection of the different chapters of the dissertation and their objectives. 
 
PART 2 assesses the environmental sustainability in the pharmaceutical industry. Both 
chemical synthesis of so-called Small Molecules (SMs) and biologicals or Large 
Molecules (LMs) such as proteins are within scope. A combined resource and emission 
based Life Cycle Assessment of batch versus continuous tabletting processes is 
presented in Chapter 4 (De Soete et al., 2013). First, the aim is to quantify the 
environmental impact of introducing continuous processing or flow as one of the 
measures of process intensification and Lean manufacturing. Second, the resource 
footprint of the SM that acts as the Active Pharmaceutical Ingredient (API) in the tablet 
is generated and recommendations for further optimisation are given. Years of research 
have indicated that the resource footprint of SMs are dominated by fossil resources (use 
of organic solvents, electricity consumption for mixing and heating, etc.). Chapter 5 
compares the footprint of chemically produced SM medicines and so-called biologics 
(in this case Monoclonal Antibodies, MABs) (De Soete et al., 2016b). Are 
biotechnologically produced medicines ‘greener’ than conventional pharmaceuticals? 
Does the dependency on fossil resources decrease for biologics? Can we expect a higher 
share of biotic renewables resources and land use? These questions are answered in 
Chapter 5. Next, since biologics have a very different mode of action and are typically 
parenterals (administered through injection in the bloodstream), the assessment is not 
just performed at compound level but rather on a technology platform level and on a 
yearly treatment level as well. 
 
Figure 8: PhD dissertation outline and connection of the 4 parts and 10 chapters. 
It is often difficult to persuade higher management of the business value of LCAs or 
environmental sustainability assessments in general. Experience learns that the results 
are often not fully valorised and are not penetrating the daily operations. While part 2 is 
mainly composed out of assessments based on predefined cases, PART 3 extracts and 
combines those aspects of environmental engineering, environmental sustainability 
assessments and Operational Excellence (OE) adding value to businesses, decision 
makers, policy, etc. To begin part 3 with, Chapter 6 identifies needs and bottlenecks 
for environmental sustainability assessments in global pharmaceutical supply chains 
(De Soete et al., 2016a). Next to literature analysis that is often used to shape the state 
of the art, the sector needs to be connected, work together and formulate current 
shortcomings and future challenges. Expert interviews and stakeholder surveys were 
conducted during the study at the EC JRC to define the needs and bottlenecks in Chapter 
6. In total, more than 300 stakeholders from predefined categories were consulted. 
Finally, a seminar on Sustainable Development in the Healthcare and Pharmaceutical 
Sector (SDHP) was organised at the JRC in Italy to connect stakeholders and define 
future challenges. The next chapters deal with specific key challenges (explained below) 
and propose solutions as visualised in Figure 8. Chapter 7 introduces the concept of 
experience curves (effect of learning and upscaling) of technologies and the use of these 
in R&D environments to anticipate on environmental burden once a technology is at full 
scale production (De Soete et al., 2014a). This way, environmental indicators can be 
introduced in R&D decision trees or so-called stage gating processes within 
development. Nonetheless, data inventory within LCA is a very time consuming process 
and often data is lacking (especially in R&D environments because data is simply not 
available yet). In manufacturing environments, data is often measured but very hard to 
get due to data management systems that are not built for the inventory of data needed 
to perform LCA (temperatures, flow rates, utility consumption rates, etc.). That is why 
Chapter 8 provides a set of regression formulas to forecast on the environmental 
sustainability of API synthesis steps based on a very limited set of predictor variables 
that are in many cases readily available (1 to 5) (De Soete et al., 2014b). Can we use 
these correlations to predict the environmental footprint of API synthesis steps to a fair 
extent in terms of uncertainty? Can we come to an optimal degree of model complexity 
versus model uncertainty and transparency? If so, can we recommend steps for 
implementation within existing data systems? Chapter 9 discusses potential bottlenecks 
in the integration of process modelling in Enterprise Resource Planning (ERP) system 
(De Soete, 2016). Why is it so hard to implement and automate environmental 
sustainability assessments? If a lot number can automatically be printed on a label on 
the folding box, why not the Carbon Footprint? Chapter 9 not only discusses the 
difficulties for implementations but proposes a framework in which customised ERP 
modules play a role in providing corporate and product sustainability assessments. To 
end with, PART 4 provides an overall conclusion and outlook with a guidance to 
integration of the results of this PhD thesis in Chapter 10. 
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De Soete, W., Dewulf, J. et al. (2013). "Exergetic Sustainability Assessment of Batch 
versus Continuous Wet Granulation based Pharmaceutical Tablet Manufacturing: a 
Cohesive Analysis at Three Different Levels." Green Chemistry 15(11): 3039 - 3048.
 
In the pharmaceutical industry, the world’s most carbon intensive business, attention is 
increasingly concentrated on eco-efficient product design and product sustainability as 
a whole (Jiménez-González, 2000; Jiménez-González et al., 2004a; Constable et al., 
2007). During the last decades, innovative chemical reactions and better performing 
equipment were developed in chemical synthesis for pharmaceutical manufacturing by 
leading companies of the American Chemical Society Green Chemistry Institute (ACS 
GCI) Pharmaceutical Roundtable (PR) such as GSK, Pfizer, Johnson & Johnson Group 
of Companies, Merck and Astrazeneca (Constable et al., 2007; Curzons et al., 2007; 
European Commission, 2011; Jiménez-González et al., 2011). However, in order to 
quantify and eventually manage sustainability of new technologies, one should measure 
their environmental performance. With reference to measuring methods, a life cycle 
approach is favoured (Chapter 1.4.2), so that displacement of environmental burden by 
e.g. outsourcing is avoided.   
 
To evaluate the environmental sustainability of Active Pharmaceutical Ingredient (API) 
production processes, quantitative tools have recently been developed (Curzons et al., 
2007; Van der Vorst et al., 2009a). Van der Vorst et al. (2009a) proposed a tool for 
assessing the integral resource consumption of individual API synthesis steps in a 
multipurpose API production plant, based on a cradle-to-gate approach. Wernet et al. 
(2009) developed a software tool to roughly estimate the resource use and environmental 
impacts of fine chemical production based on the molecular structure, circumventing 
the need for a process analysis. However, these tools do not give any representative 
indication on the environmental burden of a finished pharmaceutical Dosage Form (DF), 
since their focus does not go beyond the API production step (Van der Vorst et al., 
2013). Drug Product (DP) production processes though, realize the true formulation of 
the API in combination with multiple excipients (e.g. binders, fillers, lubricants, 
surfactants, etc.) in a so called DF (e.g. tablet, capsule, syringe, etc.). 
 
Table 2: Pharmaceutical excipients and their role in formulation processes (Martinez et 
al., 2002). 
Excipient Role Substances 
Filler When the amount of drug substance is insufficient to 




Desintegrant In order to have a favourable release in the human 
body, desintegrants promote moisture penetration 
and dispersion of the matrix. Desintegrants overcome 
cohesive strengths by compression through its 
swelling mechanisms. 





Lubricant Lubricants reduce friction at the die wall during 
compression, reduce adhesion and promote powder 




Binder The role of the binder is to facilitate the 
agglomeration and adhesion of particles in wet 
granulation. The binder also helps to hold the tablet 




Filler-Binder Special fillers used in low-to-moderate dose drugs 





Surfactant Increases the wetting of the powder mass or tablet 










Coating agents should provide protection to the 
atmosphere, improve aesthetics or modify drug 
release. 
HPMC, ethyl 
cellulose latexes and 
polymers and esters 
of methacrylic acid 
The internal matrix of a tablet consists of the API along with its formulation excipients 
(Table 2 represents possible excipients according to their function), which are 
responsible for the tablet behaviour through the drug’s life cycle (including granulation, 
compaction and release in the human body) (Franch-Lage et al., 2011). Disintegration, 
which seems to be the rate-limiting step for the dissolution of drugs, can be manipulated 
by choosing the optimum excipient proportions (Al-Mohizea et al., 2007). API and 
excipients should be homogeneously distributed, since a non-uniform distribution of 
API can be critical in releasing low mass proportion APIs in the human body. The latter 
determines the final quality of Solid Dosage Forms (SDFs). NIR hyperspectral 
techniques with multivariate curve resolution methods showed their use in the fast 
assessment of the surface distribution of API and excipients (Franch-Lage et al., 2011). 
Important tablet characteristics that should be considered and evaluated when changing 
excipients proportions or implementing a new technology are the disintegration rate, 
hardness, weight, dissolution and API bioavailability (Shao et al., 2007). 
 
In the Biopharmaceutics Classification System (BCS), drugs are classified into four 
categories according to the compound’s solubility and intestinal permeability. The first 
class consists of the compounds that are generally very well absorbed. These drugs have 
a high solubility and high permeability. The bioavailability of the second class drugs is 
typically dissolution-rate limited. These drugs have a low solubility but a high 
permeability. Class three consists of drugs with high solubility and low permeability 
while class four encloses those with low solubility and low permeability, resulting in 
very poor oral bioavailability (Martinez et al., 2002). 
 
One should bear in mind that the main concerns in pharmaceutical industry are safety 
and efficacy. Unlike in bulk food industry, small changes of drug composition for 
environmental reasons can impact safety and/or efficacy and become life-threatening. 
Another important aspect is the agility of the supply chain (lead time). Given that 
medication demand fluctuates, supply should be flexible and highly adaptable to 
possible changes in market needs (Janssen-Cilag S.P.A., 2011a). 
 
Tablets, by far the most widely used DFs, are made in a so called tablet press through 
for instance direct compression. Figure 9 illustrates the working principles of a rotary 
press. 
 
Figure 9: Rotary press production cycle. (a) top view; (b) unfolded view. (1) die table; (2) 
fill cam; (3) paddled feed wheel; (4) die fill area; (5) paddled metering wheel; (6) pre-
compression roller; (7) main compression roller; (8) ejection cam; (9) upper punch; (10) 
die; (11) lower punch (Sinka et al., 2009). 
However, the production of tablets mostly requires a preliminary granulation phase to 
enhance the flowability of the powder mix and finally to optimize tablet properties 
(Franch-Lage et al., 2011). Generally, a granulation solution is added to improve 
dissolution rates and agglomerate particles by capillary and viscous forces until more 
permanent bonds are formed by subsequent drying phases (wet granulation). Most 
established production lines are installed with batchwise operating granulators. 
Transition to continuous processing in the pharmaceutical industry lays far behind 
compared to bulk processing industries (e.g. food industry), because of high quality 
standards and rather small theoretical batch sizes. However, recent developments 
showed continuous processing to be favourable in DP production processes as well in 
terms of flexibility, compactness and process analytical controllability (Vervaet and 
Remon, 2005). Upon DP production, the dosage form should eventually be packaged, 
distributed and transported to the pharmacy or hospital. Figure 10 shows a basic 
representation of the supply chain of a pharmaceutical drug manufacturing plant, 
subdivided into three system boundaries. Mind that every step in the supply chain should 
be provided with utilities (e.g. electromechanical power, heating media, cleaning agents, 
etc.) and generates waste streams which are not visualized in this flow diagram for the 
sake of simplification. 
 
Figure 10: Basic representation of the supply chain of a pharmaceutical drug 
manufacturing plant, subdivided within three system boundaries: (α) process level; (β) 
plant level, gate-to-gate; (γ) overall industrial level, cradle-to-pharmacy. Mind that every 
step in the supply chain should be provided with utilities (e.g. electromechanical power, 
heating media, cleaning agents, etc.) and generates waste streams which are not visualized 
in this flow diagram.  
 
A case study addressing environmental sustainability of all aforementioned production 
steps in the life cycle of pharmaceuticals would be innovative and would most likely 
trigger the development of new assessment tools embracing the complete life cycle of 
pharmaceuticals, including its End-of-Life phase. 
 
With this chapter, the author aims at providing a state of the art exergy based 
environmental sustainability assessment of batch versus continuous wet granulation 
based tablet manufacturing at three different levels. Following a deep focus on the DP 
production processes itself (in this case tableting), system boundaries will be expanded 
towards a comprehensive cradle-to-pharmacy approach taking into account API 
production, DP production, packaging and distribution and transport processes. Hence, 
the overall impact of a pharmaceutical at the disposal of the customer is calculated for 
the cradle-to-pharmacy approach, together with its most sensitive parameters. Finally, 
the contribution of DP production processes to the total environmental burden of the 
pharmaceutical supply chain is illustrated. The medicine under analysis is 
TRAMACET®, a high dose analgesic, produced at a pharmaceutical manufacturing 
plant of Janssen-Cilag SpA (part of the Janssen Group and Johnson & Johnson). Impact 
assessment is mainly resource based (strongly supported by e.g. A Resource-Efficient 
Europe – 7th Flagship Initiative under the Europe 2020 Strategy) by means of 
thermodynamics (European Commission, 2011). The method proved the advantage of 
using thermodynamic principles in pharmaceutical industrial systems, as well as in other 
sectors, towards a more sustainable production (Dewulf et al., 2000; Dewulf and Van 
Langenhove, 2002; Dincer and Rosen, 2004; Dewulf et al., 2005; Dewulf et al., 2007a; 
Dewulf et al., 2007b; Tsatsaronis, 2007; Dewulf et al., 2008; Van der Vorst et al., 2009b; 
Alvarenga et al., 2013). In order to provide a complete analysis of both ways in which 
industrial systems are interacting with the ecosphere (resource depletion and waste 
emission), the Carbon Footprint (CF) is proposed as emission based eco indicator. This 
way, the chapter aims both at a resource and emission based approach towards 
environmental sustainability of two different granulation technologies in tablet 
manufacturing at process level (α), plant level (β), and overall industrial level (γ). 
 
 
Methodology and results of this study are represented according to the ISO 14040 and 
ISO 14044 series, next to the more completely elaborated ILCD Handbook Guidelines 
(ISO, 2006; European Commission - Joint Research Centre - Institute for Environment 
and Sustainability, 2010). 
 
The relative nature of LCA is partially due to the applied Functional Unit (FU). The 
primary purpose of a FU is to provide a reference to which all inputs and outputs are 
related. In order to yield intuitive, representative results, the FU in this study has been 
defined as 1 tablet of TRAMACET® which equals an approximate weight of 441 mg. 
One should bear in mind that this approach is in contrast to most fine chemical LCA 
studies (and takes us one step further to the real functionality of the medicine) that often 
take 1 mole or 1 kg of product as FU (Jiménez-González et al., 2004a; Van der Vorst et 
al., 2011). 
 
Product systems under study are the conventional batchwise and recently developed 
continuous production mode of TRAMACET®, a centrally acting synthetic analgesic 
drug (Janssen Pharmaceutica NV, 2004). The former one is located at the 
pharmaceutical manufacturing plant of Janssen-Cilag SpA at Latina, Italy, the latter one 
is located at the Product Development Centre (PDC) of GEA Pharma Systems - 
Collette™ in Wommelgem, Belgium. Active Pharmaceutical Ingredients (APIs) 
Paracetamol (Acetaminophen) and Tramadol are dosed in an 80%(w/w) solid dosage tablet 
form. At process level (α), six main core processes can be distinguished: (α-1) 
dispensing; (α-2) granulation; (α-3) mixing; (α-4) compression; (α-5) coating and (α-6) 
packaging, of which each is subdivided into different separated subprocesses. For 
instance, the batchwise granulation process (α-2), making use of a top spray fluid bed 
granulator (Glatt®), can be described by introducing seven unit processes, while the 
continuous granulation process, making use of a twin screw extruder (ConsiGma™, 
GEA Pharma Systems – Collette™) can be characterized with only five unit processes 
(partly by combining agglomeration and mixing of the powder in one single step). 
Unlike the batch production system, in which all core processes are carried out in 
different and separated equipment, continuous granulation (α-2), mixing (α-3) and 
compression (α-4) are performed in one single continuous equipment platform 
(ConsiGma™), which reduces the production area. All core processes need many kinds 
of supporting utilities to be delivered at process level such as electricity, steam, 
compressed air and cleaning water. The former can be produced on-site (e.g. steam 
production in natural gas boilers) within the plant level (β) or can be produced 
somewhere in the overall industrial level (γ) (e.g. electricity retrieved from the Italian 
grid). In both cases, shifting from batch to continuous production does not affect the 
way in which utilities are produced, but mainly the quantitative amount of utilities 
needed. A more detailed subdivision of all processes within scope is to be found in 
Annex A2 and detailed flowcharts are available in Annex A3. 
 
In specifying the system boundaries in a cradle-to-pharmacy LCA on pharmaceuticals, 
one has to account for several life cycle stages: (1) API production; (2) drug product 
(DP) production (e.g. tablet production); (3) packaging and (4) distribution and 
transport. As described above, the foreground product system is subdivided into the core 
process system (α level) and the on-site supporting process system, being the Janssen-
Cilag SpA manufacturing plant at Latina, Italy (β level, gate-to-gate approach). 
Background processes are represented in the overall industrial system (γ level, cradle-
to-pharmacy approach). As a result, this study provides a comprehensive resource 
footprint at three separated levels, creating the ability of better identifying the location 
of resource losses through the supply chain. The environment interacts with the α, β and 
γ level in supplying elementary flows (natural resources), and receiving elementary 
waste flows (e.g. CO2, discharged wastewater, etc.). Product flows and intermediate 
flows are exchanged between α, β and γ level and should not interact directly with the 
environment. Figure 11 shows a representation of the three product systems and its 
interactions with each other and with the environment (ecosphere). 
 
Figure 11: Three LCA system boundaries. The α level (process level) represents the six 
core processes. The β level (plant level) represents the on-site supporting core processes 
at the Janssen-Cilag SpA manufacturing plant in Latina, Italy. The overall industrial 
environmental processes in the technosphere define the γ level. The environment interacts 
with the α, β and γ level by supplying elementary flows (natural resources), and receiving 
elementary waste flows (e.g. CO2, discharged wastewater, etc.). Product flows and 
intermediate flows are exchanged between α, β and γ level and should not interact directly 
with the environment. 
 
The Life Cycle Inventory (LCI) clearly is the most time-consuming step in LCA (Van 
der Vorst et al., 2009a). At process level, most of the data were gathered at the Janssen-
Cilag SpA manufacturing plant in Latina, Italy. Data on the continuous production line 
ConsiGma™ were retrieved from the Product Development Center (PDC) of GEA 
Pharma Systems – Collette™ in Wommelgem, Belgium. Industrial plant operational 
documents provide typical targeted data in conducting LCI (e.g. validation reports, 
maintenance procedures, equipment manuals, P&IDs, cleaning procedure reports, batch 
reports, MSDS files and ingredient tracing documents). Table 3 gives a condensed 
overview of typical data sources and targeted process and plant level data for 
constructing an LCI. Exergetic data of background processes were extracted from 
ecoinvent v2.2, the Swiss database offering science-based, industrial, international LCA 
and Life Cycle Management (LCM) data and services (Frischknecht and Rebitzer, 
2005). 
 
Table 3: Summary of targeted LCI data on core and supporting core processes (α level & 
β level) and its plant specific data sources. 
Documents/data sources Targeted data 
Validation reports Mass input (α), mass yields, core processing 
equipment parameters (α), supporting processes 
operating parameters (β), equipment utility 
consumption, QA/QC, maintenance procedures 
Equipment manuals Nominal power consumption, equipment part 
analysis, equipment utility consumption, 
maintenance procedures 
P&IDs Equipment analysis, utility supply, product 
transport, identification electricity consuming 
moving parts, pumps, motors 
Cleaning procedure reports & Standard 
Operating Procedures (SOPs) 




Process set-up times, run times, cleaning times, 
manual parameter settings 
Materials Safety Datasheet (MSDS) files, 
Bill of Materials (BOM) & ingredient 
tracing documents 
Chemical composition, supplying companies, 
production processes, supplier location, transport 
categories 
Expert interviews Detailed information on specific processes 
 
At α and β level, the impact assessment is performed through Exergy Analysis (EA) 
which mirrors the resource consumption and resource consumption efficiency of a 
certain process, product or service, based on the principles of thermodynamics (Apaiah 
et al., 2006; Hammond, 2007) (Chapter 1.4.1). This approach at different levels allows 
one to identify and locate exergy or resource quality losses at the plant. The impact 
assessment method used at γ level is the Cumulative Exergy Extracted from the Natural 
Environment (CEENE) (Dewulf et al., 2007a). Compared to the Cumulative Exergy 
Demand (CExD), proposed by Bösch et al. (2006), this method can be considered as an 
extended resource footprint since it covers eight impact subcategories of resource use: 
(1) fossil resources; (2) metal ores; (3) nuclear energy; (4) land resources including 
biomass production; (5) renewable resources other than biomass; (6) minerals; (7) 
atmospheric resources and (8) water resources (Bösch et al., 2006; De Meester et al., 
2006; Dewulf et al., 2007a). Coupling this resource based approach with an emission 
based approach increases the relevance of the indication to judge the total environmental 
burden of a given product. The Carbon Footprint (CF), expressed in kg CO2-eq, showed 
its relevance as emission based indicator in energy intensive industries. The latter is 
approached as the equivalent total amount of CO2 and other greenhouse gases (GHG) 
emitted over the full cradle-to-pharmacy approach of a pharmaceutical (Wiedmann and 
Minx, 2007). 
 
In calculating the impact indicators, exergy content of material and energetic resources 
were computed based on the reference conditions of Morris and Szargut (1986) (Morris 
and Szargut, 1986). For solid chemical species, the most stable state of the pure elements 
at 𝑇0 = 298.15 K and 𝑝0 = 101.325 kPa were employed. Whenever possible, for organic 
chemicals, the group contribution method was used (Szargut et al., 1988). Table 3 
illustrates the latter with an example (Acetaminophen, API). 
Table 3 Example of Szargut’s group contribution method for organic chemicals: 
Acetaminophen, API. 
Group Amount (#) ex°𝑗
𝐶𝐻(kJex/mol) Total (kJex/mol) 
CH3- 1 752.03 752.03 
NH-- 1 195.56 195.56 
C-- (arom) 2 436.45 872.90 
CO- 1 277.76 277.76 
HC- (arom) 4 547.15 2,188.60 
OH- 1 -51.34 -51.34 
Chemical exergy of Acetaminophen: 4 235.51 kJex/mol 
 
For salt formation with organic molecules (e.g. sodium starch glycolate), the group 
contribution method was combined with the Gibbs free energy of the salt formation and 
crystallization processes, following upon the dissolution of the reference compound 
(e.g. Na(OH)s). The exergy content of packaging materials were found in literature 
(Gong, 2005). The exergy content of PVC and detergent were calculated with the group 
contribution method. Aluminum foil exergy content was calculated assuming a 
composition of 95% Al and 5% Al2O3 (Morris and Szargut, 1986). 
 
When using liquid mixtures or aqueous solutions, a term for molar mixing exergy was 
added up to the total chemical exergy content of the substance:  
𝑒𝑥𝑚𝑖𝑥 =  𝑅 × 𝑇0 × ∑ 𝑥𝑖 × ln(𝛾𝑖 × 𝑥𝑖)
𝑖
 
with 𝑅 the universal gas constant, 𝑇0 the temperature of the reference state and 𝑥𝑖 and 
𝛾𝑖 the molar fraction and activity coefficient of compound 𝑖 respectively (Szargut et al., 
2005). Note that mixing exergy will add a negative term to the total exergy of the 
mixture, since work is necessary to separate mixture compounds.  
 
Morris and Szargut (1986) refer to the reference compounds for the nine gaseous 
elements C, H, O, N, Ar, Ne, He, Kr, Xe as the gaseous compounds of atmospheric air 
at 𝑇0 = 298.15 K and 𝑝0 = 101.325 kPa, assuming ideal gas behaviour. When 
temperature or pressure differences occur, the physical exergy of air changes according 
to the following formula: 
𝑒𝑥𝑃𝐻 =  |𝑐𝑝 × [(𝑇 − 𝑇0) − 𝑇0 × ln
𝑇
𝑇0




in which 𝑐𝑝 is the isobaric specific heat capacity of air, 𝑅 the universal gas constant and 
𝑇0 and 𝑝0 the temperature and pressure of the reference state respectively (Cornelissen 
and Hirs, 2002). 𝑇 and 𝑝 are the respective temperature and pressure of the airstream 
under study. Note that exergy calculations were explained in detail in Chapter 1.3.7. 
 
As for purified water, condensed water, superheated water and steam, the chemical 
exergy is calculated based on the molarity of the reference species in seawater (Morris 
and Szargut, 1986). Physical exergy of water and steam was calculated using the 
following established formula: 
𝑒𝑥𝑃𝐻 = (𝐻 − 𝐻0) −  𝑇0 × (𝑆 − 𝑆0)  
in which 𝐻0, 𝑇0, 𝑆0 are the enthalpy, the temperature and the entropy of the water at its 
reference state (𝑇0 = 298.15 K and 𝑝0 = 101.325 kPa) respectively (Szargut et al., 2005). 
𝐻 and 𝑆 are the respective enthalpy and entropy of the stream under consideration. 
 
The exergy content of natural gas was calculated using the gas composition of the 
supplier and the compound’s Gibbs free energy of formation. Note that this could easily 
be calculated as well with the empirical formula for fuels and biomass: 
𝑒𝑥𝑐ℎ = 𝛽 × 𝐿𝐻𝑉  
with LHV the Lower Heating Value of the fuel and 𝛽 the exergy to energy ratio, 
depending on the atomic composition of the substance (Szargut et al., 1988). The energy 
content in 1 kJ of electricity can be made available for one hundred per cent in work 
delivery, so its exergy content is by definition 1 kJex. 
 
To calculate the life cycle impact data, the CEENE method was coupled with the 
ecoinvent v2.2 life cycle database. An X factor allows the calculation of the former for 
the 184 classified resource reference flows, after Dewulf et al. (2007): 





in which CEENEj (MJex) is the total cumulative exergy extracted from the natural 
environment for a product or service 𝑗, 𝑋𝑖 the 𝑋 factor of the 𝑖
th reference flow (MJex per 
functional unit) and 𝑎𝑖𝑗 the cumulative amount of the reference flow expressed in its 
functional unit (Dewulf et al., 2007a). 
 
The IPCC GWP 100a Carbon Footprint (CF) was calculated based on the emission 
factors of the ecoinvent reference flows. 
 
While in bulk chemical processes, by-product formation is often unavoidable and 
sometimes even profitable, in pharmaceutical tablet manufacturing process allocation is 
rather limited. Most of chemical feedstock resources at process level will contribute to 
tablet formation only. Nevertheless, allocation should be considered in assigning 
process plant utilities to the different unit processes at process level (α). The latter is 
based upon physical causalities – in this case exergy - as is encouraged in the ILCD 
Handbook (European Commission - Joint Research Centre - Institute for Environment 
and Sustainability, 2010). 
 
Taking into account the production setup at process level (α), few assumptions had to 
be made, mostly due to lack of data or the introduction of justified simplifications to 
avoid redundant model complexity. Generally, it should be stressed that no cooling 
water consumption is taken into account because of lack of consistent plant data and the 
rather modest contribution to total resource extraction (Van der Vorst et al., 2009a). 
Cooling water is used for dehumidifying drying air and for cooling the granulator barrel. 
For cleaning of the ConsiGma™, the current cleaning procedures of the batch 
Tramacet® production were adopted because cleaning is highly relative to the specific 
powder characteristics. However, this is likely to result in an overestimation of resource 
consumption due to cleaning of the continuous production line since less material should 
be cleaned and Cleaning in Place (CIP) can be installed. For the production of tablet 
excipients, the most representative ecoinvent flows were used. For very specific 
materials (e.g. detergents), a mixture of flows was implemented according to the 
composition of the chemicals. CEENE values of APIs were obtained from previous 
studies (Van der Vorst et al., 2009a). 
 
Through the results and discussion section, resource extraction at process (α) and plant 
level (β) will be represented by means of five functional categories: (1) chemicals; (2) 
heating media; (3) electromechanical power; (4) cleaning agents and their disposal and 
(5) compressed air. At overall industrial level (γ), additional subdivision of resource 
extraction will be provided through the CEENE impact categories. 
 
Out of the overall mass and energy balances at process level, thermodynamic analysis 
resulted in consistent exergy balances over each unit operation within the 
pharmaceutical production chain of TRAMACET®. Focusing on granulation, the heart 
of pharmaceutical tablet manufacturing, Figure 12a illustrates the resource consumption 
within the batchwise granulation phase (α-2), expressed in kJex/tablet. The high 
contribution of chemicals to the total resource extraction in granulation is due to the 
Active Pharmaceutical Ingredient (API) and excipients. The contribution to heating in 
the spraying and drying phase is attributable to steam consumption for dry air heating. 
Likewise, electricity is consumed mainly in the spraying and drying phase. Cleaning of 
the Glatt® top spray fluid bed granulator is performed at the end of the granulation 
process. Figure 12b shows that continuous granulation of Tramacet® within the 
ConsiGma™ consumes up to 29.0% less resources compared to batch granulation. 
While the load of API and excipients remains more or less the same (apart from slightly 
different mass yields), a reduction of 72.0% utility consumption can be deduced from 
Figure 12b. The latter is especially caused by a more efficient heating in the granulator 
barrel and reduced power consumption of the granulator drive. Expanding the focus to 
the overall process level reveals the high contribution of packaging materials to the total 
resource consumption (up to 54.0%), caused by the high relative mass of packaging 
materials per packed tablet (1.81 g/tablet). For the TRAMACET® case however, only 
10 tablets were packaged per folding box (primary packaging), whereas approximately 
25 tablets per folding box can be assumed as default value in pharmaceutical 
manufacturing (Janssen-Cilag S.P.A., 2011b). 
Figure 12: (a) Cumulative resource consumption expressed in kJex/tablet within the 
batchwise granulation phase (α-2). The high exergetic value of chemicals is incorporated 
mainly in API and excipients. The contribution to heating media in spraying and drying 
media is due to steam consumption for dry air heating. Likewise, electricity is consumed 
mainly in spraying and drying phases. Resources for cleaning agents and their disposal 
are allocated to the final phase, in which cleaning is performed; (b) Cumulative resource 
consumption expressed in kJex/tablet within the continuous granulation phase (α-2). 
 
In shifting from batch to continuous manufacturing, a total resource consumption 
reduction of 10.2% (65.6 to 58.9 kJex/tablet) was obtained, taking into account all 
resource inputs at process level. However, since more or less the same amounts of API, 
excipients and packaging materials were needed in both batch and continuous 
manufacturing setups, excluding this so-called transiting exergy showed a total utility 
consumption reduction of 34.0% (Figure 13). 
Figure 13: Cumulative exergetic resource consumption at process level (α), plant level (β) 
and overall industrial environmental level (γ), excluding transiting exergy in API, 
excipients and packaging materials. Contribution to resource consumption is expressed 
in functional categories (in kJex/tablet) for batch versus continuous drug product (DP) 
production processes. 
 
Results of the process efficiency analysis are shown in Table 4. η1 and η2 represent the 
simple and rational efficiencies respectively expressed by the ratio of the sum of exergy 
contents of product and waste and the exergetic input components on the one hand, and 
the ratio of product exergy and exergy content of input components on the other hand. 
A third type of efficiency η3 was introduced to better reflect the utilisation efficiency of 
process utilities (e.g. steam, hot water consumption, compressed air, etc.). In this 
definition, transiting exergy in API, excipients and packaging materials was subtracted 
from both numerator and denominator. The irreversibility generation provided in Table 
4 is the amount of exergy lost through the process due to process inefficiencies. This 
amount of exergy can never be recovered as such, being a direct consequence of the 
second law of thermodynamics (law of entropy) (Dewulf et al., 2000). It is to be noticed 
that less exergy is irreversibly lost following the implementation of the continuous 
production line (up to 43.0% reduction). For process efficiencies and irreversibility 
generation of all core processes (e.g. dispensing, granulation, mixing, etc.), the reader is 
referred to Annex A4. 
 
Table 4: Summary of batch versus continuous wet granulation based tablet 
manufacturing resource efficiency analysis and irreversibility generation at process level 
(α). 
 Batch Continuous 
Simple efficiency (η1) 78.6% 86.5% 
Rational efficiency (η2) 71.7% 80.0% 
Utility efficiency (η3) 24.4% 32.8% 
Irreversibility generation 14.0 kJ/tablet 8.0 kJ/tablet 
 
 
At plant level, the contribution of utilities to total resource consumption is higher since 
most process utilities are produced on-site (e.g. steam from natural gas boiler), whereas 
at process level the contribution of packaging materials seems to be dominant. In 
shifting from batch to continuous manufacturing, a total resource consumption reduction 
of 15.2% (111 to 94.0 kJex/tablet) was calculated, taking into account all resource inputs 
at plant level. Excluding transiting exergy showed a reduction of 25.9% (64.6 to 47.7 
kJex/tablet, see Figure 13). In the existing batchwise configuration of the pharmaceutical 
manufacturing of TRAMACET® an input of 111 kJex results in a waste generation of 
18.3 kJex per tablet (47.0 kJex) at the manufacturing plant of Janssen-Cilag SpA. Bearing 
in mind the total input at the process level in batch setup (65.6 kJex), one would expect 
an irreversibility generation of 45.6 kJex at the plant. 57.6% of total resource input at the 
plant is lost, mainly by heat losses in steam generation, pressure losses in reverse 
osmosis, electricity inputs and wastewater disposal. 41.1% is irreversibly lost, while 
16.5% is considered as waste that can be recovered in some way (e.g. wastewater, 
exhaust air rest heat). Losses at plant level could be reduced by 18.0% if wastewater is 
valorised or recycled in some way for cleaning or cooling purposes, while up to 8.0% 
of all plant losses could be avoided by recycling the rest heat in exhaust air. 
 
Table 5: Summary of batch versus continuous wet granulation based tablet 
manufacturing resource efficiency analysis and irreversibility generation at plant level 
(β). 
 Batch Continuous 
Simple efficiency (η1) 58.9% 67.4% 
Rational efficiency (η2) 42.4% 49.9% 
Utility efficiency (η3) 28.6% 34.9% 
Irreversibility generation 45.6 kJ/tablet 30.7 kJ/tablet 
 
 
Some of the utilities (e.g. electricity from the Italian grid) or material feedstock 
resources (e.g. API, excipients, packaging materials) are produced elsewhere in the 
overall industrial environment. This γ level approach comprises all production steps 
from cradle-to-pharmacy. The CEENE value of one tablet of TRAMACET® at 
pharmacy gate numbers up to 2.3 MJex/tablet in the batch production setup. By 
introducing the ConsiGma™ as a continuous production line, the primary results 
showed a reduction of only 2.2% (2.2 MJex/tablet) taking into account all resources.  
 
Since TRAMACET® is a high dose drug (API percentage more than 80.0%(w/w)), it is 
conceivable that API synthesis steps (which are identical for both batch and continuous 
drug production phases) will to some extent neutralize the efforts made towards greener 
drug product (DP) production processes. Focusing on the DP production step only by 
excluding transiting exergy revealed a 14.7% reduction of cumulative resource 
consumption (138 to 118 kJex/tablet) at the cradle-to-pharmacy level (γ), as shown in 
Figure 13. Overall, pharmaceutical manufacturing of TRAMACET® can be associated 
with a Coefficient of Performance (COP) of 2.1%, which is a low ratio, typical for the 
complex pharmaceutical industry (Van der Vorst et al., 2011). 
 
Expressed in functional categories, cumulative resource extraction at γ level proved to 
be dominated by the chemical category (due to the API production step), while at 
process and plant level, resource consumption was dominated by the use of packaging 
materials and utilities respectively. Excluding transiting exergy in API, excipients and 
packaging materials, Figure 13 visualizes the high contribution of the electromechanical 
power and heating media categories. Out of the rather high increase of the contribution 
of heating media at plant level compared to the process level, one can identify on-site 
steam production. As for electricity, an increased contribution is noticed at overall 
industrial level, retrieved from the Italian electricity grid (off-site production). 
Approaching environmental impact of DP production of Tramacet® from a resource 
point of view at the cradle, a resource footprint of the tablet drug under analysis is 
disclosed. 65% of resource extraction from the natural environment is due to fossil 
resource depletion, 15% to water resources, 15% to land occupation and biomass 
production and approximately 5% to nuclear energy and renewable resources other than 
biomass (Figure 14). By implementing the continuous production line of GEA Pharma 
Systems – Collette™, the fossil resource contribution to total resource extraction proved 
to decrease predominantly due to a lower utility consumption. Overall, comparing this 
resource footprint of DP production processes with the API synthesis steps raises the 
awareness of an even higher contribution of fossil resource extraction for API synthesis 
(up to 75%), which confirms previous findings (Van der Vorst et al., 2009a; Van der 
Vorst et al., 2011). As for DP production processes, the substantial contribution of land 
occupation and biomass production (15%), which used to be barely noticed in API 
synthesis, proved to be caused by the use of starch based excipients (e.g. filler or binding 
material) and the application of paper and cardboard as mainly cellulose based 
packaging materials. As for distribution and transport processes, resource extraction 
could almost entirely be assigned to fossil resource consumption (Figure 14). 
 
As already has been stated in Chapter 4.1, a resource based approach towards 
environmental sustainability creates the possibility of acting proactively, while focusing 
on emissions might eventually favour end of pipe solutions. However, a combined 
impact assessment is the preferred way to really understand both ways in which nature 
is interacting with our industrial systems. From an emission point of view, a Carbon 
Footprint (CF) reduction of 2.0% (0.22 to 0.21 kg CO2-eq/tablet) was obtained at γ level 
in shifting from batch to continuous manufacturing of TRAMACET®. Focusing on DP 
production revealed a CF reduction of 16.2%. This reduction in GHG emissions showed 
to be strongly correlated with the fossil resource part reduction of total resource 
extraction, as earlier stated by Huijbregts et al. (2006), which evidences a resource 
oriented focus to act proactively (Huijbregts et al., 2006). An average GHG emission of 
0.215 kg CO2-eq/tablet, as obtained within this case study, confirms earlier assumptions 
made by e.g. England’s NHS Sustainable Development Unit highlighting the 
remarkably high contribution of pharmaceuticals to the NHS England CF (up to 22%) 
(NHS Sustainable Development Unit, 2012). However, little knowledge was acquired 
about the importance of different pharmaceutical production steps contributing to the 
total environmental burden of these pharmaceuticals. 
 
Through the preceding paragraphs, the reader has sensed the importance of the API 
production processes in the overall industrial environmental system approach for the 
TRAMACET® case study (see Figure 14). In order to fairly represent changes in 
shifting from batch to continuous DP production processes, the concept of excluding 
transiting exergy in APIs was introduced. However, more general results were obtained 
by performing short, local sensitivity analysis that disclosed an increased relevance of 
the impact of DP production processes for low dose drugs (e.g. sedative drugs or 
hormones). The API concentration seemed to be the parameter with highest sensitivity 
towards environmental burden from a resource point of view. The amount of tablets 
packaged per folding box (primary packaging), proved to be the second most sensitive 
parameter. To illustrate this sensitivity, a typical low dose tablet formulation of 10 mg 
API, LIPITOR® (Pfizer’s most successful blockbuster drug), was modelled assuming 
the same batchwise DP production process as TRAMACET®. The results as visualized 
in Figure 14 indicate the importance of the DP production processes and packaging 
processes. Further on, since the CEENE of excipient materials is lower than that of the 
API, total resource extraction for the estimated LIPITOR® drug proved to be 
significantly lower than that of TRAMACET® (0.63 MJex/tablet versus 2.3 MJex/tablet). 
In the end, identification of the former sensitive parameters contributes to the possibility 
of designing sustainable next generation pharmaceuticals, which is of highest 
importance in pharmaceutical research and development towards innovative process 
intensification. 
 
Figure 14: Contribution in total resource extraction (kJex/tablet) of the different stages in 
the pharmaceutical production chain of high dose drug TRAMACET®, taking into 
account all upstream and downstream related processes to the production. Note that, for 
low dose drugs (e.g. sedative drugs or hormones), the contribution of the API chemical 
synthesis will decrease. The decrease in API production will be somewhat neutralized by 
the addition of more binder and filling materials (excipients). Since the CEENE of 
excipient materials is lower than that of the API, it is to be expected that the total CEENE 









Figure 15: Exergetic resource extraction contribution of different production phases of 
TRAMACET® (high dose drug) versus a typical low dose tablet formulation of 10 mg 
API (LIPITOR®), presuming the same production process as the batchwise 
TRAMACET® production. Mind the importance of the drug product (DP) production 




In the light of accomplishing a more sustainable pharmaceutical production, more 
specifically reducing its resource consumption, a comparative exergy based 
sustainability assessment of batch versus continuous wet granulation based tablet 
manufacturing is proposed for the TRAMACET® case (high dose drug). The potential 
implementation of the continuous ConsiGma™ production line (GEA Pharma Systems 
– Collette™) at the pharmaceutical manufacturing plant of Janssen-Cilag SpA at Latina, 
Italy would mean a significant step forward towards green engineering and green 
pharmaceutical manufacturing. Recent developments towards in-line blending and 
coating can even further reduce the environmental burden of Drug Product (DP) 
production processes. Based on Exergy Analysis (EA) and Exergetic Life Cycle 
Assessment (ELCA), a resource consumption reduction of 10.2%, 15.2% and 2.2% at 
process (α), plant (β) and overall industrial level (γ) respectively was obtained. Focusing 
on DP production processes by excluding transiting exergy in API, excipients and 
packaging materials resulted in a reduction of 34.0%, 25.9% and 14.7% at the respective 
boundary systems. From an emission point of view, a Carbon Footprint (CF) reduction 
of 4 g CO2-eq/tablet was obtained. 
 
The study stresses the significantly high contribution of API chemical synthesis steps to 
the total environmental burden for high dose drugs such as TRAMACET®. However, 
the environmental impact of DP production processes should not be underestimated, as 
the latter can become predominant for low dose drugs (e.g. sedative drugs, hormones, 
etc.). Furthermore, attention should be paid to the amount of tablets packaged per 
folding box, since raising this parameter proved to be a rather straightforward way of 
reducing the environmental impact per tablet. Nevertheless, one should bear in mind 
that results of this case study cannot not just be generalised. Eventually, in order to fully 
understand the various contributions of the different steps in the pharmaceutical supply 
chain to the total environmental burden, more cases of different kinds of dosage forms 
(e.g. liquids, semi-liquids, gases) should be investigated, leading to the establishment of 
a more generic model comprising all steps in pharmaceutical manufacturing. On the 
long term, one should strive for interfaced, modular models enabling user friendly 
scenario analysis by changing operational parameters, by simply dragging and dropping 
new equipment, or by implementing new production lines into an existing model to ease 
the accessibility for decision or policy makers. 
 
Redrafted from: 
De Soete, W., Rentería Gámiz, A. G., et al. (2016). "Small Molecules versus 
Biologicals: The Environmental Resource Footprint." Nature Biotechnology to be 
submitted.
 
Since their introduction on the market biologicals or Large Molecules (LMs) were 
predicted to be the forthcoming blockbusters because of their unique characteristics in 
targeting before often undruggable diseases (Sindelar, 2013; Tsomaia, 2015). Especially 
within the field of Monoclonal Antibodies (MABs) the biological origin of the cell bank, 
fermentation processes, their typical parenteral administration and the development of 
new drug delivery devices implied new challenges in terms of technology, safety, 
efficacy, regulations and sustainability (Sindelar, 2013). Compared to the chemically 
produced Small Molecules (SMs), one had to deal with a completely new field of 
medicines. Most of those new aspects are controlled by the Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA). However, when it 
comes to – in particular environmental – sustainability, very little is known about these 
new medicines compared to SM Active Pharmaceutical Ingredients (APIs) (Jiménez-
González and Woodley, 2010). How do LMs behave in terms of environmental resource 
footprinting? How ‘bio’ are biological processes? What is the effect of long acting LMs 
on medicine consumption during treatment? Are we indeed consuming less fossil 
resources compared to the very energy intensive SM synthesis routes with typically a 
contribution of about 80% of the resource footprint due to fossil resources (Wernet et 
al., 2010; Van der Vorst et al., 2011; De Soete et al., 2013; De Soete et al., 2014a; De 
Soete et al., 2014b)? The types of data needed to perform an environmental 
sustainability assessment are often not (yet) well documented in LM manufacturing 
which makes it very difficult and time-consuming to give proper answers to the 
questions above (Jiménez-González and Woodley, 2010). 
 
This chapter proposes the first resource based environmental sustainability assessment 
of the production of LMs versus SMs. The pharmaceutical products within scope are 
STELARA® 45mg, SIMPONI® 50mg, PREZISTA® 800mg and TRAMACET® 
400mg of which the first two are LMs and the last two SMs. The LMs are MABs 
targeting auto-immune diseases such as psoriasis plaque. For patients with these types 
of auto-immune illnesses, such long-acting-release products (LARs) not only improve 
lifestyle by minimizing exposure to the needle, but also generally improve patient 
outcomes by improving patient compliance and reduce peak-and-valley blood levels 
(through the characteristics of a long acting platform) (Andreakos et al., 2002; 
Schwendeman et al., 2014). PREZISTA® is known as a protease inhibitor (SM) to treat 
the Human Immunodeficiency Virus (HIV) whereas TRAMACET® is an opioid 
painkiller. Figure 16 graphically represents the scope of this research chapter; a cradle-
to-gate analysis of LMs versus SMs. In order to answer the above formulated questions, 
the authors defined three objectives: (1) to calculate the relative contributions to the 
resource footprint (composition); (2) to conduct absolute resource consumption analysis 
at product level (per dosage form) and (3) to conduct absolute resource consumption 
analyses at the treatment level (per Defined Daly Dose, DDD). 
 
Figure 16: Representation of the scope of this ch apter: a cradle-to-gate analysis of the 
production of Large Molecules (LMs) versus Small Molecules (SMs). The production 
stages included are Active Pharmaceutical Ingredient (API) production, Fill & Finish 
(LM), Drug Product (DP) production (SM) and Packaging. The LM visualized on top is a 
graph designed by Johnson & Johnson and adopted from the information portal on 
STELARA® (Janssen Biotech Inc., 2016). 
 
Methodology and results of this study are represented according to the ISO 14040 and 
ISO 14044 series, next to the more completely elaborated ILCD Handbook Guidelines 
(ISO, 2006; European Commission - Joint Research Centre - Institute for Environment 
and Sustainability, 2010).  
 
For the relative contribution analysis, 1 finished (packed) dosage form is used as a 
Functional Unit (FU). The same is valid for the absolute comparisons at product level. 
One should make the comment here that it is by no means the intention of the author to 
make absolute one-to-one comparisons. The idea is to trace back the general trends in 
technology platforms (in this case long acting platforms of MABs versus immediate 
release Small Molecules both tackling – to some extent – different type of immune 
deficiency disorders). To be able to make more fair absolute comparisons, the Defined 
Daily Dose (DDD) is used as a metric at the treatment level. According to the WHO, 
the DDD is “the assumed average maintenance dose per day for a drug used for its main 
indication in adults” (WHO Collaborating Centre for Drug Statistics Methodology, 
2015). This comparative analysis will only be done for those three medicines targeting 
immune diseases. 
 
Related to the Large Molecules (LMs) under analysis, this Life Cycle Assessment 
(LCA) comprises a cradle-to-gate approach accounting for the following life cycle 
stages: (1) Biologic Active Pharmaceutical Ingredient (API) LM Manufacturing 
(upstream in Leiden, The Netherlands, and downstream purification in Cork, Ireland; 
(2) Fill and Finish of the syringes, safety device and needle cap in Schaffhausen, 
Switzerland; (3) Packaging in Schaffhausen, Switzerland and (4) logistic transport to 
the European Distribution Centre (EDC), La Louvière, Belgium, in case of 
STELARA™ and transoceanic shipment to Indianapolis, United States, in case of 
SIMPONI™. 
 
For the Small Molecules under analyses, equal system boundaries were drawn, being 
cradle-to-gate, with of course different unit processes: (1) Chemical synthesis of the API 
SM at Grünenthal Group, Germany, for TRAMACET® and Cork, Ireland, for 
PREZISTA™; (2) Drug Product Production (in this case tabletting through wet 
granulation and rotary compression) and (3) Blister Packaging in Gurabo, Puerto Rico, 
for PREZISTA™ and Latina, Italy for TRAMACET®. For both cases, distribution to 
the EDC in La Louvière, Belgium was modelled. 
 
At process level, most of the data were gathered at the respective sites as mentioned 
above, except for some proxy data that was used for the Gurabo site. As was already 
illustrated in Chapter 4.2.4, industrial plant operational documents provide typical 
targeted data in conducting LCI, especially in the field of SMs (e.g. validation reports, 
maintenance procedures, equipment manuals, P&IDs, cleaning procedure reports, batch 
reports, MSDS files and ingredient tracing documents). Table 3 on page 67 gives a good 
protocol with typical data sources and targeted process and plant level data for 
constructing an LCI for SMs. For LCA data, ecoinvent 2.2 was used. Because biological 
processes are much more difficult to control and the variability on the process data is 
generally higher than in the case of SMs, the table for data inventory looks somewhat 




Table 6: Summary of targeted LCI data on core and supporting core processes (α level & 
β level) and its plant specific data sources at the respective plants mentioned above (in 
case of LMs STELARA™ and SIMPONI™). 
Documents/data sources Targeted data 
Validation reports Mass input (α), mass yields, core processing 
equipment parameters (α), supporting processes 
operating parameters (β), equipment utility 
consumption 
P&IDs Equipment analysis, utility supply, product 
transport, identification electricity consuming 
moving parts, pumps, motors 
Batch reports 
SOPs 
Process set-up times, run times, cleaning times, 
manual parameter settings 
Materials Safety Datasheet (MSDS) files, 
Bill of Materials (BOM) & ingredient 
tracing documents 
Chemical composition, supplying companies, 
production processes, supplier location, transport 
categories 
Expert interviews Detailed information on specific processes, 
maintenance procedures, cleaning procedures 
 
As for this chapter, the resource footprint of the four medicines under analysis was 
calculated using a cradle-to-gate Life Cycle Assessment (LCA). The Cumulative Exergy 
Extracted from the Natural Environment (CEENE) was used as impact assessment 
methodology, yielding a resource footprint subdivided in eight subcategories: (1) fossil 
fuels; (2) metal ores; (3) nuclear energy; (4) land resources and biotic renewables; (5) 
renewable resources other than biomass; (6) minerals; (7) atmospheric resources and (8) 
water resources (Bösch et al., 2006; De Meester et al., 2006; Dewulf et al., 2007a). For 
the sake of clarity, the results will be expressed in kg of crude oil exergy equivalents.  
 
Depending on the types of data that were available and accessible for the different 
medicines or platforms under analysis, allocation is to be performed to a certain extent. 
In the absence of bottom-up up engineering data, top down building or plant 
consumption data was allocated to the medicine under analysis. The latter is based upon 
physical causalities – in this case exergy - as is encouraged in the ILCD Handbook 
(European Commission - Joint Research Centre - Institute for Environment and 
Sustainability, 2010). Obviously the choice for bottom-up or top-down building level 
approach for data inventory will influence the uncertainty on the results, as will the 
modelling choices and parameters used.  
 
 
Coming to assumption and limitations that should be carefully addressed in the 
interpretation of the results, it is important to state that it is not the intention to make 
absolute comparisons of medicines, but rather characterise the resource consumption in 
producing MABs through the long acting parenterals platform and compare it to the 
most used dosing forms of Small Molecules, being blistered tablets. It is a first 
exploration of technology platforms of Large Molecule production. 
 
 
The relative contributions to the resource footprint of the four medicines under analysis 
is shown in the upper part of Figure 17. The contribution of fossil resources amounts up 
to 69.3% and 64.8% of the resource footprint for the production of PREZISTA® and 
TRAMACET® respectively (both finished as blistered tablets). This high contribution 
is mainly due to the use of solvents and other types of chemicals, electricity consumption 
for the production of utilities, etc. The water footprint (5.7 and 7.7% respectively) is to 
be explained by the production and use of Process Reaction Water (PRW) and cleaning 
media. Land resources and biotic renewables (biomass production, up to 17.7%) are due 
to the use of starch based excipients but not the least to the paper, cardboard and wood 
used in the different packaging stages. Last, nuclear (4.6 and 7.4%) and abiotic 
renewable (2.8 and 3.8%) resources are used in the production of the applied electricity 
mix (and will as a result vary significantly from one production site to another). It was 
to be expected that the production of biologicals (in this case MABs) 
Chopter 5: Smo/1 Molecules versus Biologicols: The fnvironmentol Resource Footprint 
LM STELARA lsM PREZISTA 
• Abiotic renev .. able resJurces • Abiotic renew able resJurces 
• Fossilfuels • Fossilfuels 
8 Land resourcesand bbti: • Land resources and bbti: z 0 renew ables renew ables 
f:: • Nuclear energv • Nuclear energv :::> z • Wa:er resources • Wa:er resources J:O s 0 ....... !:::: 
a) c) z {/') 
0 0 
SIMPON I TRAMACH u ~ g; 0 
• Abiol:ic renew able resJurces f:: u • Abiotic renev1able resJurces ..._, 
~ 
a Fossil fuels 8 Fossil fuels ~ 
8 l and resourcesand bbti: 8 Land resourcesand bbti: 
rene-Nables renew ables 
• Nud ear B'lergv • Nuclear energy 












0 0 ,05 
"' 00 ..:.: 




~ ...:I :::> 
~ 
J:O 0 s ~ ...:I ~ t3 z 0 ~ 
:::> u {/') 





























~ u 0 








• Abiol:ic ren~uable resJurces 8 Fossil fuels 8 Land resourcesand bbti: • Nuclear energv • Wa:er resources 
renew ables 
94 
would consume less fossil resources. Lower volumes, less chemicals and very often 
aqueous solvents are used instead of the very fossil intensive solvents consumed in 
chemical synthesis. Besides, a cell culture is being cultivated with medium that contains 
sugar based components indicating more land use. However, these expectations were all 
but trending in the results. In contrast to what was expected, Figure 17a) and b) show 
very similar results to Figure 17c) and d). The relative contribution of fossil resources 
is only moderately lower in the production of LMs (MABs) compared to SMs (on 
average 63.5 compared to 67.1%). This is due to the fact that fermentation processes to 
cultivate the cells typically take about 45 days in case of STELARA® and 60 days in 
case of SIMPONI®. First, fermentation requires electricity for heating the vessel jacket. 
Second, following GMP compliance, LM production requires a grade A to grade C 
cleanroom, according to the GMP classification (which in this case corresponds to 20 to 
45 air changes per hour depending on the room) (European Commission, 2008). 
Maintaining these conditions for 45 or 60 days consumes electricity and natural gas to 
operate at the required Heating, Ventilation and Air Conditioning (HVAC). To illustrate 
the contribution of HVAC, 57.0% of all electricity used through the supply chain of 
Figure 17: Representing on top the relative contributions (composition) of the resource 
footprint of Large Molecules (LMs) STELARA® (a) and SIMPONI ® (b) (left) and Small 
Molecules (SMs) PREZISTA® (c) and TRAMACET® (d) (right).  The bar charts are 
illustrating the absolute contributions per Dosage Form (DF) at product level and per 
Defined Daily Dose (DDD) at treatment level for the upper and lower bar charts 
respectively. For the sake of comparability, only the medicines treating immune 
deficiency diseases are used for absolute comparisons. The y axis of the bar charts is 
expressed in kg of crude oil exergy equivalents. The y axis for the comparison at treatment 
level are log transformed for the sake of a clear presentation. 
STELARA® is consumed by HVAC, of which 50.0% in upstream operations (mainly 
fermentation) and 7.0% in downstream operations such as harvesting and separation. 
The contribution of land use and biotic renewables though, proved to be only moderately 
higher in case of LMs (on average 22.4 compared to 17.0%) due to what was postulated 
above (starch and sugar based excipients in medium solutions, bigger packaging devices 
on a unit base, etc.). From this analysis, it was to be concluded that the relative resource 
footprinting of LMs is much more fossil dependent than what was expected and that the 
contribution of land use and biotic resources (bio) was all but dominating. 
 
Focusing on the autoimmune disease portfolio and looking at the absolute numbers per 
Dosage Form (DF) (product level), i.e. Active Pharmaceutical Ingredient (API) 
production, Drug Product Production (DPP), Delivery Device Production (DDP) and 
packaging, STELARA® has the highest resource footprint followed by SIMPONI® and 
PREZISTA® (0.21, 0.19 and 0.06 kg crude oil-Eq respectively). The difference between 
the two MABs and PREZISTA® is not surprising. While PREZISTA® is a relatively 
dense blister packed tablet, using wet granulation or direct compression, the amount of 
natural resources needed is to be allocated over the amount of tablets packed in the 
number of blisters in one folding box. STELARA® and SIMPONI® are parenterals with 
a high footprint related to Delivery Devices Production (DDP) as well, such as the safety 
injector (use of metal springs, HDPE, PE, glass fibers for the syringe, rubber 
components, etc.). Next, a rather complicated folding box is used to pack only one 
syringe. The reason why the production of SIMPONI® still has a lower footprint than 
STELARA®, notwithstanding an extra fermentation time of 15 days, is the higher yield 
(grams of product after first Direct Product Capture, DPC) and a more efficient 
chromatography in the downstream process to separate the MABs from the rest of the 
harvested media.  
It should be stressed that from a functionality and efficacy point of view one has to 
include the treatment effect for the respective disease patterns (Debaveye et al., 2016). 
While for instance HIV patients need to swallow an 800mg PREZISTA® tablet every 
day, STELARA® only requires 6 injections a year to treat severe psoriasis plaque. This 
is reflecting the technological functionalities of long acting parenterals (e.g. proteins 
such as MABs) and has to be taken into account in the assessment. To include this 
aspect, we use the DDD as defined by the WHO and explained in the methodology 
section (WHO Collaborating Centre for Drug Statistics Methodology, 2015). The lower 
part of Figure 17 represents this and the result is remarkable (mind that the y-axis is log 
transformed in this graph). On a DDD basis (treatment level), the absolute consumption 
of natural resources is 0.0016, 0.0054 and 1.2 kg crude oil-Eq for STELARA®, 
SIMPONI® and PREZISTA® respectively (treatment level). On a yearly basis, the 
resource footprint of treating HIV with PREZISTA® is 750 times lower than treating 
psoriasis plaque with STELARA® because of the long acting platform enabled by MAB 
injectables. It should again be stated for the sake of completeness that this is an 
indication of how technology platforms are performing rather than a comparison of 
single medicines. From a Life Cycle Thinking (LCT point of view), one should be 
careful in generalising results and extrapolating to drugs with other functionalities. 
 
First, related to natural resource footprinting, this study revealed that the relative 
footprint of biologicals is not so much shifting towards the ‘bio’ feedstocks as expected. 
Producing LMs – and in particular MABs – is still a very fossil resource intensive series 
of operations. Second, it was proven that it is of utmost importance to take into account 
the functionality of the (pharmaceutical) product under analysis to make a fair 
comparison. One could say that, due to the character of the long acting platforms, the 
LMs under analysis are not only emerging from the medical ‘undruggable’ space 
perspective, but are having a lower footprint on a yearly treatment basis compared to 
conventional SM chemical synthesis as well and can thus be considered as more 
environmentally sustainable. More cases should be assessed to yield more generic 
results and clearly system boundaries should be expanded to optimise the Functional 
Unit (FU) for comparability.  
 
Related to future research, the author shares some key messages or main 
learnings/bottlenecks below. First of all, because of the very data intensive analyses, a 
lot of process and procurement data that would affect the results of an LCA is still hardly 
available on many LM production sites: the use of single use equipment and discharge 
patterns, allocation of buffer media consumption to the specific downstream 
chromatography steps for purification, etc. In terms of what is better from an 
environmental perspective, single use bags and equipment versus reusable reactors and 
columns is still an unsolved question. All but least is the challenge to tackle the very 
high contribution of HVAC as it is the highest contributor to fossil resources and the 
complete footprint in general. It should be investigated if a recycling rate that high is 
really necessary from a compliance point of view to remove all particular matter and 
potential pathogens in this very contained manufacturing environment. Another 
development of major importance is the breakthrough of innovation in process 
intensification through continuous manufacturing (e.g. continuous lyophilisation) that 
could potentially lower the footprint due to smaller room volumes, contained equipment, 
lead times, etc. In SM production, continuous manufacturing is to be considered as the 
major breakthrough of this decennium. This research has pioneered in the environmental 
resource footprinting of LM production and has postulated recommendations for further 
technological developments that could foster sustainable development of the biologics 
business in the pharmaceutical industry. 
  
  
Chopter 5: Smal/ Molecules versus Biologica Is: The fnvironmentol Resource Foorprint 
100 
Part 3: Enhancing the Business Value of 
Environmental Sustainability Assessments 
101 
Chopter 5: Smal/ Molecules versus Biologica Is: The fnvironmentol Resource Foorprint 
102 
 
Partly redrafted from: 
De Soete, W., Jiménez-González, C., et al. (2016). "Challenges and 
Recommendations for Environmental Sustainability Assessments of Pharmaceutical 
Products in the Healthcare Sector." Green Chemistry submitted. 
 
The aim of this chapter, conducted during an intensive study period at the European 
Commission’s Joint Research Centre, Institute for Environment and Sustainability, 
Sustainability Assessment Unit (JRC IES SA), is to map current challenges in order to 
advance the state of the art of environmental sustainability assessments, to share 
experiences and connect professionals and eventually to identify needs, bottlenecks and 
priority action points for businesses and policy. This is accomplished through; (1) a 
stakeholder survey; (2) expert interviews and (3) roundtable discussions with 
sustainability professionals in the field (Figure 18). In order to create a high leverage 
effect and a broad encouragement of the outcomes, a variety of stakeholder communities 
were consulted: (1) private organisations; (2) policy and governmental research and 
decision support bodies; (3) NGOs; (4) universities and research institutions; (5) sector 
federations, agencies and consortia and last (6) consumers (hospitals, pharmacists, 
patients, physicians and GPs).
Figure 18: Schematic representation of the study outline: (1) research questions; (2) 
methodologies and (3) envisaged outcomes. 
 
 
For this study 13 field experts were approached with experienced functions ranging from 
Sustainability Directors in industry, Product Stewardship Directors, LCA Project 
Managers, Executive Managers, academic Professors and so forth. Out of the 13 
invitations, 8 expert interviews were conducted, resulting in a response rate of 62%. To 
protect the privacy of the experts at hand and of their legal entities, the sections in results 
and discussion are reflecting on the discussions and visions within the group. They shall 
not represent any statement of either the individual or its affiliations. With respect to the 
expert interviews, 3 private drug producing companies were questioned, 2 non-profit 
corporations governed by a single Board of Directors, 2 private sustainability consulting 
companies and 1 academic entity. 
 
Concerning the stakeholder survey, the author invited (1) Private organisations; (2) 
Policy, governmental (research) bodies & NGOs; (3) University/research institutions; 
(4) Sector federations/consortia and (5) Consumers (hospitals, pharmacies, patient 
organisations, physicians). 344 potential participants were invited over the different 
stakeholder subcategories. They were selected based on their track record, proven 
relevance to the scope of this research, corporate sustainability reports, etc. However, 
several people conducting different roles within one legal entity were approached while 
almost every entity has sent in an aggregated entity vision or response. Unfortunately, 
we did not receive any responses from the consumer category, despite three reminders. 
As a result, this category was left out of consideration, ending up with a total of 340 
invitees. Of these 340, 174 were unique identifiers, yielding a response rate of 24% (41 
responses). A unique identifier is defined as an individual or group of individuals 
representing a legal entity that equals a unique entry in the database of potential 
participants (i.e. the 340 potential participants covered 174 unique legal entities). Table 
7 in Chapter 6.3.2 provides more details about invitations, unique identifiers and 
responses. Figure 19 gives an overview on the aggregation ratio per stakeholder group. 
The stakeholder survey itself that was circulated is to be found in Annex A5. 
 
The roundtable discussions were organised in Q4 of 2015 at the JRC’s Institute of 
Environmental Sustainability, Sustainability Assessment Unit (IES SA). Several private 
organisations active in the pharmaceutical and more general in the healthcare sector with 
a broad range of experiences with sustainability assessments, the European Sector 
Federation EFPIA, the United Nations Development Program on Sustainable 
Procurement in the Health Sector (UNDP SPHS) and the Sustainable Development Unit 
of the UK’s National Health Service (NHS SDU) were invited to the European 
Commission’s Joint Research Centre in Ispra, Italy, where several crosscutting Units of 
different JRC Institutes joined the seminar. The final aim of the seminar was to discuss 
and report on recommendations for the sector to further advance sustainability 
assessments in the field. 
 
 
Many of the challenges and focus points that were drawn from the literature study were 
taken up as key issues/questions in these expert interviews. The next paragraphs will 
highlight the visions and best practices obtained from the expert interviews according 
to four predefined discussion topics. 
 
The main driving force to conduct sustainability assessments is unanimously agreed 
upon to be twofold: (1) internal process optimisation, (2) external communication 
towards stakeholders. The hotspot analysis of environmental impacts (especially 
resource based) throughout the value chain seems a sound base to identify optimisation 
potential, often in terms of process intensification (e.g. batch to continuous 
manufacturing, process flow integration, etc.), while for external communication 
aspects emission-based indicators are more popular (e.g. Carbon Footprint). Next to the 
two aforementioned drivers, sustainability attributes are helpful in the Design to Value 
(DtV) process to make any enterprise more competitive and more efficient in total cost 
and resource efficiency.  
 
When it comes down to sustainability assessment strategies, the upcoming trend in the 
pharmaceutical and healthcare sector is the evaluation of healthcare pathways as a 
whole, instead of focusing on the stand-alone medicine as a product (Debaveye et al., 
2016). Expanding the system boundaries from product level (manufacturing) to product-
service level (healthcare pathway) was found to be the way forward towards assessing 
the environmental burdens coming with the real value delivered by the sector: human 
health. Another strategic action towards including environmental sustainability in 
design processes (so called Quality by Design, QbD) is the inclusion of sustainability 
attributes and metrics in development decision trees and stage-gating processes (De 
Soete, 2016). While streamlined LCA (e.g. FLASC tool, and De Soete et al, 2014) is 
more and more being applied in early research phases together with qualitative measures 
(e.g. preferred solvents, toxic substances evaluation, etc.), full-blown resource based 
LCA is used for optimizing case studies in retrofitting or for the evaluation of second 
and third generation medicines. 
 
In terms of sourcing and quality assurance of outsourced LCAs to third parties, a lot of 
private entities see value in cooperating with universities and knowledge institutions in 
general for internal optimisation purposes. Universities are judged to be in front of the 
pack related to knowledge development and delivery of wanted profiles to the industry. 
Outsourcing to third party consultants is generally done for attributional LCAs and for 
benchmarking or sector wide purposes. In this case, often a quality check or intermediate 
reporting is performed between the Life Cycle Inventory (LCI) and the Life Cycle 
Impact Assessment (LCIA), falling back on the very iterative character of an LCA. Only 
a minor share of the pharmaceutical companies and shareholding entities in the Value 
Chain (VC) of the healthcare pathway perform LCAs internally, possibly putting a threat 
on central data management of LCIs. 
 
 
Some current shortcomings of LCA methodologies to support business and policy 
decision making with focus on the pharmaceutical and healthcare sector are represented 
bullet wise below. These were gathered from interviews with the experts involved in 
this research. 
 Stakeholder involvement: In the light of improving data quality and enhancing 
the use of primary Life Cycle Data (LCD), both upstream and downstream SC 
actors should be taken into account. Upstream suppliers represent e.g. fine 
chemical producers, base chemicals, building blocks (Small Molecules, SM); 
feeding media, resins, disposables (Large Molecules, LM) and delivery device 
and packaging suppliers. Downstream actors are e.g. logistic suppliers, hospital 
networks, wholesalers, national health services and in the end the patient. Other 
actors that might be considered in a full healthcare pathway system are patient 
federations, General Practitioners (GPs), etc. 
 System boundaries: A clear shift is trending from product systems to product-
service systems. The very same is valid in the pharmaceutical/healthcare sector. 
More and more companies are extending the system boundaries of their LCAs. 
Embracing the full treatment pathway (with hospital visits, GP visits, etc.) in a 
healthcare system is shaping a more comprehensive picture of the burdens and 
benefits exerted at the level of the three areas of protection in LCA. The system 
boundaries need to be aligned to the research question that needs to be answered, 
and sometimes these are not thoroughly planned. 
 Streamlined LCA: Fast screening methods and streamlined LCA methods are 
increasingly used in early stage assessments at low Technology Readiness Levels 
(TRLs). Integration of LCA tools into existing engineering or Enterprise 
Resource Planning (ERP) systems seems to be the way forward to generate LCA 
results in a fast way at the desirable stage-gates of development. 
 Communication: Outreaching with midpoint results is still a difficult concept for 
non-LCA experts, while endpoints could be easier to understand (e.g. the 
Disability-Adjusted Life Years or DALY concept) but are less reliable in terms 
of model and data uncertainty. Optimisation potential should be translated 
towards specific, prioritised key actions to enhance the value for decision makers. 
 Efficacy: The primary focuses of healthcare providers are efficacy, compliance 
and safety for the patient. A major challenge is to include these aspects in LCAs. 
Bioavailability is typically decreasing for new, innovative compounds since they 
tend to be more and more complex. Through study of clinical trials phase one, 
two and three, the bioavailable fraction of API intake can be taken into account 
in the Functional Unit. However, the transition from the inclusion of blood levels 
(instead of kg API or one tablet) to the treatment effect, taking into account the 
efficacy for the patient is challenging. 
 Pharmaceuticals In the Environment (PIE): Unfortunately, very little is known 
about what happens with pharmaceutical residues and metabolites after the use 
phase of the product. For some pharmaceuticals, characterisation factors were 
established through exposure, fate, effect and damage factors (Alfonsín et al., 
2014). The PHARMAS FP7 project is one of the few dealing with the issue of 
ecological and human health risk assessments of antibiotics and anti-cancer drugs 
found in the environment. While fate and exposure factors of APIs could 
reasonably well be derived, identifying and measuring metabolites remains a 
future challenge. 
 Lack of Life Cycle (LC) Data: It has been identified that the lack of primary 
process data to construct Life Cycle Inventories (LCIs) is one of the most 
important bottlenecks in LCAs of pharmaceutical products. The combination of 
the high added value of products, confidentiality, Intellectual Property Rights 
(IPR) and competitiveness makes B2B data sharing along the value chain 
difficult without independent, objective third parties. As a result, the next 
paragraph deals with recommendations to the sector on how to tackle data 
unavailability. 
 
The general consensus on data sharing reached amongst the experts is that they clearly 
see the benefits of sharing primary data, especially through the supply chain wrapped-
up in business models engaging the n-x suppliers as well. However, the sector is 
carefully observing what the downsides might be. Every data point published can be 
used by scouting/accounting agencies for benchmarking organisational behaviour and 
analysis of business results calculating life cycle inventories back to monetary flows. 
Therefore, transparency through the SC should be carefully provided, safeguarding the 
competitive advantage of every individual SC actor. Possible measures to be taken are 
the use of black box data models through the use of so-called system processes in LCI 
instead of unit processes, working with a third party database provider such as a sector 
federation, etc. Primary data should be used as much as possible, secondary data can be 
obtained through proxies, modelling tools (e.g. Finechem, FLASC™) and databases 
(Curzons et al., 2007; Weidema, 2012; Ciroth et al., 2013). For the use of secondary 
data, the sector would benefit from fine chemical/pharmaceutical entries of solvents, 
building blocks, reagents, excipients, packaging materials, etc. in life cycle databases. 
When asking who should be the host of such a database, the sector prefers a third party 
such as the European Federation of Pharmaceutical Industries and Associations (EFPIA) 
or the Sustainable Procurement in the Health Sector (SPHS) Secretariat from the United 
Nations Development Program (UNDP). Referring to other sectors, Plastics Europe took 
the very same role as the first European Sector Federation representing a ‘Node’ for the 
plastics industry. In addition to enhancements on data availability and relevance, the 
systematic inclusion of uncertainty and sensitivity analysis is strongly recommended, 
particularly as the LCI and LCA, as discussed above, by definition incorporate large 
uncertainties. Although the aim is to enhance the quality of the assessments, without 
uncertainty and sensitivity analysis, decisions made using LCA could be less than 
optimal. As a final remark, the experts mentioned that time and commitment are 
probably the two biggest hurdles to establish such a system today. 
 
As a last discussion topic touched upon during the expert interviews, standardisation 
and harmonisation of both LCI and LCIA methodologies within the healthcare sector 
were questioned. As oil become clear from the stakeholder surveys as well, most used 
standardised guidelines for conducting LCA are ISO 14040/44, ELCD, GHG Protocol 
PAS 2050, Bilan Carbone, NHS Carbon Footprint Guidance for Pharmaceuticals and 
Medical Devices, the World Business Council (WBC) Sustainable Development 
Guidelines, BSI for consumer goods and the MEASURE Roadmap for applying 
LCA/LCM in innovation projects. The choice is merely depending on the market to be 
served (Bilan Carbone for France, NHS Guidance/BSI for the UK, etc.) which shows 
the emergence of a standardised method that is recognized by all markets. The general 
Product Environmental Footprint (PEF) guidelines of the European Commission were 
tested by several pharmaceutical companies and the feasibility of using the guidelines 
was discussed during the interviews. The main drawback is the very diverse range of 
impacts of pharmaceutical products with the aim at defining Product Category Rules 
(PCRs). Different studies have indicated a very large range in all impact categories due 
to a very diverse synthesis of APIs, biotechnological drugs, etc. A recommendation 
would be to find a feasible aggregation of drug types where sub-ranges are fairly limited. 
The industry stresses the importance of having this diversity within medicinal 
treatments, especially when dealing with companion diagnostics when medicines will 
be tailored to the specific genetic information of the patient. The author would like to 
make the remark here that these ranges will tend to decrease when more LCI data is 
available. The LCI and impact assessment issue is inherently connected to each other 
and is to be seen as a major future challenge. 
 
As a third technique to gather state of the art and ideally to come up with new insights 
and best practices not to be found in scientific literature, the authors have sent out 
stakeholder surveys (to be found in Annex A5) to five subcategories of stakeholders that 
were to be questioned according to the experts: (1) Private organisations; (2) Policy, 
governmental (research) bodies & NGOs; (3) University/research institutions; (4) Sector 
federations/consortia and (5) Consumers (hospitals, pharmacies, patient organisations, 
physicians, GPs). 344 potential participants were invited over the different stakeholder 
subcategories. However, several people conducting different roles within one legal 
entity were approached while almost every entity has sent in an aggregated entity vision 
or response, which was a good approach for gathering different visions from 
sustainability teams, product stewardship teams, compliance, etc. Unfortunately, we did 
not receive any responses from the consumer category, despite three reminders. As a 
result, this category was left out of consideration, ending up with a total of 340 invitees. 
Of these 340 participants, 174 were unique identifiers (explained in Chapter 6.2.2), 
yielding a response rate of 24% (41 responses). Table 7 provides a more detailed 
analysis of the involved stakeholder groups, the amount of invitees, the amount of 
aggregated invitees per legal entity, the absolute amount and percentual aggregated 
responses per legal entity and finally the response rate per invited legal entity. 
 
Table 7: Stakeholder invitation statistics and response rates: (1) Individual invitees (#): 
absolute amount of invited individuals per stakeholder group; (2) Aggregated invitees (#); 
(3) Aggregated responses (#); (4) Aggregated responses (%); (5) Response rate per invited 
entity (%) 
 














Private organisations 119 56 17 41 30 
Policy, governmental 
(research) bodies & NGOs 
81 23 5 12 22 
University/research 
institutions 
27 21 16 39 76 
Sector federations/consortia 113 74 3 8 4 
SUM or weighted percentage 340 174 41 24 - 
 
The ratio of 
𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐼𝑛𝑣𝑖𝑡𝑒𝑒𝑠 [#]
𝐴𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝑖𝑛𝑣𝑖𝑡𝑒𝑒𝑠 [#]
 is defined as the aggregation ratio per stakeholder 
group and is visualised in Figure 19. The rather low aggregated response rate (Figure 
20b) of policy, governmental (research) bodies and NGOs compared to the response rate 
per invited entity (resp. 12% and 22%) is partly due to a large aggregation ratio (3.5) 
compared to the average (1.9) (Figure 19). The opposite is valid for universities and 
research institutions (1.3), which can be considered to be more active and front running 
in developing and disseminating on LCA methodologies as well, partly explaining the 
high response rate. The response rate per invited sector federation or knowledge 
consortium was not expected to be only 4%. A reasonable explanation for this low 
number is that the author reached out to the European Sector Federation EFPIA and the 
sector federations of the member states, which are either not that active in this field 
and/or were engaged to discuss this matter at the level of the overarching EFPIA. It was 
found to be very hard to engage consumer (patient) organisations. Of the 2 overarching 
entities approached, none of them took part in the survey. Analysing the geographical 
distribution of the participating parties the United Kingdom, Belgium and the United 
States of America pop out (Figure 20a). It should be mentioned that Asia and Latin 
America was not included in this study, where mainly (contract) manufacturing is taking 
place. The rather high participation rate of these countries can be linked with the 
presence of working groups/organisations like ACS and its Pharmaceutical Roundtable 
in the USA and RSC and the NHS SDU CSPM in the UK. Belgium is the EU’s third 
highest export country of pharmaceuticals (37 billion Euros in 2014) and is one of the 
leading countries in innovative pharmaceuticals with R&D and manufacturing sites of 
JNJ, GSK, Pfizer, Baxter, etc. Up to 40% of total revenue is reinjected into innovation 
investments in R&D. The authors were able to link a high R&D activity with a high 
sustainability and compliance awareness (OECD/EU, 2014; EFPIA, 2015). At the time 
of patent loss, generics are eager to take over the market unless the brand company 
develops a so-called second generation medicine which can be approved if there are 
significant improvements in patient compliance, efficacy, resource efficiency, 
sustainability, etc. Once approved by the FDA/EMA, a second patent can ‘protect the 
market’ from the innovative medicine producers. On the other hand, once generics are 
one the market, it’s seems that R&D intensive, innovative medicine producers try to 
make the difference with e.g. a more comfortable coating, a higher patient compliance 
and a better sustainability profile in order to remain competitive on the market. 
 
 
Figure 19: The x-axis represents the aggregation ratio per stakeholder group (with an 
average of 1.9 indicated by the vertically dashed line) defined as the amount of invitees 
divided by the amount of aggregated invitees. The y-axis represents the different 
stakeholder groups (with the average per legal entity indicated by the red box). 
 
 
Figure 20: (a) Geographical spread of the responses. The United Kingdom, Belgium and 
the United States of America pop out. It should be mentioned that Asia and Latin America 
was not included in this study, where mainly (contract) manufacturing is taking place. 
The authors were able to link a high R&D activity with a high sustainability and 
compliance awareness; (b) Aggregated percentual response rate per stakeholder group. 
 
Zooming in on the structure of the survey, three main topics were questioned: (1) 
Scoping and applications of LCA; (2) Data (un)availability and Life Cycle Inventory 
(LCI) modelling and (3) Life Cycle Impact Assessment Methods (LCIAM). The next 
paragraphs elaborate on the output generated by the stakeholder survey, subdivided in 
the three aforementioned thematic fields. 
 
More than 75% of all respondents use LCA for hotspot determination to identify the 
biggest burdens through the Supply Chain (SC). Aforementioned most popular 
application is followed by product optimisation and retrofitting (61%). Other 
stakeholders in the healthcare sector use LCA for sustainability reporting (59%), product 
development (44%), B2B communications (34%) and B2C communications (24%). 
Remarkable is that outreach of results to the wider society (outside of sector federations 
or bilateral B2B efforts) is rather low (24%) and is the lowest ranked application. While 
in other sectors LCA or in general environmental sustainability assessment is used in 
dissemination and marketing material, the pharmaceutical and healthcare industry is a 
rather closed community. However, this is gradually changing and there is a definite 
need to tackle data life cycle data unavailability, to improve data transparency and 
reliability, etc. As was already touched upon in the results section from the expert 
interviews, the participants generally do not think that a Product Category approach is 
the way forward. 71% of them prefer a product-specific approach over a product group 
approach whereas a very large range in all impact categories exists due to a very diverse 
synthesis of APIs, biotechnological drugs, dosing forms, etc. This product-specific 
mind-set is confirmed with the fact that 41% of all applicants use streamlined LCA (less 
detailed but with specific parameters). 37% of the practitioners use full-blown LCA 
while for 39% the choice between streamlined and full-blown LCA is inherently 
connected with the type of application (multiple choice question). Interesting is that of 
all practitioners using full-blown LCA, 73% use a cradle-to-gate (CtG) approach, 34% 
a cradle-to-cradle (CtC) approach and 27% a gate-to-gate (GtG) approach (multiple 
choice). It is commented that the combination of GtG, CtG and CtC is most useful in 
identifying hotspots and eliminate burdens through the value chain. Next, the 
terminology ‘cradle-to-cradle’ seems to be misleading for quite some practitioners 
(34%). If any, there is very little re-use in the healthcare sector (especially not in case of 
pharmaceuticals). The answers for CtC should in fact be Cradle-to-Grave. Even in that 
case, in reality there are very little studies available on the fate and exposure factors for 
the derivation of characterisation factors for End-of-Life (EoL) scenarios in the field of 
Pharmaceuticals In the Environment (PIE). Some studies were performed deriving 
characterisation factors for EoL scenarios of API excretion, however this has not been 
done for metabolites so far (Alfonsín et al., 2014; Li et al., 2016). Probably the most 
lively topic related to the goal and scope of an LCA is the applied Functional Unit (FU) 
(Ciroth and Srocka, 2008). Currently, it is common to encounter straight mass FUs such 
as ‘kg’, ‘mole’ or a ‘batch’ for pharmaceutical products and a ‘unit’ for medical devices, 
delivery devices, etc. Fair comparisons between products and services are only possible 
if the FUs are actually comparable (Grießhammer et al., 2005). 76% of all participants 
acknowledge there is a need to expand system boundaries in order to take into account 
healthcare services related to a certain pharmaceutical product (e.g. physician visits, 
hospitalisation, pharmacy, …) and likewise a shift in FUs from physical attributes (e.g. 
‘kg API’, ‘1 tablet’) to the service or treatment offered to the patient (e.g. 1 year of 
treatment). Of course for comparability reasons, this ‘1 year of treatment’ should have 
the same therapeutic effect as the alternative; a comparison that is hard to make, even 
with a very multidisciplinary research team. That is probably why 17% are not 
convinced of this shift and another 7% has no clear opinion.  
 
As has been touched upon in Chapter 6.3.1.3 dealing with data life cycle data availability 
through the value chain and the visions from the expert panel, primary Life Cycle Data 
(LCD) for inventory building and transparency within data systems remains to be 
considered as a key issue. As a main source of primary data inventory, the respondents 
ranked the specified entries as follows: (1) Bill of Materials (BOM), 56%; (2) Batch 
Production Reports (BPRs), 49%; (3) Material Safety Data Sheets (MSDS), 44%; (4) 
equipment manuals, 41%; (5) Validations/Qualification Reports (QA/QC), 37%; (6) 
Piping and Instrumentation Diagrams (P&IDs), 32%. When the participants were 
questioned on what is to be perceived as the biggest hurdle in LCA overall, 
confidentiality in data sharing and the lack of both primary and secondary LCD covered 
more than 60% of all responses. The lack of integration of process design tools and LCA 
tools, insufficient B2B communication to obtain primary data from suppliers and a lack 
of harmonisation on how to gather secondary LCD covered the remaining 40%. It is 
clear that in order to give recommendations for the latter 40%, the issues in 
confidentiality in data sharing and the lack of secondary LCD need to be tackled. As 
officially launched the 6th of February 2014 by the Director General of the DG JRC, 
and the Deputy Director General of the DG ENV, the European Framework offers the 
Life Cycle Data Network (LCDN). The Network allows for flexibility while facilitating 
the availability of LCD from different organisations and sources (Sanfélix et al., 2013; 
Recchioni et al., 2015). While it was clear from the expert interviews that data sharing 
within the pharmaceutical sector is still a very sensitive topic, 85% of the participants is 
convinced that the lack of secondary LCD on chemical building blocks, solvents, 
intermediates, APIs, etc. is a crucial aspect that should be tackled. 83% of all participants 
agree that the establishment of a ‘Healthcare Node’ or ‘Pharmaceuticals Node’ in the 
LCDN or a similar system at a sector federation level – with respect for the IP and 
competitiveness of data providers – would be a preferred solution to overcome the issue 
of data unavailability.  
 
As the harmonisation of Life Cycle Inventories (LCIs) is being improved by the creation 
and sharing of secondary LCD through the proposed network in the previous chapter, 
Life Cycle Impact Assessment (LCIA) approaches are still very diverse. Looking at 
midpoint categories, 83% of the participants usually accounts for climate change 
through the IPCC Carbon Footprint (CF), 59% accounts for water consumption, 46% 
for fossil resource consumption and about 46% for human toxicity. Fossil resource 
consumption has been proven to correlate with climate change indicators such as the 
IPCC CF (Huijbregts et al., 2006; Huijbregts et al., 2010; De Soete et al., 2014b). Water 
consumption and human toxicity proved to be relevant impact categories in expressing 
the environmental impact of pharmaceutical production processes (additionally in 
relation with the human health benefits) (Debaveye et al., 2016). 56% of the healthcare 
LCA practitioners never use endpoint indicators related to the three Areas of Protection 
(AoP). Human health, natural resources and ecosystems species is being accounted for 
by 39, 29 and 24% of the questioned stakeholders respectively. The lack of 
harmonisation in the choice of LCIA methodologies to serve different goals and 
different markets is a key aspect that should be tackled, according to 73% of the survey 
participants. 66% stated that the European Commission’s Product Environmental 
Footprint (PEF) guideline could be a solid base for harmonisation.  
 
In order to initiate communication, knowledge and data sharing and feeding into 
discussion groups within the sector, starting the debate on current methodological 
practices and constraints, the authors organised a two days seminar with presentations 
and roundtable discussions. The final aim of the seminar was to exchange ideas between 
different stakeholders (public, private and policy) and to consolidate general 
recommendations for the sector, taking into account the feedback from the expert 
interviews and the stakeholder survey. The seminar was organised in Q4 of 2015. 
Several private organisations (Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, 
Boehringer-Ingelheim, etc.) active in the pharmaceutical and more general in the 
healthcare sector with a broad range of experiences with sustainability assessments, the 
European Sector Federation EFPIA, the United Nations Development Program on 
Sustainable Procurement in the Health Sector (UNDP SPHS) and the Sustainable 
Development Unit of the UK’s National Health Service (NHS SDU) were invited to the 
European Commission’s Joint Research Centre in Ispra, Italy, where several 
crosscutting JRC Units joined the seminar. It was organised by the Institute of 
Environmental Sustainability, Sustainability Assessment Unit (IES SA) and Ghent 
University. 
 
During the first day focus was on dissemination and matchmaking with presentations 
from the European Commission of the Life Cycle Data Network (LCDN) and the 
Product and Organisational Environmental Footprint (PEF & OEF) and introductory 
presentations from the invited parties. The second day, several roundtable discussions 
were hold on key topics that arouse during day one, the expert interviews and the 
stakeholder survey with the aim of formulating recommendations for the sector to 
further advance sustainability assessments in the field. 
 
A second meeting was held on the occasion of a periodic meeting between the members 
of the Coalition on Sustainable Pharma and Medical Devices (CSPM) of the UK’s NHS 
SDU in London to further fine-tune and align on potential solutions. 
 
The key recommendations and action points condensed by the author are the following: 
1 In order to integrate pharmaceutical production in the healthcare pathway 
and to make comparative LCAs on a patient level, it is highly 
recommended to integrate the complete healthcare pathway in the system 
boundaries of a certain treatment, not only the pharmaceutical product 
(Penny et al., 2015). Assessing full healthcare pathways allows for 
identifying burdens within holistic system boundaries (e.g. HVAC at 
hospitals) and allows for comparison with treatment benefits in terms of 
health gains (Quality Adjusted Life Years, QALYs). In the end, this is 
what the sector is delivering to clients; human health is the value. 
2 The establishment of a ‘Node’ in the LCDN or a similar data system is a 
highly recommended step to eliminate data gaps, to further expand our 
knowledge on the sustainability of healthcare processes. The sector 
prefers this Node to be held operational at the level of the (European) 
sector federations such as EFPIA. Another potential Node owner could be 
the UNDP SPHS, the American Chemical Society (ACS), etc. The use of 
black box modelling or the use of so-called system processes in LCI 
modelling, verified by third parties is highly recommended to safeguard 
the Intellectual Property (IP) and competitiveness of industrial actors. This 
should by no means affect the data quality that is delivered to the Node. 
3 More and more organisations are testing how to extract primary data 
sources from Enterprise Resource Planning (ERP) systems. Primary data 
sources are still preferred over secondary LCD. Several publications 
highlight the plausibility and potential success of connecting engineering 
modelling software (e.g. ASPEN) with LCA software or discuss the 
feasibility of incorporating LCA calculations directly into ERP systems to 
work with primary data (De Soete, 2016; Kralisch et al., 2016). The author 
strongly stimulates further development in merging aforementioned 
fields. 
4 There is a clear understanding that there is a lack of harmonisation of 
impact assessment methodologies in e.g. the UK’s NHS Carbon Footprint 
Guidance, the International Reference Life Cycle Data System (ILCD) 
Handbook, the guidelines from the World Business Council on 
Sustainable Development (WBCSD), etc. (European Commission - Joint 
Research Centre - Institute for Environment and Sustainability, 2010; 
European Commission - Joint Research Centre - Institute for Environment 
and Sustainability, 2012; NHS Sustainable Development Unit, 2012; 
World Business Council on Sustainable Development, 2016). There is a 
clear need to harmonise further developments instead of making solutions 
even more diffuse for different stakeholders. The European Commission’s 
Product Environmental Footprint (PEF) Guidelines might be a good 
alternative, following on the ILCD Handbook (European Commission, 
2013). However, at this stage, the PEF and Organisation Environmental 
Footprint (OEF) at corporate level are still in pilot testing phase. The 
pharmaceutical sector is not subject of any of those pilots, but should be 
able to grasp learnings (pro’s and con’s) from the chemical and consumer 
products pilots. In future, it should be evaluated to what extent the PEF 
and OEF can help harmonisation in the pharmaceutical and healthcare 
sector. 
 
This chapter is the result of the work of many participant groups and devoted individuals 
to bring sustainability assessments of pharmaceuticals products or services within the 
healthcare sector to the next level. Through expert interviews, stakeholder surveys and 
roundtable discussions, the team triggered a dialogue in the community resulting in a 
prioritisation of bottlenecks in conducting environmental sustainability assessments of 
pharmaceutical products and services within the healthcare sector. Next, 
recommendations and key actions are suggested in order to overcome aforementioned 
hurdles. The most challenging bottleneck proved to be the lack of primary process data 
in order to build life cycle inventories and the lack of secondary data within life cycle 
databases. To tackle the first priority, a preferred list of targeted documents was given 
by practitioners to extract primary data from. Next, new developments were highlighted 
in coupling Enterprise Resource Planning (ERP) systems with life cycle metrics and 
vice versa. With respect to the second priority 83% of all survey participants agreed that 
the establishment of a ‘Healthcare Node’ or ‘Pharmaceuticals Node’ in the EU Life 
Cycle Data Network (LCDN) or a similar system at a sector federation level – with 
respect for the IPR and competitiveness of data providers – would be a preferred solution 
to overcome the issue of data unavailability. The team strongly suggest and will keep 
on facilitating roundtable discussions and debates (e.g. at EFPIA, NHS SDU, etc.). Next, 
the team urges to make use of existing platforms from the European Commission and 
UNEP or others to streamline data inventories. More stakeholders (especially patient 
populations) should be convinced to take part in the debate. It is a strong belief of all 
stakeholders involved that this study should be used as a guidance to steer further 
research and development in industry, academia and policy in order to serve and support 
decision making processes. 
  
 





De Soete, W., Boone, L., et al. (2014). "Environmental resource footprinting of drug 
manufacturing: Effects of scale-up and tablet dosage." Resources Conservation and 
Recycling 91: 82-88.
 
In the chemical and pharmaceutical industry, both companies and research institutes 
have been developing metrics and tools to assess and manage the ‘greenness’ of their 
products and services throughout the last decades. A distinction is made between process 
oriented indicators (e.g. E-factor, Process Mass Intensity, etc.) and life cycle oriented 
eco-indicators (e.g. Carbon Footprint) (Lapkin and Constable, 2009; Jiménez-González 
et al., 2013). With reference to green chemistry and green engineering, process 
indicators are traditionally used to assess and eventually enhance the environmental 
sustainability of products and processes; however, a life cycle approach is favoured to 
avoid outsourcing of burdens (Dewulf et al., 2007a). The latter includes the cumulative 
environmental burden exerted through all steps of the supply chain - and more generally 
the life cycle - of a certain product or service, including both upstream and downstream 
processing, ranging from raw material extraction to the End-of-Life waste treatment 
(Azapagic, 1999; Russell et al., 2005). A more elaborated view on metrics, assessment 
methods, etc. was given in Chapter 1. Next to the development and profound elaboration 
of assessment methods with respect to the pharmaceutical industry, some fast 
assessment tools were developed to estimate the environmental sustainability of Active 
Pharmaceutical Ingredient (API) production processes (Curzons et al., 2007; Wernet et 
al., 2009). These generic tools, typically circumventing the need for an in-depth process 
analysis, rely on empirical models built on rather scarce confidential data. A more 
detailed, less generic model was developed at Ghent University in order to evaluate the 
integrated resource consumption of a multipurpose pharmaceutical production plant of 
the Janssen Group, Johnson & Johnson (Van der Vorst et al., 2009a; Van der Vorst et 
al., 2011). Taking into account the Drug Product (DP) production process 
(pharmaceutical production step in which the API is formulated in combination with 
various excipients in a so-called dosage form), the American Chemical Society (ACS) 
Green Chemistry Initiative Pharmaceutical Roundtable (GCIPR) developed a 
simplified, mass accounting fast Life Cycle Assessment (LCA) tool (Jiménez-González 
et al., 2013).  
 
With aforementioned assessment tools, an important step was taken towards generic 
environmental sustainability assessments of pharmaceuticals. However, these tools do 
not yet account for the early and late development stages of a pharmaceutical drug 
product, which typically comprise abound 14 out of 20 years of the patent term (Rees, 
2011; Ellery and Hansen, 2012). Moreover, they cannot predict future environmental 
impacts at industrial scale when the pharmaceutical is at an early development stage. 
This forecasting perspective should be embedded in a tool aiming at the provision of 
eco-indicators intended for integration in R&D decision trees (De Soete et al., 2013). 
This way, one can anticipate on the environmental burden of even first generation 
medicines by including eco-indicators as criterion for decision-making at important 
development stages or stage gates, next to drug bio-availability, patient compliance, 
cost-effectiveness, etc. The predictive impact assessment can be accomplished through 
evaluation of environmental burdens of production technologies at different production 
scales (e.g. lab scale, clinical production scale, pilot scale, industrial manufacturing 
scale). Note that in other sectors (e.g. the energy sector) power-law relationships were 
already established in order to predict e.g. the fuel consumption and costs of energy 
conversion technologies (Caduff et al., 2010; Caduff et al., 2012). 
 
Figure 21: Pharmaceutical drug manufacturing supply chain, represented within the 
triple system boundary approach: process level (α), plant level (β) and overall industrial 
level (γ). Comparative analysis 1 and Comparative analysis 2 represent the two main 
objectives of this chapter: Comparative environmental sustainability assessment of four 
consecutive scales of tablet manufacturing through Wet Granulation (WG1 versus WG5 
versus WG30 versus WG240) (Comparative analysis 1) and comparative environmental 
sustainability assessment of PREZISTA® 800 mg (WG) versus PREZISTA® 2 x 400 mg 
(Direct Compression, DC). Note that utility production (e.g. electricity, heating media, 
etc.) is not represented in this figure for the sake of simplification. 
 
The objective of this chapter is twofold. First of all, it analyses cumulative resource 
consumption of pharmaceutical tablet manufacturing of PREZISTA® 800 mg through 
Wet Granulation (WG) at four consecutive scales (WG1 = 1 kg/h, WG5 = 5 kg/h, WG30 
= 30 kg/h and WG240 = 240 kg/h resp.) and proposes the experience curve (Figure 21). 
PREZISTA® is a well-known second-generation protease inhibitor used to slow down 
Human Immunodeficiency Virus (HIV) infections. This typically high weight tablet 
requires wet granulation by capillary and viscous forces to enhance the flowability of 
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Comparative analysis 1: 




Lage et al., 2011). Second, the study conducted for this chapter evaluates the 
environmental impact from a life cycle perspective of a daily consumption of 
PREZISTA® 2 x 400 mg versus the bioequivalent 800 mg which was launched to 
enhance patient compliance. This tablet allows patients to take only one tablet once a 
day instead of taking two 400 mg tablets per day. In contrast to the PREZISTA® 800 
mg tablet, production of the PREZISTA® 400 mg tablet covers Direct Compression 
(DC) of the powder mix, yielding good tablet properties as presented in Figure 21. 
Environmental sustainability assessment in this study was conducted at three different 
system boundaries, which enables identification, localisation and eventually reduction 
of environmental burdens, in this case resource extraction. Exergy Analysis (EA) was 
used at process level (α) and plant level (β) while a cradle-to-gate Exergetic Life Cycle 
Assessment (ELCA) was conducted at the overall industrial level (γ) (Dewulf et al., 
2007a; Dewulf et al., 2008). Life cycle stages taken into account are API production, 
DP production and Packaging (Figure 21). 
 
In pursuit of harmonisation in reporting methodology of a Life Cycle Assessment 
(LCA), the following paragraphs briefly elaborate the chosen methodological 
framework according to the ILCD Handbook Guidelines (European Commission - Joint 
Research Centre - Institute for Environment and Sustainability, 2010). 
 
In order to provide a reference to which all inputs and outputs are normalized, the 
Functional Unit (FU) or final demand of the product system was defined as one daily 
intake of PREZISTA®. Given that the PREZISTA® 800 mg tablet is bioequivalent to 
two PREZISTA® 400 mg tablets (both representing one daily intake of the patient), this 
functional unit is valid for both research questions from a life cycle thinking point of 
view.  
 
The considered product system is visualised in Figure 21. It comprises Active 
Pharmaceutical Ingredient (API) production, Drug Product (DP) production and 
Packaging of PREZISTA® at the overall industrial level (γ, cradle-to-gate). At process 
(α) and plant (β, gate-to-gate) level the focus lies on DP production and Packaging since 
none of the proposed research questions affect the API synthesis steps in any way. At 
the point at which DP development and DP scaling to larger batches is initiated in a 
development project, the scale-up of API synthesis has reached a rather mature state 
(Gad, 2008; Janssen Pharmaceutica NV, 2013). Consequently, through this study, the 
production scale of API was assumed to be constant at full manufacturing scale. In the 
first comparative analysis DP production comprises five core processes: Dispensing 
(αWG-1); Wet Granulation (WG) (αWG-2); Sieving and Blending (αWG-3); Compression 
(αWG-4) and eventually Coating (αWG-5), of which each is subdivided into different 
separated subprocesses. The comparative character of this first research question (effect 
of scale-up and learning on cumulative resource consumption) is to be found in the 
complete Drug Product (DP) production system of which four scales of production are 
investigated. This means that Dispensing (αWG-1), Wet Granulation (WG) (αWG-2), 
Sieving and Blending (αWG-3), Compression (αWG-4) and eventually Coating (αWG-5) is 
influenced by the scale-up of the process. The three smallest production scales WG1, 
WG5 and WG30 are located at the R&D facilities of the Janssen Group (Johnson & 
Johnson) in Beerse, Belgium. The industrial manufacturing scale WG240 is operated at 
the manufacturing site of the Janssen Group in Gurabo, Puerto Rico. In the Direct 
Compression (DC) scenario of the second comparative analysis, the wet granulation step 
disappears. Using SPSS Statistics, a power-law experience curve was established for 
this manufacturing technology at plant level (β). An experience curve accounts for the 
scaling effects and learning effects (efficiency gains in technology over time) since 
easily 10 years can lay between testing at lab scale and full scale implementation in a 
manufacturing environment. All aforementioned core processes need to be supplied with 
process utilities which are produced at the production plant within the gate-to-gate level 
(β) (e.g. steam production in on-site natural gas boilers) or outsourced to the overall 
industrial level (γ) (e.g. Belgian grid electricity production mix). Utility production and 
interrelated background processes in the industrial metabolism (indirect resource 
demand) are not visualised in Figure 21. 
 
Foreground data at process (α) and plant (β) level were gathered at the Janssen site in 
Beerse, Belgium, except for the industrial manufacturing scale (WG240). Data of the 
latter wet granulation system were gathered at the Janssen-Cilag SpA manufacturing 
plant in Latina, Italy, which were used as a proxy for the matching wet granulation 
system in Gurabo, Puerto Rico, except for the outsourced production (e.g. electricity 
production). During the timeframe of the project, it was not possible to analyse the 
production plant in Puerto Rico. However, the foreground production process is exactly 
the same in Latina (Italy) as in Gurabo (Puerto Rico). Both production sites of Johnson 
& Johnson are equipped with a large scale top spray fluid bed granulator, consuming a 
fairly equal amount of resources, except for spatially differentiated background 
processes (e.g. electricity production). Targeted data to derive environmental stressors 
were found in operational batch reports, validation reports, cleaning procedures, 
equipment manuals, P&IDs, commissioning files, MSDS files, Bill of Materials (BOM) 
and economic procurement data (see Table 3 in Chapter 4.2.4). With these data, mass 
and energy balances could be established to be used in the qualification and 
quantification of interactions of the process and plant level with the industrial 
metabolism. Background data for the processes in the industrial metabolism at γ level 
were extracted from the ecoinvent v2.2 database (Frischknecht and Rebitzer, 2005), 
except for the API synthesis. Data on the API production processes were retrieved out 
of a range of formerly conducted studies of similar synthesis steps (some of them carried 
out at the same plant) as an average proxy since no ecoinvent data was available (Van 
der Vorst et al., 2009a; Wernet et al., 2010; De Soete et al., 2013; Van der Vorst et al., 
2013). This way, resource extraction was calculated back to the extraction of elementary 
natural resources to be characterized in the Life Cycle Impact Assessment (LCIA). 
 
The analysis conducted at process (α) and plant (β) level was performed through Exergy 
Analysis (EA) evaluating the quantity and quality of material and energetic resource 
consumption based on the second law of thermodynamics (Apaiah et al., 2006; 
Hammond, 2007). At cradle-to-gate (γ) level, the environmental stressors affecting the 
resource use impact category were quantified by the Cumulative Exergy Extracted from 
the Natural Environment (CEENE), subdividing resources in seven subcategories. This 
Life Cycle Impact Assessment (LCIA) method covers (1) Renewable resources other 
than biomass, (2) Fossil resources, (3) Nuclear energy, (4) Metal ores, (5) Minerals and 
mineral aggregates, (6) Water resources and (7) Land occupation and biomass 
production (De Meester et al., 2006, Dewulf, Bösch, 2007a). More detailed information 
about EA and ELCA was presented in Chapter 1.4 and 4.2.6. 
 
The calculation methods used to compute the exergy content of resources was already 
described in Chapter 4.2.6. What follows below is a very brief overview of the most 
important principles and formulas. At process (α) and plant (β) level, the chemical 
exergy content of components was computed based on the reference conditions 
introduced by Morris and Szargut (1986). For organic chemicals, the group contribution 
method was used. As for inorganics, the Gibbs free energy of formation was calculated 
and taken into account (Szargut et al., 1988; Szargut et al., 2005). The physical exergy 
of material and energetic resources (e.g. hot water and steam) was calculated according 
to the following formula: 
𝐸𝑥𝑃𝐻 = (𝐻 − 𝐻0) − 𝑇0 × (𝑆 − 𝑆0)  
in which 𝐻0, 𝑇0, 𝑆0 are the enthalpy, the temperature and the entropy at its reference 
state (𝑇0 = 298.15 K and 𝑝0 = 101.325 kPa) respectively (Szargut et al., 2005). 𝐻 and 𝑆 
are the respective enthalpy and entropy of the stream under consideration. The following 
derivation was used to calculate the physical exergy content of compressed air: 
𝑒𝑥𝑃𝐻 =  |𝑐𝑝 × [(𝑇 − 𝑇0) − 𝑇0 × ln
𝑇
𝑇0




in which 𝑐𝑝 is the isobaric specific heat capacity of air, 𝑅 the universal gas constant and 
𝑇0 and 𝑝0 the temperature and pressure of the reference state respectively (Cornelissen 
and Hirs, 2002). 𝑇 and 𝑝 are the respective temperature and pressure of the compressed 
air volume. 
 
Conducting a combined process and life cycle analysis implies the inclusion of a large 
quantity of interrelated processes and production factors or environmental stressors (e.g. 
resource use, land use, etc.) in the industrial metabolism (in this case specifically the 
fine chemical, pharmaceutical and energy sectors). In accounting for the indirect 
demand of the industrial background system to produce one functional unit (daily 
intake), one inherently adopts process specific assumptions and limitations with respect 
to the ecoinvent background database or formerly conducted studies regarding 
geographical location, time horizon, production scale, etc. In conducting this LCA, 
specific attention was paid to outsourced utility production such as electricity 
production, especially in the case of WG240, where the pharmaceutical manufacturing 
site of Gurabo (Puerto Rico) was taken as a proxy for the Latina site (Italy). Zooming in 
on the foreground system, fewer assumptions needed to be made since more specific 
process data were available. For all scenarios process and site specific data were 
inventoried and used in the analyses, except for the manufacturing at full scale 
(WG240). For the latter system process specific data were retrieved from Chapter 4.2.4, 
in which the same top spray fluid bed granulation process was analysed at a 
pharmaceutical manufacturing site of the Janssen Group in Latina, Italy (De Soete et al., 
2013). The rationale for this approximation was mentioned above in the description of 
the product systems. 
 
 
Quantitative thermodynamic analysis of all core processes in Drug Product (DP) 
production and Packaging (e.g. dispensing, wet granulation, mixing and blending, 
compression, coating, etc.) required in the manufacturing of PREZISTA® 800 mg by 
Wet Granulation (WG) at four consecutive scales (resp. WG1 = 1 kg/h, WG5 = 5 kg/h, 
WG30 = 30 kg/h and WG240 = 240 kg/h) yielded mass and energy balances and 
eventually exergy balances at the three system boundaries. The latter results in a 
quantified total exergetic resource consumption (MJex/daily intake), which is shown in 
Figure 22. The authors opted for a functional classification of resources according to the 
following subdivision: (1) Active Pharmaceutical Ingredient (API); (2) Excipients; (3) 
Packaging materials; (4) Electromechanical resources; (5) Compressed air; (6) Heating 
media and (7) Cleaning media. 
Figure 22: Cumulative exergetic resource consumption (MJex/daily intake) of four 
consecutive production scales of PREZISTA® 800 mg tablet manufacturing by means of 
Wet Granulation (WG) (resp. WG1 = 1 kg/h, WG5 = 5 kg/h, WG30 = 30 kg/h and WG240 
= 240 kg/h). Results are shown in functional categories at process level (α), plant level (β) 
and overall industrial level (γ) respectively. The consumption and production of cleaning 
media (hot water, Cleaning in Place, detergents, etc.) proved to possess the highest 
influence on the experience curve scope. 
 
At process level (α), total resource extraction for the manufacturing of one daily dose of 
PREZISTA® (in this case one 800 mg tablet) amounted up to 0.44 MJex at smallest scale 
(WG1) while this amount proved to be reduced by 58, 79 and 83% at WG5, WG30 and 
WG240 respectively (Figure 22, Table 8). Since more or less the same amount of 
feedstock materials is needed in the production of one single tablet at different scales 
(apart from minor mass yield changes in the tablet production and material losses due 
to handling and storage), the reduction in integral resource consumption in the scale-up 
of technologies is due to a more efficient production, supply and use of process utilities. 
In this case, the reduction in resource use is due to a reduced consumption of 
electromechanical resources and compressed air, next to more efficient heating 
processes (e.g. electrical heating versus natural gas) and more advanced cleaning 
procedures (e.g. Cleaning in Place, CIP at larger production scales). 
 
Table 8: Percentage reduction of integral resource consumption at scales WG5, WG30 
and WG240 (%) (Reference: WG1). 
 α (process level) β (plant level) 
γ (overall industrial 
level) 
WG5 58 62 23 
WG30 79 83 33 
WG240 83 93 37 
 
 
Since most of the consumed utilities at process level (α) were produced at plant level (β) 
(e.g. steam production and hot water production as cleaning media), total resource 
consumption increased significantly at plant level (β) when compared to process level 
(α). At plant level (β) the total resource extraction for the manufacturing of the 800 mg 
PREZISTA® tablet amounted up to 2.41 MJex at smallest lab scale (WG1), 0.91 MJex at 
WG5, 0.40 MJex at WG30 and 0.16 MJex at industrial manufacturing scale (WG240). 
Percentage reductions of integral resource consumption with reference to the smallest 
lab scale setup (WG1) are listed in Table 8. Figure 22 shows the remarkably high 
contribution of cleaning media to the total exergetic resource demand at small scales 
within these system boundaries (gate-to-gate). Taking into account the applied 
functional unit (one daily intake), more cleaning cycles were needed to produce a certain 
amount of daily intakes compared to production at larger scale. Furthermore, for heating 
of cleaning media, e.g. in the production of a hot water cleaning recipe, electrical heat 
exchangers are used at small scales, while steam heat exchangers (fed by natural gas 
boilers) are used in industrial manufacturing. The exergetic efficiency of the latter 
generally is higher compared to the exergetic efficiency of electrical heat exchangers, 
which explains the contribution reduction of cleaning media to total resource extraction 
at larger scales (Hammond, 2007).  
 
The aforementioned clarification explains the relatively high absolute value of the 
experience factor that was obtained for this technology (-0.57). In the experience curve 
𝑦 = 𝐴 ∗ 𝑥𝐵, 𝑥 indicates the production scale in kg/h, 𝑦 is the exergetic resource 
consumption at plant level (β) in MJex/daily intake, while 𝐴 and 𝐵 stand for the exergetic 
resource consumption at smallest lab scale (WG1) and the experience factor 
respectively. A power-law experience curve 𝑦 = 2.40 ∗ 𝑥−0.57 was obtained with a 
regression coefficient (R²) of 0.99 and a 95% Confidence Interval (CI) on the experience 
factor (-0.57) of [-0.714 -0.416]. The sharply decreasing curve (high scaling factor) is 
mainly due to the inefficient cleaning steps at smaller production scales compared to the 
Cleaning in Place (CIP) at full manufacturing scale as was argued in the previous 
paragraph. 
 
Expanding the boundaries of the product system under study to the overall industrial 
level (γ) reveals mainly the resource demand of outsourced burdens contained in the 
production of Active Pharmaceutical Ingredients (APIs), excipients, packaging 
materials and grid electricity (Figure 22). At smallest lab scale (WG1) it amounts up to 
7.70 MJex/daily intake of which 55% is due to the API production chain, 35% is due to 
the production and supply of cleaning media (highest impact of electricity production 
for the heating of cleaning media) and approximately 6% is due to the production of 
primary and secondary packaging materials. It should be kept in mind that the API 
production is assumed to be operated at full manufacturing scale, as stated previously. 
If the batch sizes of API synthesis steps are not yet at full scale or in case the synthesis 
route is typically a very complex one, the impact contribution of the production steps 
might be even higher (Van der Vorst et al., 2011). At industrial scale (WG240), utility 
consumption per daily intake was reduced significantly at process level (α); 
consequently, the relative contribution of material resources to the cumulative resource 
extraction at overall industrial level (γ) is even higher. 87% of the total 4.88 MJex/daily 
intake is due to the API production chain and 9% is related to the production of 
packaging materials. This high outsourced burden is partly due to the fact that 
PREZISTA® is a high dose drug. Low dose pharmaceuticals generally show a much 
smaller impact due to the API production steps (see Chapter 4.3.4) (De Soete et al., 
2013). Next to the former subdivision of resources in functional categories, the value of 
material and energetic resources can be subsumed as well by their functionality at the 
cradle of resource extraction: (1) Renewable resources other than biomass; (2) Fossil 
resources; (3) Nuclear energy; (4) Metal ores; (5) Minerals and mineral aggregates; (6) 
Water resources; (7) Land occupation and biomass production (Figure 23). This 
extended footprint revealed that about 66% of all extracted resources in the production 
of one daily intake of PREZISTA® are fossil resources, 14% of the footprint is due to 
land occupation and biomass production while 8%, 7% and 4% is due to water resources, 
nuclear energy and renewable resources other than biomass respectively. Linking both 
ways of classifying resources disclosed that both API and manufacturing utilities 
(heating media, electromechanical power, cleaning media) are highly correlated with 
the amount of fossil resources required through the supply chain, whereas primary and 
secondary packaging materials mainly influence the contribution of land occupation 
induced by biomass needs. The former can be justified by unravelling the complex 
industrial metabolism of the API synthesis. Especially the use of solvents, working at 
high temperatures and complex multistep synthesis routes explain the carbon intensity 
of APIs. On the other hand, the latter relationship between the use of packaging materials 
and the contribution of land occupation and biomass to the total resource footprint is to 
be clarified by the land intensive paper and cardboard production. At smaller scales, the 
relative contribution of fossil resources slightly increases because of the extra fuel 
resources needed in the production and relatively inefficient heating of cleaning media. 
The general trend revealed that industrial manufacturing in larger batches is less 
resource intensive (up to 37%). 
 
Since all existing scales of wet granulation used in pharmaceutical tablet manufacturing 
were analysed and studied, it seems reasonable to recognize the power-law relationship 
𝑦 = 2.40 ∗ 𝑥−0.57  and the rather high slope of the experience curve of resource 
extraction in pharmaceutical tablet manufacturing when enlarging production scales. 
The establishment of such experience curves can trigger a closer look at the underlying 
- more generic - principles of scaling/learning/experience factors applied to different 
technologies. 
 
The development of the PREZISTA® 800 mg tablet on different scales emerged from 
patient compliance reasons. About half of the patients taking PREZISTA® 400 mg took 
PREZISTA® 2 x 400 mg at the same time to get to their required daily intake. 
Unfortunately, HIV patients need to take even more medicines to treat the complications 
of their HIV infection (e.g. pneumonia). Reducing the daily amount of pills offers a 
better life quality from a patient compliance point of view. As a consequence, the 
development of a PREZISTA® 800 mg tablet was favourable from both a social and 
economic point of view. Through this section, the resource oriented environmental point 
of view in comparing PREZISTA® 800 mg and PREZISTA® 2 x 400 is highlighted, 
representing one aspect of the environmental consequences of developing PREZISTA® 
800 mg. 
 
When comparing PREZISTA® 2 x 400 mg produced by Direct Compression (DC) and 
PREZISTA® 800 mg produced by Wet Granulation (WG) at process level (α), a 
decrease in resource demand of 13% was found, mainly due to the more efficient 
packaging phase in the production of PREZISTA® 800 mg tablets and the use of more 
complex excipients in the production of PREZISTA® 2 x 400 mg tablets. However, 
when analysing the different production processes it seems that the process mass yield 
is higher in DC compared to WG. As a result, more API and excipients is needed in 
order to produce one daily intake of PREZISTA® 800 mg since more material is lost. 
The extra resources extracted from the natural environment to produce this lost amount 
of API and excipients elsewhere in the industrial network together with the energy 
intensity of the granulation step neutralize the advantages of the more efficient 
packaging of PREZISTA® 800 mg within the cradle-to-gate analysis. At overall 
industrial level (γ), the absolute amount of resource extraction in the manufacturing of 
PREZISTA® 2 x 400 mg and in the manufacturing of PREZISTA® 800 mg shows no 
significant difference (5.14 versus 5.15 MJex/daily intake). However, out of Figure 23, 
it can be deduced that a shift appears in relative contributions of resource categories. As 
mentioned above, less API and excipients is needed in the production of PREZISTA® 
2 x 400 mg via DC but the kind of excipients needed in DC is different and of higher 
resource quality compared to WG. More packaging materials per Functional Unit (FU) 
are needed in the production of PREZISTA® 2 x 400 mg compared to the production 
of PREZISTA® 800 mg, which evidences the higher contribution of land occupation 
for biomass production. In general, it could be concluded that in meeting social and 
economic demands by launching the PREZISTA® 800 mg tablet, no trade-off in 
environmental burden occurred. 
 
Figure 23: Cumulative exergetic resource consumption (MJex/daily intake) of 
PREZISTA® 2 x 400 mg (Direct Compression, DC) and PREZISTA® 800 mg (Wet 
Granulation, WG30). Results are shown in functional categories (a) and resource 
categories (b) at overall industrial level (γ) (cradle-to-gate). The category ‘other’ includes 
the supply chains of electricity, heating media and compressed air. The results show a 
shift in relative contributions of resource categories to total resource extraction, but no 
significant difference occurs in absolute terms because of the trade-off between the extra 
granulation step in WG30 and the less efficient packaging phase in DC. (Note: categories 
‘metal ores’ and ‘minerals’ in the CEENE footprint are not represented in this figure. In 





In this chapter the effect of scale-up (and learning) and tablet dosage (daily intake) on 
the cumulative resource extraction in the production of one daily dose of PREZISTA® 
was investigated. Overall, the effect of scale-up and learning on the resource 
consumption of Drug Product (DP) production proved to possess a power-law 
relationship 𝑦 = 2.40 ∗ 𝑥−0.57 when shifting from smallest lab scale (WG1 = 1 kg/h) to 
industrial manufacturing (WG240 = 240 kg/h). The main message is twofold. First, 
deriving general trends in the experience curve of established technologies and its 
behaviour is a powerful backbone in the development of forecasting tools. This way, 
one can proactively include environmental indicators in R&D decision trees. Second, 
the author wants to stress the importance of taking into account R&D processes in 
assessing the environmental impact of products in an R&D intensive sector such as the 
pharmaceutical sector. Tablet dosage (2 x 400 mg tablets versus 1 x 800 mg tablet) did 
not significantly affect the environmental burden. The surplus of resources extracted due 
to the energy intensive granulation step in the production of the 800 mg tablet neutralizes 
the benefits of the more efficient packaging of the 800 mg tablet. It could be concluded 
that in meeting social and economic demands by launching the PREZISTA® 800 mg 
tablet, no trade-off in environmental burden occurred. On the long term, future research 
should strive to take into account R&D processes and all services related to pipeline 








De Soete, W., Debaveye, S., et al. (2014). "Environmental Sustainability 
Assessments of Pharmaceuticals: An Emerging Need for Simplification in Life Cycle 
Assessments." Environmental Science & Technology 48(20): 12247-12255.
 
At an ever increasing rate innovative chemistry and technology platforms are reshaping 
pharmaceutical manufacturing environments to become real factories of the future as 
being more productive, lean and flexible (Crabtree, 2010; Bianchi et al., 2011; Rees, 
2011). Within a global perspective, the streamlining of production supply chains tends 
to deliver complete treatments instead of isolated pharmaceuticals to meet customer 
demand (Bianchi et al., 2011; Rees, 2011). Whether or not this willingness to strive for 
innovation is a sustainable one can be evaluated using a wide range of assessment 
methods and indicators. With respect to the fine chemical and pharmaceutical industry, 
process oriented metrics such as Process Mass Intensity (PMI) and the E-factor are 
already known for a while, unlike life cycle based metrics which have been introduced 
occasionally in assessment methods adopted by big pharma (Jiménez-González, 2000; 
Jiménez-González et al., 2004a; Lapkin and Constable, 2009; Jimenez-Gonzalez et al., 
2011). Various Life Cycle Assessments (LCAs) were conducted in primary and 
secondary pharmaceutical manufacturing comparing different types of chemistry and 
technologies to support decision makers (e.g. batch versus continuous pharmaceutical 
manufacturing) (Jiménez-González et al., 2004a; Dewulf et al., 2007b; Wernet et al., 
2010; De Soete et al., 2013; Van der Vorst et al., 2013). Next to detailed case studies, 
generic tools were developed to assess the environmental sustainability of 
pharmaceutical products (Curzons et al., 2007; Van der Vorst et al., 2011). Testimony 
to this is for instance the streamlined life cycle assessment tool based on 
GlaxoSmithKline’s FLASC™ tool (Fast Life Cycle Assessment of Synthetic 
Chemistry), developed by leading members of the American Chemical Society (ACS) 
Pharmaceutical Roundtable (PR) such as GSK, DSM and BMS (Curzons et al., 2007; 
Jiménez-González et al., 2013). Recent developments in the field of Product 
Environmental Footprinting (PEF) and Product Category Rules (PCR) triggered a 
debate on how to assess the environmental sustainability of a company’s product 
portfolio (European Commission, 2013). This led to a challenging discussion about 
assessing averaged product categories or product groups rather than single products in 
identifying hotspots and estimating the total environmental sustainability of one’s 
product portfolio. By all means however, a case by case system comparison at any level 
of aggregation would be a complex, time-consuming task. A methodological framework 
in which forecasting models are used to predict environmental burden of products could 
be favourable to avoid time-consuming case studies. To facilitate the establishment of 
such a framework, correlation models between process parameters and environmental 
impact of products or product groups would be a first step. Formerly performed research 
by e.g. Wernet et al. already proved the dependency of some environmental impact 
categories on molecular structures (Finechem tool), however when supply chain data is 
accessible in an organization, readily available Enterprise Resource Planning (ERP) data 
on procurement, process operational variables (e.g. time, temperature, pressure), Bill of 
Materials (BOM), etc. could be integrated and would be a preferred way to derive the 
environmental impact of products and processes (Fischer and Hungerbuhler, 2000; 
Wernet et al., 2009). The author does acknowledge that in many organizations, 
additional efforts have to be made to reach this level of data management integration. 
 
In the scope of the study performed in this chapter, the authors first examine the 
environmental sustainability of the production of five Active Pharmaceutical 
Ingredients (APIs), comprised of 40 different chemical synthesis steps in total (Table 
9). With focus on cumulative resource extraction, results are reported at the overall 
industrial level (γ), taking into account the cradle-to-gate life cycle of the API (Figure 
24). With the use of thermodynamic Life Cycle Analysis (LCA), process inefficiencies 
are localized throughout the supply chain, identifying the hotspots of resource 
consumption. From a process engineering point of view, this is useful knowledge with 
respect to process optimization. The influence of the nature of deployed resources (e.g. 
building blocks, solvents, etc.) and used equipment on the integral resource consumption 
through the complete supply chain of API synthesis are highlighted, which in turn 
contributes to the created knowledge platform related to resource extraction during the 
synthesis of an API. This knowledge platform creation enabled the authors to propose 
justified parameters in the prediction of the real impact of API synthesis processes on 
our natural resource supply. 
 
Subsequently, usefulness of correlation models is proven compared to averaged product 
groups as a simplification of LCA applications. Several predictor variables such as 
process operational parameters or simple process-oriented resource consumption 
indicators are used for the modelling of the cumulative resource consumption of 
chemical synthesis steps through the supply chain (γ). To find a justified balance in 
significant model complexity and embedded information on the one hand and usability, 
readily availability of data and capability of merging models with existing ERP data 







In order to arrive at an environmental sustainability assessment from a resource point of 
view of five Active Pharmaceutical Ingredients (APIs), first a qualitative analysis of 40 
chemical synthesis steps was performed by studying 40 Batch Production Reports 
(BPRs), also known as the recipes, containing detailed process dependent data (e.g. time, 
temperature, pressure, etc.) of 2 839 Basic Operations (BOs) (e.g. cooling, heating, 
pumping, purging, etc.) (Table 9). For each chemical synthesis step, a BPR was 
available as illustrated in Figure 24 for Levocabastine production. 
Table 9: Number of Batch Production Reports (BPRs) and Basic Operations (BOs) in the 
production of five Active Pharmaceutical Ingredients (APIs). 
API # BPRs # BOs 
(A) Domperidone 10 492 
(B) Risperidone 7 502 
(C) Ketoconazole 8 733 
(D) Mitratapide 7 471 
(E) Levocabastine 8 641 
 
 
Figure 24: Simplified flowchart of Levocabastine production visualized within the three 
system boundaries of data inventory: process level (α), plant level (β) and overall 
industrial level (γ). Mind that in this study, the Active Pharmaceutical Ingredient (API) is 
the final product (flow G). Downstream processing into dosage forms (e.g. liquids), 
packaging, distribution, use phase and End-of-Life phase are not taken into account (red). 
The blue part indicates the core processes of the value stream and their upstream supply 
chain, while the green parts indicate utility production and waste treatment (downstream 
supply chain). These green indicated processes are supporting all synthesis steps, not 
merely step 1 and 8, as postulated in this flowchart as a matter of simplifying complexity. 
 
At process level (α), quantification was performed by constructing mass and energy 
balances of each BO so as to map all inputs and outputs of a BO to its primary end 
product. For quantification at plant level (gate-to-gate, β) and overall industrial level 
(cradle-to-gate, γ), process data was coupled with a model to analyse integral resource 
consumption of individual chemical production processes in a multipurpose 
pharmaceutical production plant of Janssen Pharmarceutica NV, developed by Van der 
Vorst et al in 2009. The model takes into account all utilities (e.g. steam generation, 
compressed air production, etc.) and waste treatment facilities (e.g. waste water 
treatment facility, distillation, etc.) needed to support the BOs at plant level (β) (Figure 
24) (Van der Vorst et al., 2009a). Furthermore, it links back this on-site utility 
production and waste processing to industrial products and processes in the cradle-to-
gate approach (γ) (e.g. natural gas to feed the steam generators), thereby coupling it with 
the ecoinvent v2.2 life cycle database, in order to create a complete Life Cycle Inventory 
(LCI) (Frischknecht and Rebitzer, 2005). Mind that what is called ‘waste’ and ‘waste 
treatment’ in this chapter is not necessarily reflecting the definitions of the EU Waste 
Framework Directive and its Flemish implementation (European Parliament, 
19/11/2008). Waste is defined as any stream not contributing to the patient value of the 
final product, from a lean manufacturing point of view (Crabtree, 2010). 
 
The Life Cycle Impact Assessment (LCIA) was done through Exergetic Life Cycle 
Impact Assessment (ELCIA) at the overall industrial or cradle-to-gate level (γ) (Szargut 
et al., 1988; Cornelissen, 1997; Cornelissen and Hirs, 2002; Dewulf and Van 
Langenhove, 2002; Dincer and Rosen, 2004; Szargut et al., 2005; Apaiah et al., 2006; 
Amini et al., 2007; Tsatsaronis, 2007; Dewulf et al., 2008; Dewulf et al., 2010; Herms, 
2011). The Functional Unit (FU) is considered to be one mole of API. The indicator 
used is the Cumulative Exergy Extracted from the Natural Environment (CEENE) (De 
Meester et al., 2006; Dewulf et al., 2007a).  
 
Based on the conducted case studies, a dataset with candidate predictor variables was 
constructed for which data of all 40 synthesis steps was inventoried at the Janssen 
Pharmaceutica NV full scale manufacturing plant in Geel, Belgium (Table 10). In order 
to predict the LOG (CEENE) of a pharmaceutical synthesis step, the Functional Unit 
(FU) is considered to be 1 mole of intermediate product. 15 variables were proposed, 
subdivided in four categories: (1) Process-oriented resource indicators; (2) Process 
operational parameters; (3) Equipment parameters and (4) Chemistry parameters. For 
this, Enterprise Resource Planning (ERP) systems, BPRs, equipment manuals, 
validation data, etc. were consulted. 
Table 10: Dataset with candidate predictor variables for which data of all synthesis steps 
were inventoried. 15 variables were proposed, subdivided in four categories: (1) Process-
oriented resource indicators; (2) Process operational parameters; (3) Equipment 
parameters and (4) Chemistry parameters. 
 
Variable Unit Description 
Process-oriented resource indicators 
Organic Solvent L/mole Total net(*) consumption of organic solvents in an intermediate synthesis step 
PMI kg/kg Process Mass Intensity:  
Quantity of raw materials input of an intermediate synthesis step (kg)
Quantity of product output from an intermediate synthesis step (kg)
 
PMI*MW kg/mole Process Mass Intensity times Molecular Weight:  
Quantity of raw materials input of intermediate synthesis step (kg)
Quantity of product output from an intermediate synthesis step (mole)
 
Molar Efficiency mole/mole Output moles of product from an intermediate synthesis step (mole)
Input moles of product of raw materials in an intermediate synthesis step (mole)
 
Process operational parameters 
Δt s/mole Time duration of an intermediate synthesis step per mole output 
ΔT °C/mole Absolute reaction mass temperature difference in an intermediate synthesis step per 
mole of output 
Equipment parameters 
# Reactors units/mole Number of reactors used in an intermediate synthesis step per mole output 
# Filters units/mole Number of filters used in an intermediate synthesis step per mole output 
# Tanks units/mole Number of tanks used in an intermediate synthesis step per mole output 
# Centrifuges units/mole Number of centrifuges used in an intermediate synthesis step per mole output 
# Dryers units/mole Number of dryers used in an intermediate synthesis step per mole output 
# Fixed equipment units/mole Σ(# Reactors, # Filters, # Tanks, # Centrifuges, # Dryers) 
Chemistry parameters 
Addition /mole The value of this boolean parameter is equal to 1 if the dominant type of reaction in 
an intermediate synthesis step is an addition type of reaction. In all other cases, the 
value is equal to 0 
Substitution /mole The value of this boolean parameter is equal to 1 if the dominant type of reaction in 
an intermediate synthesis step is a substitution type of reaction. In all other cases, 
the value is equal to 0 
Elimination /mole The value of this boolean parameter is equal to 1 if the dominant type of reaction in 
an intermediate synthesis step is an elimination type of reaction. In all other cases, 
the value is equal to 0 
(*) Total net consumption of organic solvents takes into account the amount of recuperated solvent through solvent 
recovery by distillation. 
 
In building the multiple linear regression models, one predictor variable was eliminated 
each time in order to end up with a simplified linear regression with only one predictor 
variable (backwards stepwise linear regression modelling) (Draper and Smith, 1981). 
For this, SPSS Statistics was used as a software package. Elimination of predictor 
variables was based on their significance (p<0.05), co-correlations between predictor 
variables and readily availability of data (Hocking, 1976). In order to evaluate models, 
the following selection criteria were proposed: (1) R² and (2) CI width. The squared 
residuals (R²) or the determination coefficient is that fraction of the variance that can be 
clarified by the regression model while the width of the Confidence Interval (CI) is the 
averaged distance between the upper and lower boundary of the 95% confidence interval 
and is expressed in kJex/moleintermediate. 
 
In order to be able to compare the multiple linear regression approach with the product 
group approach, the average value of the LOG(CEENE) dataset was used. The 
correlation was evaluated comparing the R² of the constant average value with the R² of 







Throughout the results and discussion chapter, the hotspots in resource consumption 
will be represented by means of seven functional categories: (1) chemicals; (2) 
electromechanical power; (3) heating media; (4) cooling media; (5) inert gasses (6) 
cleaning agents and (7) transport and treatment. Aforementioned resource categories do 
account for their supply and treatment or disposal as well (e.g. (1) production and use 
of chemicals, waste treatment and disposal). An additional and parallel subdivision of 
resource consumption will be provided according to the CEENE impact categories. 
 
Out of the mass and energy balances at the overall industrial level (γ), Exergetic Life 
Cycle Impact Assessment (ELCIA) resulted in cumulative resource consumption data 
for the production of five Active Pharmaceutical Ingredients (APIs), comprising 40 
synthesis steps. The total cumulative resource consumption proved to amount up to 4.3 
± 3.0 GJex/moleAPI, indicating a very wide spread between the five respective APIs. 
While the spread on the absolute cumulative resource consumption is rather high, Figure 
25 explicitly indicates a recurrent pattern in the relative contribution of chemicals and 
their production on the one hand, and utilities and their production on the other hand. 
Chemicals showed to account for approximately 80% to cumulative resource 
consumption while utility production roughly consumes 20% of cumulative resource 
extraction in fine chemical and primary pharmaceutical production, confirming earlier 
findings in environmental sustainability assessments in the energy intensive 
pharmaceutical industry of e.g. (Wernet et al., 2010) and (Van der Vorst et al., 2011). 
For all that, this study provides a further breakdown of the contribution of chemicals to 
the total cumulative resource extraction. Of all chemicals considered, the building 
blocks used in the beginning of the synthesis steps proved to be responsible for 22.5 ± 
9.3%, whereas reagents proved to account for 10.2 ± 5.9%. Solvents showed to be the 
biggest contributor by far with 67.2 ± 12.7%, while catalysts showed almost no 
contribution to total resource extraction due to chemicals (0.1 ± 0.1%). The large spread 
on the contribution of chemical building blocks (which also induces a larger spread on 
reagents and solvent use) can be explained by unravelling the synthesis routes of the 
five APIs. Depending on the chemistry and the structure of the final API, some synthesis 
routes may start with relatively simple building blocks. More complex APIs may require 
rather complex building blocks from the overall industrial environment which causes 
their synthesis route at the pharmaceutical manufacturing plant not to start from scratch 
consequently. Out of Figure 25, which indicates the contribution to cumulative exergetic 
resource consumption through functional categories (%) in the production of (A) 
Domperidone; (B) Risperidone; (C) Ketoconazole; (D) Mitratapide and (E) 
Levocabastine at the overall industrial level (γ), it is clear that Levocabastine does not 
correspond to the 80%/20% rule of thumb that was proposed above. For that reason, the 
next paragraph specifies the production of Levocabastine in a more detailed way, in 
order to fully understand the striking difference with the other four cases. 
 
Figure 25: Contribution to cumulative exergetic resource consumption (%) in the 
production of (A) Domperidone, (B) Risperidone, (C) Ketoconazole, (D) Mitratapide and 
(E) Levocabastine at the overall industrial level (γ). The contribution to resource 
consumption is expressed in functional categories. Chemicals showed to account 
approximately for 80% to total resource consumption while utility production roughly 
consumes 20% of resource extraction in fine chemical and primary pharmaceutical 
production. Exception within these five cases is Levocabastine with its high demand for 





With 8.73 GJex/moleAPI, Levocabastine showed to be the highest contributor of all cases 
to the cumulative exergetic resource extraction, but it also proved to possess a 
remarkable difference in relative contributions. Unmistakable was the hotspot 
contribution of electromechanical resources (2.14 GJex/moleAPI). Looking back to the 
Basic Operations (BOs) occurring in the respective synthesis steps of Levocabastine 
(Figure 24) revealed the physical origin behind this result. While step 4 is most 
favourable in terms of thermodynamics, step 5, 7 and 8 show significant 
electromechanical exergy consumption due to extensive mixture stirring and subsequent 
drying operations. In total, more than 50 hours of drying at 70°C demand power 
consumption to pump drying air and to stir the wet powder. The long duration (predictor 
variable Δt) of these BOs causes the electromechanical resources to contribute to a 
higher extent to total resource consumption compared to the other cases. The findings 
on the relevance of process oriented parameters (e.g. Δt) and equipment parameters 
contributed to the establishment of the set of candidate predictors in the multiple 
regression modelling as well. From another point of view, the resource footprint 
(according to the relevant CEENE categories) was investigated and related to the high 
demand for electrometrical resources. Figure 26 shows the cumulative exergetic 
resource consumption (GJex/moleintermediate) through the eight step synthesis pathway of 
Levocabastine. Bearing in mind that the green electricity mix used at the manufacturing 
site of Janssen Pharmaceutica NV in Geel was taken into account as a background utility 
in the used model of Van der Vorst et al., Figure 26 clearly relates the high demand for 
electromechanical resources in step 5, 7 and 8 to an increased demand of land 
occupation, biomass production and fossil resources at the cradle of resource extraction. 
As a result, aforementioned resource categories showed to be the most important 
hotspots in the cumulative resource consumption of the full synthesis pathway of 
Levocabastine (Figure 26). Mind that synthesis step 6 is performed parallel to the linear 
route of step 1 to 5, as became clear out of Figure 24. In step 7, the CEENE of both 
routes and extra resources used in synthesis step 7 adds up to the total CEENE of this 
step. 
 
Figure 26: Cumulative exergetic resource consumption (GJex/moleintermediate) through the 
eight step synthesis pathway of Levocabastine. Contribution to resource consumption is 
expressed according to the relevant CEENE categories. This figure clearly relates the high 
demand for electromechanical resources in step 5, 7 and 8 to an increased demand of land 
occupation, biomass production and fossil resources at the cradle of resource extraction. 
 
To conclude, it was observed that there was little variance in the relative contributions 
of functional categories to total cumulative resource extraction. Except for 
Levocabastine, the results were in line with earlier statements of (Wernet et al., 2010). 
On the contrary, the spread on the absolute values of cumulative resource extraction 
proved to be considerably large (4.3 ± 3.0 GJex/moleAPI). With a factor 10 difference in 
absolute cumulative resource extraction, it makes no sense to use product groups as an 
estimation of the impact of a certain product. Out of these findings the emergence 
arouses to construct correlation models to estimate the absolute cumulative resource 
consumption through the complete supply chain (γ) to a better extent than just with an 
average value of product groups. 
 
The results obtained from the above mentioned case studies reveal the need for a 
pharmaceutical company to assess the order of magnitude of their cumulative resource 
consumption (γ), rather than the relative contribution of different sources (which is 
reasonably of the same order of magnitude). This can be done by introducing an average 
value for product categories or through forecasting modelling. In order to select 
appropriate predictor variables to be used in the multiple linear regression models, the 
following line of thought was pursued. First, all candidate predictors where tested on 
their distribution (Mosteller and Tukey, 1977). To assure the normal distribution of 
candidate predictors, logistic or square root transformations were performed according 
to the nature of the original Poisson distribution of the candidate predictors (Mosteller 
and Tukey, 1977; Weisberg, 1980; Huijbregts et al., 2010). Next, single regressions of 
all 15 single predictor variables were computed to test which parameters could best 
estimate the response variable Cumulative Exergy Extracted from the Natural 
Environment LOG(CEENE) of a pharmaceutical synthesis step. Figure 27 shows that 
process-oriented resource indicators, process operational parameters and the number of 
reactors used in a synthesis step (n = 40) proved to be good predictors of the 
LOG(CEENE). Chemistry parameters showed no correlation at all since they were 
defined as boolean parameter assigning a value of 1 to the most dominant type of 
reaction only. It should be said that a similar correlation could be established for other 
life cycle impact categories as well such as climate change or ozone depletion. 
Huijbregts et al. established relationships between straightforward resource oriented 
indicators (e.g. Cumulative Energy Demand) and indicators within other impact 
categories (e.g. CO2-eq or Ozone Depletion Potential) for a wide range of products 
(Huijbregts et al., 2010). Based on the correlation coefficients in Figure 27, the acquired 
knowledge from identifying aforementioned hotspots in several case studies and 
potential readily availability of data through Enterprise Resource Planning (ERP) 
systems (e.g. organic solvent use versus PMI), five predictor variables were selected out 
of different subcategories so as to construct the five multiple linear regression models: 
(1) Organic Solvent; (2) Molar Efficiency; (3) Δt; (4) ΔT and (5) # Reactors (Figure 27).  
 
Chopter 8: Forecasting and Stream/ining: Simplification in Life Cycle Assessments 
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Figure 27: Linear correlation of LOG(CEENE) of a pharmaceutical synthesis step (n = 
40) with 15 predictor variables, subdivided in four categories: (1) Process-oriented 
resource indicators (grey); (2) Process operational parameters (light green); (3) 
Equipment parameters (pink) and (4) Chemistry parameters (green). Process-oriented 
resource indicators, process operational parameters and the number of reactors used in 
a synthesis step proved to be good predictors of the LOG(CEENE). Chemistry parameters 
showed no correlation at all. Five predictor variables were selected: (1) Organic Solvent; 
(2) Molar Efficiency; (3) Δt; (4) ΔT and (5) # Reactors 
 
 
Figure 28: Model construction procedure (models γA, γB, γC, γD, γE). • indicates the 
logarithm of the calculated LOG(CEENE) (kJex/moleintermediate) values for all 40 synthesis 
steps, ─ is the model prediction of LOG(CEENE) (kJex/moleintermediate) for the 
corresponding steps while … represents the 95% confidence interval (kJex/moleintermediate) 
(n = 40, sorted by increased impact).   
 
Figure 28 represents the construction procedure of the five regression models. The first 
model, model γA includes the complete set of five response variables. For every 
subsequent model (indicated by subscripts B, C, D and E), one predictor variable was 
eliminated from the multiple regression model (according to the procedure described in 
materials and methods, Chapter 8.2.2) so as to finally end up with a regression with only 
one predictor variable.    
 
𝐿𝑂𝐺(𝐶𝐸𝐸𝑁𝐸𝐴)
= 3.575 + 0.269 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡) − 0.693
∗ 𝐿𝑂𝐺(𝑀𝑜𝑙𝑎𝑟 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦) + 0.550 ∗ 𝐿𝑂𝐺(Δ𝑡) − 0.201 ∗ 𝐿𝑂𝐺(Δ𝑇)
− 0.043 ∗ 𝐿𝑂𝐺(# 𝑅𝑒𝑎𝑐𝑡𝑜𝑟𝑠) 
 
Evaluating model γA, prediction variables ΔT and # Reactors showed no significant 
contribution to the prediction of CEENEA (p = 0.13 and 0.79 respectively) and proved 
to be correlated strongly. Moreover their model parameters showed the opposite sign of 
what one would have expected, as a higher ΔT and a higher # Reactors would result in 
a higher cumulative resource demand. Eliminating these two predictor variables resulted 
in model γC: 
 
𝐿𝑂𝐺(𝐶𝐸𝐸𝑁𝐸𝐶)
= 4.280 + 0.266 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡) − 0.709
∗ 𝐿𝑂𝐺(𝑀𝑜𝑙𝑎𝑟 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦) + 0.328 ∗ 𝐿𝑂𝐺(Δ𝑡) 
 
With just a slight decrease in R² (0.856 versus 0.866) model γC showed to be slightly 
more reliable in terms of precision and accuracy than model γA. Due to a lower 
uncertainty in predictor variables, the width of the confidence interval proved to be 
smaller (0.227 versus 0.281 kJex/moleintermediate). As can be seen in Table 11, further 
elimination of predictor variables caused models γD and γE to lose their predictive power 
to a large extent. In case only the use of organic solvent was included, the R² decreased 
to 0.667 and the confidence interval expanded to a width of 0.240 kJex/moleintermediate 
(model γE): 
𝐿𝑂𝐺(𝐶𝐸𝐸𝑁𝐸𝐸) = 5.032 + 0.648 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡)  
This would suggest that a model with three predictor variables (Organic Solvent, Molar 
Efficiency and Δt) would be helpful to provide more intuitive understanding and to 
unravel the physical relationships between simple process-oriented resource indicators 
such as Organic Solvent use and Molar Efficiency and process operational parameters 
such as Δt on the one hand and the cumulative resource consumption of an API synthesis 
step on the other hand. For the reader’s interest, all proposed models can be found in 
Annex A6. Based on the availability of data and the desired accuracy and precision, the 
practitioner may select the most favourable model. Table 11 shows the scores on the 
selection criteria of each correlation. 
Table 11: Resource consumption correlation models and scores on their selection criteria. 
Model Predictor variables R² CI width (kJex/ 
moleintermediate) 
Response variable = LOG(CEENE) 
γA Organic Solvent, Molar Efficiency, Δt, ΔT, # Reactors 0.866 0.281 
γB Organic Solvent, Molar Efficiency, Δt, ΔT 0.865 0.251 
γC Organic Solvent, Molar Efficiency, Δt 0.856 0.227 
γD Organic Solvent, Molar Efficiency 0.741 0.256 
γE Organic Solvent 0.667 0.240 
 
 
The previous paragraph evaluated the predictive power of the five proposed multiple 
linear regression models with the criteria described in the materials and methods section. 
Model γE showed the worst scores on all criteria. Nevertheless, no matter what model 
was used, all models showed a better correlation with LOG(CEENE) than the mean of 
the dataset which equals 5.167 kJex/moleintermediate (R² = 3.40E-30) and represents the 
product group. One can imagine the product group average to be a horizontal curve at 
LOG(CEENE) = 5.167 in Figure 28. 
 
Whereas in literature, the use of organic solvents or the Process Mass Intensity (PMI) 
were postulated to be good estimates of the cumulative resource consumption of an 
Active Pharmaceutical Ingredient (API) synthesis step, the correlation can be optimized 
to a large extent and be more reliable upon inclusion of two more parameters (Δt and 
Molar Efficiency). Depending on the availability of data in one’s organizational ERP 
system, the practitioner can apply one of the models taking into account the reported 
underlying uncertainty. The authors advise to use at least three predictor variables 
whenever possible since models with less predictors score significantly worse on all 
model selection criteria. Including additional predictor variables might in some cases be 
an unnecessary, time-consuming and complicated task which may not benefit the 
predictive character and can eventually weaken the interpretation of such a model. The 
correlation models proposed in this chapter can and will be used in other cases to be 
validated for prediction. In future, ideally, an organization should be able to derive the 
environmental impact of its portfolio from enterprise resource data, linking supply 
chains back to the cradle of resource extraction. This study has taken a step in that 
direction with a strong statement in the discussion of environmental sustainability 
assessment of product groups rather than assessing the real impact of one’s product 
portfolio with available enterprise resource data. The author acknowledges that the latter 
might not be an easy task but it definitely yields a more reliable approach than the 
product group method. The regression formulas are currently adopted by the UK’s NHS 
Sustainable Development Unit (SDU) in their report on how to calculate and 
communicate environmental impacts of pharmaceuticals (NHS Sustainable 
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When Goldratt first introduced his Theory of Constraints (ToC) in The Goal (1984) and 
The Critical Chain (1997), he did not only refer to manufacturing Value Chains (VCs) 
sending the boy scouts on the narrow forest trail (Goldratt, 1997; Goldratt and Cox, 
2014). A metaphoric way of debottlenecking that found its way in various types of 
management, from office management to business management, from visual 
management on the floor to the most advanced planning systems. A few decades before, 
yet another great scientist called Dennis Meadows published his severe concerns on 
exponential growth due to the industrialism and a limited supply of resources (Meadows 
and Meadows, 2007). At first glance, striving towards higher efficiencies and economic 
growth evermore would be in contrast with Meadows’ Limits to Growth. However, 
under the Malthusian ceiling, intensification in processing industries is all about doing 
more with less (Malthus, 1798; Dewulf et al., 2000; Dewulf et al., 2010). Whether it was 
Thomas Malthus, Dennis Meadows or Eliyahu Goldratt that pulled the strings, they all 
shared a complementary vision towards sustainment and sustainability. 
 
Sustainable development in its broadest sense could possibly best be described as 
“development that meets the needs of the present without compromising the ability of 
future generations to meet their own needs”, suggested by Brundtland and the World 
Commission on Environment and Development (WCED) (Brundtland, 1987). The 
aforementioned definition lacks a comprehensive description of ‘needs’. From an 
individual or microeconomic perspective, we could reflect the needs of a human being 
to the Maslov Hierarchy and the utility of that human being given to a certain attribute 
of a product or service (Kainuma and Tawara, 2006). However, from a societal point of 
view, sustainability professionals often subdivide between economic prosperity, 
environmental sustainability and social sustainability (the triple bottom line) (Elkington, 
1998; Taormina and Gao, 2013). 
 
Next to sustainability and sustainable development, sustainment is key in quantifying, 
monitoring and eventually maintaining our efforts towards sustainable development, 
continuous improvement, Operational Excellence, etc. Measuring performance 
(prosperity, environmental sustainability and social sustainability) is of utmost 
importance to evaluate continuous improvement actions or eco-design alternatives in 
early R&D development stages. A widely used methodology to assess sustainability is 
Life Cycle Sustainability Assessment (LCSA), reaching out to economic prosperity 
(Life Cycle Costing, LCC), environmental LCA and social aspects through SLCA. 
Environmental LCA has extensively been used since the past decade to assess whether 
or not a (established, enabling or prospective) technology or product is environmentally 
sustainable, to perform eco-design, for sustainability reporting, to comply with NGO 
requests, but above all for internal process optimisation (Van der Vorst et al., 2009b; De 
Soete et al., 2013; Jiménez-González et al., 2013; De Soete et al., 2014a; De Soete et 
al., 2014b; Jimenez-Gonzalez and Overcash, 2014; Cespi et al., 2015; Kralisch et al., 
2015). To this extent it overlaps strongly with the field of Operational Excellence (OE) 
and the Lean heritage. Until now, the link between ICT tools for Operational Excellence 
or Business Administration (BA) in general is hardly connected to the data-intensive 
process modelling software such as ASPEN® or LCA software such as Simapro or 
OpenLCA. 
 
Several studies, regulations and European Directives have shown the need for a more 
efficient way to perform LCA through value chains (Cespi et al., 2015; European 
Commission, 2015b; Passer et al., 2015). As an example, Environmental Product 
Declarations (EPDs) are becoming mandatory for all building materials within the 
construction sector (Passer et al., 2015). An EPD is a standardised type of report from 
an LCA. This means that for every building material sold on the market, an LCA has to 
be conducted, nearly impossible without a certain degree of automation. Together with 
the European Centre of Innovation and Technology (EIT) and the EIT on Raw Materials, 
the Digital Agenda (DA) and the Internet of Things (IoT), the European Commission 
sets objectives for the growth of the European Union (EU) by 2020 (ISA, 2015). The 
DA proposes to better exploit the potential of Information and Communication 
Technologies (ICTs) in order to foster innovation, economic growth and progress. With 
a strong policy driven focus, the emergence of more efficient LCA methodologies and 
their use cases are obviously present. Of interest to the reader, other examples are the 
European Plastics Federation (PlasticsEurope), the Green Procurement Initiative of the 
United Nations Development Program (UNDP), etc. The next paragraph will elaborate 
on the possible bottlenecks in integrating such a system as described above, how we can 
overcome this urge and what are the clear wins towards fully integrating these systems. 
 
 
Depending on the type and scale of organisation, the sector to which it delivers products 
and services and its stakeholders, organisational data is structured in business IT and 
ICT tools and systems. In the processing industry, the horizontal structure of an 
organisation (Production, Planning, Finance, Legal Affairs, Procurement, HR, EHS&S, 
QA/QC, Engineering, Validation, etc.) stores thousands of terabytes (or pages) creating 
a data-dependent structure in need of smart and consistent logging systems. Some of 
them are integrated in so-called Enterprise Resource Planning (ERP) systems, such as 
SAP and Infor LN. ERP systems are used for a variety of applications as shown in Figure 
29, which can potentially be subdivided in four categories: (1) Business Intelligence; (2) 
Enterprise Management; (3) Commercial Applications and (4) Customised ERP 
Systems or modules. A widespread example is production planning, which can be based 
on forecasting, stock levels (push production), a planning rhythm wheel, etc. Whenever 
the market is saturated or is characterised by a stable demand, push production is often 
applied. A Manufacturing Resource Planning (MRP) system steers the production based 
on stock levels and will send orders to suppliers to replenish in-house stock levels. 
 
 
Figure 29: ERP systems are used for a variety of applications, which can potentially be 
subdivided in four categories: (1) Business Intelligence; (2) Enterprise Management; (3) 
Commercial Applications and (4) Customised ERP Systems or modules. A widespread 
example is production planning, which can be based on forecasting, stock levels (push 
production), a planning rhythm wheel, etc.    
 
An ERP system is generally custom configured for a certain enterprise. The customised 
applications of resource planning systems are endless (Res et al., 2011). Such 
customised applications might ease the daily operations of e.g. warehouse management 
(efficient order pick-up, standardised work, etc.). 
 
The introduction of this chapter touched upon the similarity between Lean and 
sustainable manufacturing, between the visions of Goldratt, Malthus and Meadows. 
Product and organisational sustainability could be quantified using organisational 
operational data in a customised ERP module, as has been proposed by De Soete et al., 
2014b. The authors provide correlations (see Chapter 8 and Annex 6) between the as 
candidate predictor variables. Ideally, through machine learning, these correlations can 
be optimised in a customised module. Further elaboration on the feasibility of new 
frameworks is given in chapter 9.3: Proposed pathways for integration. The subchapters 
below describe some of the bottlenecks in relying on ERP data and in the integration of 
tools for corporate and product sustainability assessments. Related to Figure 29 one 
should take into account these bottlenecks in building customised ERP modules. 
 
Production line sensors, logging systems or Supervisory Control And Data Acquisition 
(SCADA) systems are connected with the ERP systems for the different business 
departments to work with through the so-called Manufacturing Execution System 
(MES). The MES could be described as the interface between the plant floor (Gemba) 
and the ERP system. Possible applications of MES are automated equipment, 
maintenance support and process control (Li et al., 2012). Data from particular sensors 
(e.g. temperature sensors, level sensors, flow rate sensors, product homogeneity through 
NIR etc.) that have no direct use in any ERP module might not penetrate through the 
MES layer (e.g. for process control). These types of data are essential in sustainability 
assessments and LCA in general to construct mass and energy balances of the production 
in scope of the analysis. Without modifications on the data submission path to 
customised ERP systems, integrating organisational and product sustainability in ERP 
modules for EHS&S and Product Stewardship is challenging. It will reduce the data 
quality of the LCA and will require more modelling in the end (e.g. through machine 
learning) instead of using primary data. 
 
Following on De Soete et. al. (2014) a feasibility study was performed on using different 
ERP data in forecasting methods for the environmental sustainability of products, as 
postulated in the previous subchapter. The lack of consistency in data feeding into ERP 
systems from e.g. operator entries on waste, solvent use, etc. was perceived to be a 
bottleneck. The use of different units for one and the same physical-chemical variable 
is another bottleneck to get to work on. A proposed way to deal with these 
inconsistencies is the proper use of Standard Operating Procedures (SOPs) and 
sustainment through properly defined Key Performance Indicators (KPIs). These 
management tools are widely used through organisations to foster consistency and to 
reduce variability in production environments leading to increased lead times. However, 
the application of these tools should be more horizontally integrated in order to strive 
for an effective and efficient usage. 
 
Once a comprehensive data system is sustained in an ERP system, Supply Chain (SC) 
transparency becomes a key issue to guarantee data quality and visibility into the 
extended SC. Moreover, it protects any processing company against supply disruptions 
and unbalanced replenishment. In general, it reduces supply risk effectively. 
Transparency will become more and more a key issue in global SCs and will further 
develop as it turns out to be crucial for wider social developments such as globalization, 
the information age, and the shifting role of states in environmental governance. 
Transparency in SCs is bound up with positive connotations: the more transparency the 
better it is for the sustainability of chains and for the empowerment of one’s consumers 
(Mol, 2015). Thus also for customised ERP modules for e.g. sustainability assessments, 
internal SC data management and external SC interfacing, confidentiality issues in data 
transparency of suppliers, etc. are potential risks or bottlenecks to be monitored and 
tackled. 
 
Nevertheless, transparency can only be guaranteed if the supply of raw materials through 
the Supply Chain (SC) is stable and a certain level of business continuity has been 
reached. The importance of business continuity plans is well recognized by 
organizations all over the world that are increasingly operating in a global, complex and 
competitive environment. Their core business and SCs can easily be interrupted by 
economic, social, political, technical and environment related unforeseen events. 
Natural disasters, diseases, financial crises, unreliable supply chains leading to 
disruptions and many more can severely impact growth and performance (Faertes, 
2015). The work of Cheung et. al. (2014) revealed a paradigm shift in which data 
generated by manufacturers within the process industries identify failures which they 
are introducing into the SC (Cheung et al., 2014). This means that transparency and 
reliability are strongly related and a consistent use of data is key to enhance performance 
and avoid disruptions. As a leading example, the pharmaceutical and medical device 
industries are developing Good Supply Practices (GSPs), next to the Good 
Manufacturing Practices (GMP) required by the Food and Drug Administration (FDA) 
and the European Medicine Agency (EMA) in order to foster reliability through the SC 
(Cheung et al., 2014). Despite all, supply disruptions are surely enough all too common. 
To mitigate delivery risk, buyers may either source from multiple suppliers or offer 
benefits to preferred suppliers to improve SC reliability (Tang et al., 2014). These 
incentives towards suppliers can either be direct (investment subsidy) or indirect 
(inflated order quantity). Preferably a mixed model of investment subsidy and/or inflated 
order quantity for the preferred supplier together with multiple supplier sourcing as 
alternative delivery in case of partial disruption is applied (Tang et al., 2014).  
 
It is not hard to imagine that if the physical supply of goods or the delivery of services 
cannot be guaranteed, the penetration of SC data and process data of n-x suppliers to 
end producers is all but apparent. Even though the supply would theoretically be 
completely secured, companies might be resistant to data sharing in order to preserve 
their competitive advantage in the global environment (De Soete et al., 2014b). 
However, well considered business models can ensure process data sharing with a 
certain degree of aggregation and black box modelling throughout the SC to enhance 
the use of primary process data of suppliers for e.g. sustainability assessments through 
Life Cycle Assessment (LCA). These data sharing models with care for business 
integrity and confidentiality has the power to lead to shared value through the SC, since 
LCA can indicate priorities for optimisation and resource consumption reduction for all 
n-x suppliers. If the model fails to deliver reliable data, it might be better to use 
secondary (averaged) market data as proxy values to reduce data uncertainty of the LCA 
results. Nonetheless, one should strive for connecting suppliers as much as possible and 
enhance the use of primary data to create shared value approaches and facilitate 
assessment of product and corporate sustainability in general.  
 
Next to data penetration, consistency, transparency and reliability, another bottleneck in 
this non-exclusive list is related to the programming and interfacing of different data 
formats to perform sustainability assessments. While correlation models of processing 
data with environmental data can be made with R, SPSS or any program for statistical 
analysis, Life Cycle Inventory (LCI) database exchange formats are commonly working 
with extensions such as .xml (extended mark-up language, such as in the ecospold 
formatting), .oLCA (OpenLCA database format) etc. (Ciroth et al., 2013; De Soete et 
al., 2014b). To convert LCI databases to work with in different software packages, the 
so-called OpenLCA format converter was developed by GreenDelta GmbH (Ciroth et 
al., 2013). However, engineering modelling software such as ASPEN and LCI databases 
do not speak the same language. Therefore, interfacing different types of data is still to 




The previous chapter highlighted some of the most abundant bottlenecks experienced in 
implementing sustainability assessments through Life Cycle Assessment (LCA), related 
to operational management within manufacturing and Supply Chain (SC) environments. 
Figure 30 illustrates a highly simplified integration of IT/ICT tools in manufacturing 
environments, where several layers can be distinguished (Schmidtmann et al., 2009; 
Hanel and Felden, 2011). Bearing in mind the tools and principle heritage of Lean 
Manufacturing and Six Sigma Management, everything starts at the Plant Floor or 
‘Gemba’, the place where value is essentially created (Bicheno and Holweg, 2009; 
Crabtree, 2010; Wilson, 2010; Liker and Convis, 2012). On the Floor, the bottom up 
construction of data systems starts with sensors based on all kinds of technologies 
(volume sensors, mass sensors, structure sensors, temperature sensors etc.). Most of 
these sensors send data signals at predefined intervals to logging systems such as 
Supervisory Control And Data Acquisition (SCADA) systems. Some process variables 
such as timings are inserted as queries through an Operator Interface (e.g. provided by 
Siemens) to be used in the construction of Batch Production Reports (BPRs) etc. The 
measured data is send to the next layer in the programming structure, being the 
Manufacturing Execution System (MES). In the MES, process data coming from the 
Floor is being used to create BPRs, calculate performance indicators such as the Overall 
Equipment Effectiveness (OEE), regulate process control systems and many more. The 
manufacturing data systems are connected to the corporate enterprise systems. The third 
layer in the framework is the Enterprise Resource Planning (ERP) system. This third 
layer allows enterprises to manage their resources from both a top down (production 
planning) and a bottom up (replenishment) approach. From NGOs, policy makers, end-
users and the whole stakeholder communities, questions arise on whether or not this 
supply chain and manufacturing is sustainable and safe. When it comes to product and 
organizational sustainability for purposes of Product Environmental Footprinting (PEF), 
Green Procurement and Product Stewardship, data seems to be lacking in order to 
conduct sustainability assessments proficiently. Years of intensive research by means of 
backwards stepwise linear regression modelling and experience proved that primary 
data to perform sustainability assessments often are measured through equipment 
control sensors (e.g. flow rates, temperatures, concentrations, pressures etc.) and sent to 
PLCs and many other systems (De Soete et al., 2014b). Nevertheless, these engineering 
data measurements are in many cases simply not penetrating through the Manufacturing 
Execution Systems (MES) because they seem to be of little value for existing ERP 
applications. 
 
An ERP system is generally customised for a certain enterprise. The customised 
applications of resource planning systems can be adjusted to the needs of an 
organisation. Correlation models between process data (e.g. temperature, mass yield, 
organic solvent use) and environmental sustainability performance (e.g. cumulative 
resource consumption, carbon emissions, etc.) that were found by De Soete et. al. (2014) 
and adopted by the Sustainable Development Unit (SDU) of the British National Health 
Service (NHS) were tested on their feasibility to be integrated in customised ERP 
applications (De Soete et al., 2014b; Penny et al., 2015). It was proven that by combining 
MES data from batch reports (e.g. time duration of a chemical synthesis step), line 
sensors (e.g. operating temperatures), Bill Of Materials (BOM) (e.g. raw material use), 
indicators for environmental sustainability could be derived (e.g. Cumulative Exergy 
Extracted from the Natural Environment, CEENE and the Carbon Footprint, CF) 
(Dewulf et al., 2007a; Weidema et al., 2008; Wiedmann, 2009; Lenzen et al., 2010; Van 
der Vorst et al., 2011; Alvarenga et al., 2013; Taelman et al., 2014). Ideally, these 
aforementioned correlations, engineering modules, design software such as ASPEN are 
to be built in in a customised ERP application for LCA (as visualised in Figure 30) in 
order to couple primary engineering data, Life Cycle Inventory databases (LCI, e.g. 
ecoinvent) and Life Cycle Impact Assessment Methods (LCIAM, such as CEENE and 
CF). The role of these different configurations and to what extent they can be automated 
to generate a ‘life footprint’ will be elaborated in chapter 9.3.2. With the construction of 
customised ERP modules for automated sustainability assessments, corporate and 
product sustainability can be quantified to be used for several applications: Corporate 
Sustainability Reporting (CSR), continuous improvement actions within the 
organisation, marketing, B2B and B2C communications, etc. Ideally, such a system 
should be sustained by the top management by means of e.g. Key Performance 
Indicators (KPIs).  
 
 
Figure 30: General framework for integrated product and organisational sustainability 
and data flux from the plant floor, the MES system, ERP systems, Life Cycle Inventory 
Databases, Impact Assessment Methods and their general translation toward corporate 
and product sustainability. 
 
An exemplary data flux is given below to make the general framework represented in 
Figure 30 more tangible. As a simplification only the packaging phase of the product 
life cycle is taken into account. A packaging line in e.g. the life sciences industries 
consumes the following resources: 
 Material resources: folding box, shipping box, plastics, euro pallet, wrapping 
foil, etc. These flows are generally available in the Bill of Materials, which 
can be extracted from procurement ERP applications. 
 Energetic resources: power consumption of the packaging line, temperatures 
of heating air in case of sealing, flow rates of heating air, compressed air 
consumption, air pressure, HVAC, potentially nitrogen gas flow rates and 
pressures. 
These flows are a lot more difficult to find and are scattered in the data 
management system. For some (e.g. flow rates) one might start from the flow 
rate sensor to the SCADA system which feeds information into the MES. 
Generally, one needs to extract these data from different data management 
systems. 
 Auxiliary substances: cleaning media, C/O resources, maintenance 
resources, etc. 
 
Once all flows with their flow properties (temperature, pressure) are extracted from 
different systems and sensors, mass and energy balances are generated in the customised 
LCA modules. These balances of the so-called foreground system need to be mapped 
with Life Cycle Databases, relating flows entering the site ‘gate’ to the cradle of resource 
consumption in order to generate a cumulative balance. Last, this so-called Life Cycle 
Inventory is subject to impact assessment calculations upon integration of Life Cycle 
Impact Assessment Methods (LCIAM) such as Carbon Footprinting and Resource 
Footprinting. 
 
What has been elaborated in the previous paragraphs is exactly what is meant with 
multidisciplinarity. The multidisciplinary approach goes back to the very diverse team 
of professionals one needs to establish sustainability assessment modules for product 
stewardship, for sustainability reporting and for plant optimisation and integration of 
waste as resources. It is an approach where environmental engineers, business and SAP 
analysts, ICT experts and operational management professionals have to sit together to 
obtain the highest shared added value through one’s supply chain and in-house 
operations. The next chapter provides a non-exclusive list of types of ERP modules for 
LCA and Life Cycle Sustainability Assessment (LCSA) in general.  
 
As has been elaborated in the previous chapters customised ERP modules could offer 
solutions for automated sustainability assessments in manufacturing or SC 
environments where primary data tend to be measured but not or only partially 
penetrating through the MES layer. Depending on the availability, transparency and 
consistency of measured data (Chapter 9.2) from the production line and SC data of n-
x suppliers, the role of the customised ERP module can differ substantially. The three 
subchapters below will highlight the use of regression analysis (touched upon in Chapter 
9.2 as well), engineering modules and engineering design software such as ASPEN. 
 
In environments where data are sufficiently being measured at the production line and 
process data penetration and transparency through the SC are satisfactory, regression 
analysis might offer a solution to generate LCA indicators such as CEENE (cumulative 
resource consumption) or Carbon Footprint directly from readily available data within 
ERP systems. The customised sustainability assessment module would result in a set of 
equations to automatically generate an environmental footprint (could be both resource 
driven and/or emission driven). This option could be classified as the most preferable 
solution when data measurements are relatively abundant, whether or not penetrating 
through the MES layer. Ideally through Machine Learning (ML), the module should be 
able to construct the set of equations and their coefficients (few of them have been 
proposed by De Soete et. al. (2014)) depending on the type of available data in order to 
reduce the uncertainty on the end result (Liu et al., 2007; De Soete et al., 2014b).  
 
In Research and Development (R&D) or other data scarce environments where often 
prospective or enabling technologies are being tested, technology can be broken down 
into so-called unit operations (e.g. evaporation, crystallisation, absorption, etc.). 
Engineering models were developed in e.g. the European PROSUITE FP7 Project in 
order to build mass and energy balances of emerging technologies through a very 
modular approach based on basic unit operations (De Meester et al., 2011). These 
engineering models can be built in a modular way in ERP systems and linked with the 
input data of the engineering models. One should bear in mind that uncertainty and 
variability of the response variable will be characterized with a rather high uncertainty 
in coupling different unit operations, each of them having a certain degree of 
uncertainty. However, this pathway might be very promising for the future to anticipate 
on environmental burdens in an early R&D development stage (De Soete et al., 2014a).  
 
A third example in this non-exhaustive list is the coupling of process engineering 
software such as ASPEN with business ERP systems. In this case the customised module 
serves as an interface between the modelling software and ERP and/or other enterprise 
resource systems. The modelling software is basically feeding into ERP systems in terms 
of integration of systems but maintains its stand-alone character. This can be a preferred 
option in design stages or if one wants to perform scenario analysis, etc. In terms of 
integration of process data and SC data it is probably the least preferred solution to foster 
shared value through the SC actors and automated corporate and product sustainability 
assessments through LCA and LCSA in general. Figure 31 exemplifies how a certain 
interface module could look like. The grey area resembles the software environment 
while the green coloured boxes refer to the four basic steps of LCA. The system 
boundaries applied on the calculations in the modelling environments are indicated in 
yellow. Upon goal and scope definition of the LCA, system boundaries of the process 
(e.g. a chemical synthesis step) to be modelled are applied in ASPEN (optionally with 
supporting utilities such as solvent recuperation through distillation at the plant level, 
otherwise, these data are extracted from ERP systems or LCA databases). The inputs 
and outputs of the process are calculated and used to generate mass and energy balances 
which are then fed into the ERP module, where the Life Cycle Inventory (LCI, based on 
elementary flows only) is constructed through the connection of the mass and energy 
balances with the industrial metabolism through LCA databases. Upon multiplication 
with its characterisation factor, every environmental stressor of the LCI matrix is 
transformed into an environmental impact which is then – according to the method used 
– classified in midpoint or endpoint categories. The LCA results can be interpreted by 
the end-user through varies output options (report, tables, diagrams, etc.). This schedule 
is providing a plausible structure of combining data from different environments to ease 
the interpretation of the above proposed roles of ERP modules. 
 
 
Figure 31: Schematic example of coupling process modelling software (e.g. ASPEN) with 
ERP systems through an interface module with LCA databases (e.g. ecoinvent). The grey 
area resembles the software environment while the green coloured boxes refer to the four 
basic steps of LCA. The system boundaries applied on the calculations in the modelling 
environments are indicated in yellow. This schedule is providing a plausible structure of 
combining data from different environments to ease the interpretation for the reader of 
the above proposed roles of ERP modules. 
 
 
With this study, the author wanted to take the discussion in introducing environmental 
sustainability of products, services and enterprises into business Enterprise Resource 
Planning (ERP) systems one step further. These new ERP applications will foster the 
sustainability transparency and performance of organisations and their Supply Chains 
(SCs). Under the condition that appropriate business models protecting competitive 
advantages are applied, internal optimisation (continuous improvement) through the SC 
actors (n-1, n-2, n-x) can be achieved leading to shared value and Sustainable Supply 
Chain Management (SSCM), facilitated by e.g. the proposed customised ERP modules. 
To get to that point, six important potential bottlenecks were highlighted: (1) Data 
management in organisations; (2) Data penetration through Manufacturing Execution 
Systems (MES); (3) Consistency in data logging; (4) SC Transparency; (5) SC 
Reliability and (6) the language issue. This is a non-exhaustive list of challenges we are 
facing that should be further explored and investigated. One cannot highlight enough 
the importance in B2B communications through the SC to make that happen. SCs are 
complex systems that rarely rely on one sector, thus an inter-sectoral, multidisciplinary 
approach will be necessary. Not but the least important challenge most probably relies 
on the fact that building bridges between disciplines, between academics and industry 
is key in this age of science and information. More specifically, the field of Life Cycle 
Assessment (LCA) can adopt and apply a substantial amount of tools and lines of 
thought from operational management such as the Lean heritage and Six Sigma and vice 
versa; the Life Cycle Thinking (LCT) approach should be more embedded in continuous 
improvement actions and Operational Excellence in order to allocate resources in an 
efficient and effective way to real bottleneck operations. The next step to take would 
ideally be to validate this proposed framework by assembling a team with all 
multidisciplinary aspects and evaluate to what extent and for wat use cases the different 
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To end this dissertation with, the author provides overall conclusions and connects the 
findings of the different chapters in a coherent end result of the work done during this 
PhD. Chapter 10.2 provides a concise guide towards further potential implementation 
of this the results PhD dissertation. Next, Chapter 10.3 until 10.5 disclose a research 
oriented outlook towards future perspectives in the field of (environmental sustainability 
assessment) in the pharmaceutical industry.  
 
While Part 2 merely unveiled the resource footprint of Small (SM) and Large Molecules 
(LM), Part 3 focussed on the applications of Life Cycle Assessment (LCA) and process 
engineering related techniques within the pharmaceutical industry. Chapter 4 assessed 
what has been named in Green Chemistry principles (GC), process intensification and 
Lean manufacturing as ‘introducing flow’. By introducing continuous manufacturing 
one does not only reduce lead times, enables pull production and creates value, one also 
reduces the resource footprint up to 34.0%. Continuous manufacturing has been 
postulated by many authors as one of the innovations of this decade in pharmaceutical 
manufacturing (Borukhova et al., 2015). The assessments done in this thesis were used 
in several business cases to put continuous manufacturing on the agenda as a more 
‘green’ alternative next to the obvious cost saving aspect. Chapter 4 and Chapter 8 
clearly revealed the very fossil intensive character of Small Molecule (SM) production 
through conventional chemical synthesis (up to 80% of the total resource footprint). It 
was of interest to investigate how this related to the environmental footprint of 
biologicals or so called LMs (Chapter 5). Against all expectations (a higher relative 
contribution of water and biotic renewables and a lower fossil resource contribution) the 
fossil contribution to the resource footprint was only moderately lower in relative terms 
for the assessed LMs (in this case Monoclonal Antibodies, MABs) while the relative 
contribution of biotic renewable resources and land use was only moderately higher (on 
average 3.6 and 5.4% respectively). This is basically due to the fact that – even when 
the feedstock is biological (e.g. a cell culture) – industrial processing requires a high 
amount of fossil resources for fermentation and downstream processing (electricity for 
heating the bioreactor vessel jacket and for HVAC, etc.). Chapter 5 also touched upon 
the fact that a fair comparison on product level between SMs and LMs is hard to make 
(typically tablets for SMs and syringes for LMs). The LMs under study are long acting 
platforms for autoimmune diseases requiring only 6 parenteral administrations per year 
instead of one or two tablets a day (depending on the dose) for the SMs. On a compound 
base (product level) the cumulative resource consumption is about 4 times higher for the 
LMs compared to the SMs under analysis, while at treatment level (depending on the 
Defined Daily Dose of the WHO), the SMs score about 250 times worse than the LMs. 
These findings clearly reveal the need for system boundary expansion from the product 
level to the full pharmaceutical treatment level and eventually the healthcare pathway 
and thus a revision of the Functional Unit (FU) used for LCAs in the pharmaceutical 
and medical sector (De Soete et al., 2016b; Debaveye et al., 2016) (see Chapter 10.3 and 
10.5). 
 
Part 3 primarily consists out of a set of methodological advancements in the field of 
resource accounting, LCA and Life Cycle Thinking (LCT) to enhance the usability and 
value for business of implementing such techniques for assessing environmental 
sustainability. Chapter 6 starts with revealing the needs, bottlenecks and upcoming 
challenges for advancing the state of the art. This was done during an intensive study 
period performed at the European Commission’s Joint Research Centre (JRC). Through 
consulting more than 300 stakeholders in the field of environmental sustainability in the 
pharmaceutical and healthcare sector and by applying a set of methodologies (expert 
interviews, stakeholder surveys and roundtable discussions), the following priorities 
were set out as a strategic agenda for future research: (1) expand system boundaries to 
healthcare pathways instead of product level; (2) establish a ‘Node’ in the Life Cycle 
Data Network (LCDN) or a similar life cycle database to improve the availability of life 
cycle data on pharmaceutical production processes; (3) develop harmonised and 
standardised methods and (4) implement engineering software or LCA calculations into 
Enterprise Resource Planning (ERP) systems to enable process engineers to take into 
account environmental performance indicators. The next chapters tackle partially above 
mentioned challenges and provide potential answers to the questions postulated in the 
objective, Chapter 3. Chapter 7 showed that in upscaling technologies, from lab scale 
over pilot scale to full manufacturing scale, primarily resource consumption due to the 
use and production of utilities exponentially decreases. While in lab scale environments, 
electricity is often used for heating purposes (electrical heat exchangers), natural gas 
boilers are favoured in full manufacturing scale whenever possible. A predefined dose 
and recipe of cleaning media after a batch or campaign is usually applied at full 
manufacturing scale through Cleaning in Place (CIP), while in lab environments, 
cleaning is basically a manual operation through which a substantial amount of 
resources get lost. Chapter 8 illustrates the use of forecasting equations based on process 
variables as predictor variables in order to perform streamlined LCA. With only 1 to 5 
readily available variables one can predict the cumulative resource consumption (or 
upon extension other impacts as well) of a chemical synthesis step with fairly well 
correlation coefficients (R²) and Confidence Interval (CI) width. R² and CI width is 
mentioned for each of the models in Figure 28, Chapter 8.3.3 and Annex A6. This 
methodology has been adopted by the National Health Service of the UK to perform fast 
calculations of the Carbon Footprint of their pharmaceuticals. This set of equations can 
be implemented in operational management tools (such as Enterprise Resource 
Planning, ERP systems) to calculate carbon or resource footprints with data measured 
from the production line. A framework of how this can be done and what could be the 
potential bottlenecks in e.g. data transparency and reliability through the Supply Chain 
(SC) is provided in Chapter 9. Below, an overall implementation guide of the 
methodologies developed during this work in operational management systems is given 
in Figure 24 and in Chapter 10.2.   
 
As a number of methodologies were developed during this PhD research that can 
consequently lead towards implementation in industry, this section intends to provide a 
short guidance on how to perform this potential stepwise implementation. First, in order 
to introduce environmental performance indicators such as the resource footprint in 
R&D decision trees as criteria within certain stage gates, experience curves of 
technologies have to be derived (as was done in Chapter 7 for tabletting through wet 
granulation) (Step 1). The experience curve can be used to derive sustainability 
performance indicators for the development of other formulations through wet 
granulation by estimating the impact once the medicine has been launched on the 
market. For prospective technologies (not existing yet, so changing the compound and 
technology), engineering models can be developed based on basic operations that can 
be scaled up as such (PROSUITE, 2009). 
 
Once the product is manufactured at full scale and environmental sustainability 
indicators are used in the design of it (Design for the Environment, DfE) (Step 1), one 
enters an environment that is typically very hard to quantify from an input-output point 
of view, typically not on a material base, but on utility base (electricity, natural gas, 
compressed air, cleaning media, different types of water, etc.). That is where forecasting 
calculations for streamlined LCA come into play. Based on few parameters, one can 
derive correlations equations (Step 2).  
 
Figure 32: Implementation guide towards the integration of environmental sustainability 
assessments into operational management systems. Step 1 is the implementation of 
experience curves to include environmental performance criteria (Design for the 
Environment, DfE). Step 2 is the calculation of forecasting equations to enable 
streamlined LCA. Step 3 is the challenging implementation and integration of these 
equations in customised Enterprise Resource Planning (ERP) or alternatively 
Manufacturing Execution Systems (MES). The final step is the sustainment of change 
through the development of Standard Operation Procedures (SOPs) and potentially Key 
Performance Indicators (KPIs). 
Once Step 2 is fulfilled for the desired processes or products, one has to integrate the 
calculations derived in Step 2 in operational management systems such as ERP systems 
(Step 3), which is a very challenging task. Various potential options are presented in this 
dissertation in Chapter 9. Step 4 is probably the most challenging task, for which we go 
back to one of the most important principles of continuous improvement and Lean 
management: sustainment. Once change has been successfully implemented, it needs to 
be sustained or the efforts will be lost sooner than later. This is done through the 
development of Standard Operations Procedures (SOPs) in which all actions are 
described for operators (entering the correct information in ERP systems, etc.), for shift 
supervisors and process engineers up to the higher management. A well designed 
sustainment plan includes Key Performance Indicators (KPIs) to evaluate the 
performance of employees and equipment/systems. The construction of SOPs and well 
defined KPIs are out of scope of this dissertation and will be dependent on the 
manufacturing area. Nonetheless, sustainment is for sure key to accomplish change 
without losing the positive effects of the efforts made. 
 
Next to the challenges that were identified by the sector in Chapter 6 through stakeholder 
consultations, the author takes the liberty of providing his overall outlook on 
methodological challenges for emerging future research to be conducted and challenges 
to be tackled. For sure, the full potential of economic and environmental cost savings 
has not been reached yet in the pharmaceutical sector. Step by step, authors are including 
more and more technological aspects and impact assessment concepts. Whereas 5 years 
ago scientists started to acknowledge we have to include the full production chain and 
not just the Active Pharmaceutical Ingredient (API), one is more and more reaching to 
a consensus that there is an emerging need for enlarging the system boundaries over 
different business segments (many corporations have pharmaceutical products and 
consumer products). Environmental sustainability assessment is no longer an 
assessment of a bunch of chemicals and their production processes; one should enlarge 
system boundaries to complete healthcare pathways and eventually national and global 
healthcare systems. As a consequence, the life cycle community needs to rethink the 
concept of the Functional Unit (FU). In too many cases, the functionality or set of 
attributes the customer wants to pay for (equals value) is not reflected in the FU. An 
example from the medical sector: a patient is not paying for drugs. A patient is buying 
drugs but pays to get better, to become healthy again. Human health is exactly the value 
that the medical sector is delivering and this is in most cases not fully reflected in the 
FU (e.g. 1 kg of API, 1 tablet, etc.). Since this PhD thesis evolved in a chronological 
way from a very condensed view on the resource consumption of API production 
towards including more functionalities in the FU and thereby embracing more parts of 
the value chain, Table 12 provides a general overview of FUs applied through the 
different chapters and their rationale of choice. 
Table 12: Overview of applied Functional Units through this thesis and their rationale of 
choice. 
Chapter Functional Unit Rationale 
CH4 Tablet of TRAMACET® Focus on batch versus continuous tabletting 
within JNJ business plan. No implication of 
downstream processing 
CH5 Finished packed Dosage 
Form 
Defined Daily Dose (DDD) 
The rationale in CH5 is exactly to show the 
difference in shifting from a very compound 
based FU towards a more treatment based one 
CH7 Daily intake of PREZISTA® Comparison between two solid dose production 
platforms (2x400mg and 1x800mg) 
CH8 Mole of API 
 
Mole of intermediate (IPI) 
High level approach of the absolute impact of 
APIs 
Increase amount of data points for backwards 
stepwise linear regression modelling and more 
detailed resolution 
The work done is this PhD is mainly focused on the manufacturing Supply Chain (SC), 
which is indicated in red on Figure 33 and the red box in drug discovery and 
development (experience curves, Chapter 7). The wider Life Cycle (LC) include the 
upstream grey area and downstream use and End-of-Life phase in the green area 
(Pharmaceuticals in the Environment, PIE). The upper grey bar represents the timeline 
from drug discovery to the end of the accounted environmental impact in time. Between 
the first two crosses which is the drug discovery and development phase (including 
clinical trial phases), 10 000 molecules are to be screened and reduced to one API and a 
dosage form has to be developed. This period typically takes about 14 years (time to 
market). Next, if approved, manufacturing and marketing of the medicine takes place. 
Finally, there is the accumulated downstream environmental burden of 14 years of 
development and 6 years of manufacturing of which we unfortunately do not even know 
the time span.  
 
Figure 33: Sustainable Supply Chain Management (SSCM) versus Sustainable Life Cycle 
Management (SLCM). As was developed in Chapter 7, the figure includes an experience 
curve module on the Drug Product Production (DPP) manufacturing step in order to 
anticipate on the environmental impact in early R&D decision processes. 
 
As soon as a potential lead molecule is found, a patent of typically 20 years is filed. Up 
to 14 years are spent on R&D, QA/QC, clinical trials, etc. A first generation medicine 
is in production for typically about 6 years (see Figure 33). Up to 40% of all revenue is 
(at least in Flanders) flowing back to R&D for new developments; a lot of - in terms of 
Lean manufacturing - Non Value Adding (NVA) processes are consuming resources 
(both capital and natural). In literature, no single LCA is to be found on the resources 
lost during the 14 years of testing, producing medicines for clinical trials, etc. It would 
be interesting to see what is the share of the burden of 14 years of R&D versus the 
manufacturing of a medicine, especially for low market volume products (e.g. 
STELARA®). The development of new, resource efficient platforms, new technologies 
should be evaluated. What is the impact and human benefit (functionality) of companion 
diagnostics? Nanomedicines? Nano carriers as long acting platforms? Different types of 
medicinal products will require different approaches for a fair assessment. This modular, 
more generic approach is a huge challenge for the near future.  
 
An even broader societal research question is how global Value Chains (VCs) are 
affecting global supply mechanisms and competing with other human needs. Next to the 
process and company level, the macro level is pushing us more and more into research 
questions related to resource scarcity, supply disruption, global trade, etc. In order to 
calculate the dependency of the medical sector on scarce materials (e.g. critical raw 
materials in medical devices) and in order to analyse how the medical sector is 
embedded in the global industrial metabolism, a macro analysis should be made to see 
what is actually being delivered to the global medical sector and what comes out as a 
product. This, connected with market behaviour (which is far more complicated for 
pharmaceuticals than for consumer goods or retail products), import, export, etc. is to 
be investigated. To analyse how the medical sector is connected to e.g. chemistry and 
energy sectors, an Input-Output Assessment (IOA) is favourable. With that information 
we can put the impact at micro level of relatively ‘low volume’ products such as 
pharmaceuticals in perspective. 
 
During this PhD dissertation the author touched several times on the synergies between 
resource based LCA and the Lean heritage, being two very different approaches in the 
end striving for a similar goal: reduce resource consumption, increase efficiency and 
turn waste into resources. The truth is that both methodologies are very complementary 
in a way and can learn a lot from each other. Within LCA, an end to end approach, one 
can apply wide system boundaries, even wider after hybridisation with Input-Output 
Assessment (IOA) on a macro level. Unfortunately, when one adopts Lean instead of 
adapting it to the case, system boundaries are rather narrow potentially leading to 
shifting the bottleneck through the life cycle. An example: a process engineer from an 
end producer business asks for a Lean assessment on its production line because his 
Overall Equipment Efficiency (OEE) has dropped significantly the last few months 
(Work Station 4, WS4 on the Value Chain, VC presented in Figure 34). Through 
applying the Lean assessment toolbox, the OEE of the production line increased to a 
favourable extent because of a reduction in change over times (C/O), less speed loss and 
less unplanned downtime on WS4. After a few months, problems arise again because 
operational unit WS3 in the VC cannot keep up with the new lead time and unevenness 
is created leading to extra stock creation (yellow triangle in Figure 34) following upon 
the WS4, which is giving capacity issues in the warehouse following WS4 in the VC, 
etc. A story that is essentially leading to waste because of debottlenecking within too 
narrowly defined system boundaries. 
Figure 34: Value Chain (VC) representation of an end producer. A Lean assessment is 
performed on Work Station (WS) 4 (green dashed line) with operations having a red 
dashed line out of scope. After a few months, problems arise again because operational 
unit WS3 in the VC cannot keep up with the new lead time and unevenness is essentially 
leading to the creation of waste instead of value, due to debottlenecking within too 
narrowly defined system boundaries. 
 
On the other hand, as Lean arouse from a business environment with one key priority: 
value, LCA can learn a lot from Value Assessments (VA) and Value Stream Mapping 
(VSM) to optimise the concept of the Functional Unit (FU) (as touched upon in Chapter 
10.3). It would be very interesting to see a combined LCA/Lean assessment from a 
multidisciplinary point of view with as aim reducing environmental impacts for the 
highest value. The scope setting of an LCA could benefit from properly defining the 
characteristics a, b, c etc. of a certain product or service in its FU to really grasp the 
effort of making a qualitative product. Such a multidisciplinary approach is highly 
recommended to enhance the business relevance and valorisation potential of LCA 
results (De Soete et al., 2015). Figure 35 illustrates a possible framework to include VA 
in the scope setting of an LCA. This new area could convince more companies to 
actually consider a combined LCA/Lean assessment from a multidisciplinary point of 
view with as aim reducing environmental impacts obtaining the highest value. More 
specifically, in addition to the commonly known framework of LCA (step one to four), 
the yellow arrows reflect initial Value Assessment (Engineering for Value) and as LCA 
is an iterative process (as are all sustainable improvement actions), Value Stream 
Managing (VSM) through the supply chain with – if needed – redesign. VA will help 
sustainability professionals and product/service designers to work together from the 
very beginning of the business model canvas. Through stakeholder consultation one 
should be able to identify to value attributes customers see in a certain product/service. 
If a physical attribute of a product is not valued by a group of customers (e.g. design of 
window frame with an insulation capacity that does not reach subsidy standards) or the 
other way around, a non-physical attribute such as the appreciation of the design of the 
window frame or colour, it will eventually change the value proposition of the product 
or service. Hence, customers only value what they are willing to pay for. From the Lean 
perspective, other attributes should be eliminated. From an integrated sustainability 
point of view, taking into account social aspects such as willingness to pay or consumer 
compliance, exactly the same holds. That is why – from a multidisciplinary point of 
view – LCA and Lean (more general Operational Excellence) should go hand in hand. 
 
Figure 35: Conventional representation of the four basic steps of a Life Cycle Assessment 
(LCA) with addition of the concepts Value Stream Engineering (VSE) and Value Stream 
Management (VSM) for a fair accounting of value within functional properties of a 
commonly defined Functional Unit (FU) (De Soete et al., 2015). 
The final paragraph of this dissertation embraces the author’s personal advice from 
learnings experienced during this PhD work towards future research(ers). What they say 
is true: keep it simple. The very first page of this dissertation quotes Friedrich Wilhelm 
Nietzsche. Apply the quote to science and one will understand that the only way to 
analyse complex systems is to acknowledge its simplicity. Breaking down complex 
systems to sub and sub-subunit operations enables one to assess prospective 
technologies that are even not yet existing.
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2.54 Q1 
6 1 Sustainability 
Assessment of 
Pharmaceuticals 










at three different 
levels 
Combining RE 
at process level 
and LCA 
(CEENE) 
Cradle-to-Gate 6 2 Green Chem. 8.30 Q1 
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7 1 Sustainability 
Assessment of 
Pharmaceuticals 
Woodley et al. 2013 3 Perspective with 
recommendations 
A future 
perspective on the 




N/A N/A 9 3 Chem. Eng. Res. 
Des. 
2.53 Q2 
8 1 Sustainability 
Assessment of 
Pharmaceuticals 




from fabrication to 
application 
CF Cradle-to-Grave 15 8 Green Chem. 8.30 Q1 
9 2 Sustainability 
Assessment in 
Healthcare 
Briggs et al. 2003 13 Case study Environmental 
pollution and the 






Cradle-to-Grave 71 5 Br. Med. Bull. 4.42 Q1 
10 2 Sustainability 
Assessment in 
Healthcare 










Cradle-to-Grave 23 3 Vaccines 3.62 Q2 
11 2 Sustainability 
Assessment in 
Healthcare 








Cradle-to-Grave 3 2 J. Clean Prod. 4.17 Q1 
12 2 Sustainability 
Assessment in 
Healthcare 













Cradle-to-Grave 1 1 Sustainability 0.94 Q3 
13 2 Sustainability 
Assessment in 
Healthcare 











14 2 Sustainability 
Assessment in 
Healthcare 
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Healthcare 
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pharmaceutical 
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Assessment of 
Pharmaceuticals 
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18 3 Life Cycle 
Assessment of 
Pharmaceuticals 
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Gate-to-Gate 79 7 Int. J. Life Cycle 
Assess. 
4.38 Q1 
19 3 Life Cycle 
Assessment of 
Pharmaceuticals 
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framework 









Cradle-to-Gate 42 5 Int. J. Life Cycle 
Assess. 
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Assessment of 
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21 3 Life Cycle 
Assessment of 
Pharmaceuticals 
Wernet et al. 2010 6 Case study Life cycle 
assessment of fine 
chemical 







Cradle-to-Gate 38 6 Int. J. Life Cycle 
Assess. 
4.38 Q1 
22 3 Life Cycle 
Assessment of 
Pharmaceuticals 













Cradle-to-Grave 9 2 Sci. Total Environ. 4.41 Q1 
23 3 Life Cycle 
Assessment of 
Pharmaceuticals 








factors for their 




Gate-to-Cradle 1 1 J. Clean Prod. 4.17 Q1 
24 3 Life Cycle 
Assessment of 
Pharmaceuticals 


















Cradle-to-Gate 0 0 Environ. Sci. 
Technol. 
6.33 Q1 
25 3 Life Cycle 
Assessment of 
Pharmaceuticals 










Cradle-to-Gate 5 3 Green Chem. 8.30 Q1 
26 3 Life Cycle 
Assessment of 
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LCA Cradle-to-Gate 4 2 J. Clean Prod. 4.17 Q1 
Annex A1: Literature review inventory related to Chapter 2 
  TAG Criterion Authors Year 
Years 
Published Publication Type Topic 
Impact 
Assessment 
Method System Boundary Citations 
Citations 
per year Journal (ISO) IF Q 
Tetraselmis 
suecica at pilot 
scale 
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Assessment of 
Pharmaceuticals 


















LCA (CML + 
EI99) 
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28 3 Life Cycle 
Assessment of 
Pharmaceuticals 
Ramasamy et al. 2014 2 Review with 
recommendations 
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assessment as a 







LCA Cradle-to-Gate 0 0 Food Bioprod. 
Process. 
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29 3 Life Cycle 
Assessment of 
Pharmaceuticals 
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30 3 Life Cycle 
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Assessment of 
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PMI + LCA Cradle-to-Gate 0 0 Green Chem. 8.30 Q1 
32 3 Life Cycle 
Assessment of 
Pharmaceuticals 
Kralisch et al. 2015 1 Review with 
recommendations 
Rules and benefits 




synthesis design: a 
tutorial review 
LCA Cradle-to-Cradle 7 7 Green Chem. 8.30 Q1 
33 4 Life Cycle 
Assessment in 
Healthcare 




infant in the US 
TRACI Cradle-to-Grave 7 2 Sci. Total Environ. 4.42 Q1 
34 4 Life Cycle 
Assessment in 
Healthcare 







of Hysterectomy in 
the United States 
Hybrid LCA   1 1 Environ. Sci. 
Technol. 
6.33 Q1 
35 5 Green Chemistry 
related to 
Pharmaceuticals 
Curzons et al. 1999 17 Methodological 
framework 
Solvent Selection 
Guide: A Guide to 
the Integration of 
Environmental, 
Health and Safety 






Process Level 10 1 Clean Products and 
Processes 
1.93 Q1 
36 5 Green Chemistry 
related to 
Pharmaceuticals 
Curzons et al. 2001 15 Methodological 
framework 
So You Think 
Your Process Is 










Cradle-to-Gate 156 11 Green Chem. 8.30 Q1 
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37 
 
5 Green Chemistry 
related to 
Pharmaceuticals 
Constable et al. 2002 14 Review with 
recommendations 
Metrics to 'green' 
chemistry - which 
are the best? 
Process 
Analysis 
Gate-to-Gate 215 15 Green Chem. 8.30 Q1 
38 
 
5 Green Chemistry 
related to 
Pharmaceuticals 
Haswell et al. 2003 13 Review Green chemistry: 





Process Level 111 9 Green Chem. 8.30 Q1 
39 5 Green Chemistry 
related to 
Pharmaceuticals 








Process Level 1 0 J. Synth. Org. Chem. 
Jpn. 
0.71 Q4 
40 5 Green Chemistry 
related to 
Pharmaceuticals 












Process Level 54 5 Ann. Rev. Mater. 
Res. 
17.98 Q1 
41 5 Green Chemistry 
related to 
Pharmaceuticals 
Koel et al. 2006 10 Case study Application of the 







Process Level 66 7 Pure Appl. Chem. 3.20 Q2 
42 5 Green Chemistry 
related to 
Pharmaceuticals 
Tucker 2006 10 Review with 
recommendations 






Process Level 87 9 Org. Process Res. 
Dev. 
2.53 Q1 
43 5 Green Chemistry 
related to 
Pharmaceuticals 











Process Level 437 49 Green Chem. 8.30 Q1 
44 5 Green Chemistry 
related to 
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Process Level 1 0 Curr. Opin. Drug. 
Disc 
5.12 Q1 
45 5 Green Chemistry 
related to 
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Cradle-to-Grave 326 36 Chem. Rev. 50.68 Q1 
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46 5 Green Chemistry 
related to 
Pharmaceuticals 




molecules by life 
cycle engineering 
as an important 






Process Level 51 6 Green Chem. 8.30 Q1 
47 5 Green Chemistry 
related to 
Pharmaceuticals 
Alfonsi et al. 2008 8 Methodological 
framework 
Green chemistry 








Process Level 309 39 Green Chem. 8.30 Q1 
48 5 Green Chemistry 
related to 
Pharmaceuticals 
Cue et al. 2009 7 Review Green process 






Process Level 21 3 Green Chem. Lett. 
Rev. 
1.52 Q3 
49 5 Green Chemistry 
related to 
Pharmaceuticals 
Fortunak 2009 7 Review Current and future 
impact of green 






Process Level 6 1 Future Med. Chem. 3.79 Q1 
50 5 Green Chemistry 
related to 
Pharmaceuticals 









Process Level 4 1 Spectr. Lett. 0.85 Q4 
51 5 Green Chemistry 
related to 
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Process Level 13 2 Trac-Trends Anal. 
Chem. 
6.93 Q1 
52 5 Green Chemistry 
related to 
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Launch of PMI 
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Today 
0.41 Q4 
Annex A1: Literature review inventory related to Chapter 2 
  TAG Criterion Authors Year 
Years 
Published Publication Type Topic 
Impact 
Assessment 
Method System Boundary Citations 
Citations 
per year Journal (ISO) IF Q 
53 5 Green Chemistry 
related to 
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Hartman et al. 2011 5 Case study Analytical Method 
Volume Intensity 









Process Level 11 2 Green Chem. 8.30 Q1 
54 5 Green Chemistry 
related to 
Pharmaceuticals 




Energy Use in 
Chemical 
Production 
LCA Cradle-to-Gate 10 2 J. Ind. Ecol. 3.70 Q1 
55 5 Green Chemistry 
related to 
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Dev. 
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56 5 Green Chemistry 
related to 
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Joshi et al. 2011 5 Review with 
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Green Chemistry: 
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0.38 Q4 
57 5 Green Chemistry 
related to 
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Soundarrajan et al. 2011 5 Case study Piperidone 
synthesis using 







Process Level 0 0 Microchem J. 3.05 Q2 
58 5 Green Chemistry 
related to 
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Kaur et al. 2012 4 Case study Comparative Study 
of Various Green 
Chemistry 







Process Level 8 2 Asian J. Chem.  0.36 Q4 
59 5 Green Chemistry 
related to 
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framework 
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related to 
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Process Level 51 13 Green Chem. 8.30 Q1 
Annex A1: Literature review inventory related to Chapter 2 
  TAG Criterion Authors Year 
Years 
Published Publication Type Topic 
Impact 
Assessment 
Method System Boundary Citations 
Citations 





61 5 Green Chemistry 
related to 
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Ciriminna 2013 3 Review with 
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Green Chemistry 







Process Level 13 4 Org. Process Res. 
Dev. 
2.53 Q1 
62 5 Green Chemistry 
related to 
Pharmaceuticals 
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how long does 






Cradle-to-Gate 5 2 Green Chem. 8.30 Q1 
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related to 
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Federsel 2013 3 Perspective with 
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64 5 Green Chemistry 
related to 
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Leahy et al. 2013 3 Perspective with 
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Seven Important 
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Effective Green 
Chemistry 
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related to 
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Osorio et al. 2014 2 Case study Photochemical 
derivatization of 
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Process Level 0 0 Anal. Methods 1.84 Q2 
66 5 Green Chemistry 
related to 
Pharmaceuticals 
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67 5 Green Chemistry 
related to 
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LCA Cradle-to-Gate 0 0 AICHE J. 2.75 Q1 
68 5 Green Chemistry 
related to 
Pharmaceuticals 
DeVito et al. 2015 1 Case study Can pollutant 
release and 
transfer registers 




of green chemistry 
practices? A case 









Process Level 0 0 Green Chem. 8.30 Q1 
69 5 Green Chemistry 
related to 
Pharmaceuticals 











Process Level 0 0 RSC Adv. 3.91 Q1 
70 5 Green Chemistry 
related to 
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71 5 Green Chemistry 
related to 
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Today 
0.41 Q4 
73 5 Green Chemistry 
related to 
Pharmaceuticals 




at Amgen: Seeing 




Process Level 0 0 Aldrichimica Acta 17.08 Q1 
74 5 Green Chemistry 
related to 
Pharmaceuticals 












Process Level 0 0 Chem. Eng. News 0.27 Q4 
75 5 Green Chemistry 
related to 
Pharmaceuticals 
Gallou et al. 2016 0 Case study Surfactant 
technology applied 
toward an active 
pharmaceutical 
ingredient: more 






Process Level 1 0 Green Chem. 8.30 Q1 
76 5 Green Chemistry 
related to 
Pharmaceuticals 










Process Level 0 0 Org. Process Res. 
Dev. 
2.53 Q1 




Van der Vorst et al. 2009 7 Case study Exergetic life 
cycle analysis for 
the selection of 
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separation 
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Cradle-to-Gate 26 4 Green Chem. 8.30 Q1 
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Van der Vorst et al. 2009 7 Methodological 
framework with 
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at process level 
and LCA 
(CEENE) 
Cradle-to-Gate 11 2 Ind. Eng. Chem. Res. 2.74 Q1 













Cradle-to-Gate 4 1 Resour. Conserv. 
Recycl. 
3.28 Q2 




Van der Vorst et al. 2011 5 Methodological 
framework 
A Systematic 










at process level 
and LCA 
(CEENE) 
Cradle-to-Gate 10 2 Environ. Sci. 
Technol. 
6.33 Q1 











at process level 
and LCA 
(CEENE) 
Cradle-to-Gate 6 2 Green Chem. 8.30 Q1 









Effects of scale-up 
and tablet dosage 
Combining RE 
at process level 
and LCA 
(CEENE) 
Cradle-to-Gate 1 1 Resour. Conserv. 
Recycl. 
3.28 Q2 




Hatoum et al. 1998 18 Case study Insomnia, health-
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workplace 






Process Level 1 0 Clin. Drug Invest. 1.61 Q3 




Alvarez et al. 2004 12 Case study Socioeconomic 






Process Level 3 0 An. Pediatr. 0.83 Q4 




Daskalaki et al. 2007 9 Case study Resource 










Process Level 14 2 Infect. Control Hosp. 
Epidemiol. 
4.50 Q1 




Manca 2008 8 Case study Quality of life, 
resource 
consumption and 













Process Level 59 7 Eur. J. Pain 3.51 Q2 




Leekha 2009 7 Case study Epidemiology and 
Control of 
Pertussis 
Outbreaks in a 
Tertiary Care 








Process Level 10 1 Infect. Control Hosp. 
Epidemiol. 
4.50 Q1 
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Process Level 6 1 Med. Intensiv. 1.33 Q4 




Gagliardino et al. 2012 4 Case study Patients' education, 















Process Level 16 4 Diabetes Metab. 3.27 Q2 
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Middle East and 





Process Level 8 2 Respir. Med. 3.09 Q2 




Roggeri et al. 2014 2 Case study Direct healthcare 










Process Level 1 1 Eur. J. Prev. Cardiol. 3.38 Q2 
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BSA Gate-to-Gate 0 0 Sustainability 0.94 Q3 
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Martyn et al. 2015 1 Case study Reduction in 
hospital costs and 
resource 
consumption 
associated with the 







Process Level 0 0 J. Med. Econ. 1.66 Q1 
95 8 Carbon 
Footprinting of 
Pharmaceuticals 
Connor et al. 2010 6 Case study The carbon 
footprint of a renal 
service in the 
United Kingdom 
CF Cradle-to-Grave 16 3 QJM-An Int. J. Med. 2.62 
Q1 
96 8 Carbon 
Footprinting of 
Pharmaceuticals 
Gatenby 2011 5 Case study Modelling the 
carbon footprint of 
reflux control 
CF Cradle-to-Grave 5 1 Int. J. Surg. 1.80 Q2 
97 8 Carbon 
Footprinting of 
Pharmaceuticals 
Lim et al. 2013 3 Case study The carbon 
footprint of an 
Australian satellite 
haemodialysis unit 
CF Cradle-to-Grave 4 1 Aust. Health Rev. 0.96 Q4 
98 9 Carbon 
Footprinting in 
Healthcare 
Connor et al. 2011 5 Case study The carbon 






CF Cradle-to-Grave 25 5 Hemodial. Int. 1.36 Q3 
99 9 Carbon 
Footprinting in 
Healthcare 




Simple Changes to 
Reduce Cost and 
Our Carbon 
Footprint 
CF Cradle-to-Grave 5 2 Am. Surg. 1.11 Q4 
100 9 Carbon 
Footprinting in 
Healthcare 








Emissions in the 
Health Sector 
CF Cradle-to-Grave 1 1 PLoS One 3.70 Q1 
101 9 Carbon 
Footprinting in 
Healthcare 
Pollard et al. 2014 2 Review with 
recommendations 
The carbon 
footprint of acute 
care: how energy 
intensive is critical 
care? 
CF Cradle-to-Gate 0 0 Public Health 1.62 Q2 




Annex A2: TRAMACET® production processes (related to Chapter 4) 
Consecutive batch core processes (α level) 
ID TAG  PROCESS 
α-1  DISPENSING 
α-1.1  Weighing & Bin Filling 
α-1.2  Pre-Mixing 
   
α-2  GRANULATION 
α-2.1  Granulation Solution Preparation 
α-2.2  Equipment Conditioning 
α-2.3  Load Raw Materials 
α-2.4  Dry Mixing 
α-2.5  Spraying 
α-2.6  Drying 
α-2.7  Sizing and External Phase Adding 
   
α-3  MIXING 
α-3.1  Mixing (Press Preparation) 
   
α-4  COMPRESSION 
α-4.1  Compression 
   
α-5  COATING 
α-5.1  Coating Solution Preparation 
α-5.2  Warm-Up 
α-5.3  Spraying 
α-5.4  Drying 
α-5.5  Cooling 
α-5.6  Wax Addition 
Annex A2: TRAMACET® production processes (related to Chapter 4) 
   
α-6  PACKAGING 
α-6.1  Packaging 
 
Supporting core processes (β level)
ID TAG PROCESS 
β-1 TRANSPORT 
β-1.1 Primary Transport 
β-1.2 Secondary Transport 
  
β-2 REVERSE OSMOSIS 
β-2.1 Reverse Osmosis 
  
β-3 STEAM GENERATION 
β-3.1 Steam Generation 
β-3.2 Water Production (Cold, 30°C) 
β-3.3 Water Production (Hot, 50°C) 
  
β-4 AIR COMPRESSION 
β-4.1 Air Compression 
  
β-5 WASTEWATER TREATMENT 
β-5.1 Wastewater Treatment 
  
β-6 AIR TREATMENT 
β-6.1 Air Treatment 
Main industrial processes (γ level)
ID TAG PROCESS 
γ-1 MATERIAL PRODUCTION & TRANSPORT 
γ-1.1 API Production & Transport 
γ-1.2 Excipient Production & Transport 
γ-1.3 Packaging Material Production & Transport 
γ-1.4 Detergent Production & Transport 
  
γ-2 TAP WATER PRODUCTION 
γ-2.1 Tap Water Production 
Annex A2: TRAMACET® production processes (related to Chapter 4) 
  
γ-3 ELECTRICITY PRODUCTION 
γ-3.1 CHP 
γ-3.2 Italian Network Electricity Production 
  
γ-4 SLUDGE TREATMENT 
γ-4.1 Incineration & residual landfilling 
  





Consecutive continuous core processes (α level) 
ID TAG PROCESS 
α-1 DISPENSING 




α-2.1 Granulation Solution Preparation 
α-2.2 Conditioning & Feeding 
α-2.3 Screw Granulation 
α-2.4 Drying 
α-2.5 Sizing and External Phase Adding 
  
α-3 MIXING 











α-5.6 Wax Addition 
  
α-6 PACKAGING 
Annex A2: TRAMACET® production processes (related to Chapter 4) 
α-6.1 Packaging 
262 
Annex A3: Detailed flowcharts of the TRAMACET® product systems (related to 
Chapter 4) 
A3: Detailed flowcharts of the TRAMACET® 
product systems (related to Chapter 4) 
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Annex A3.2: Batch Flowchart TRAMACET®  system (related to Chapter 4) 
  
β-6 AIR TREATMENTβ-5 WASTEWATER 
TREATMENT
β-3 STEAM GENERATION β-2 RO
 

























































































β-5.1-P1 CLEAN WATER DISCHARGE
β-5.1-P2 SLUDGE
β-6.1 Air Treatment
































































































































































































































































































β-3.2 Water Production 
(Cold, 30°C)
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   γ-4 SLUDGE TREATMENT
γ-2 TAP WATER 
PRODUCTION
 
  γ-3 ELECTRICITY PRODUCTION
 
          γ-1 MATERIAL PRODUCTION & TRANSPORT
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AIR to α&β 
elementary flow from nature
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Annex A3.5: Continuous Flowchart TRAMACET®  system (related to Chapter 4) 
β-6 AIR TREATMENTβ-5 WASTE WATER 
TREATMENT
β-3 STEAM GENERATION β-2 RO
 























































































β-5.1 Waste Water 
Treatment
β-5.1-P1 CLEAN WATER DISCHARGE
β-5.1-P2 SLUDGE
β-6.1 Air Treatment































































































































































































































































β-3.2 Water Production 
(Cold, 30°C)
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Annex A4: Resource efficiency TRAMACET® production (related to Chapter 4) 
Definition of three types of efficiencies. (1) simple efficiency; (2) rational efficiency; (3) 
utility efficiency. 
EFFICIENCY FORMULA 
Simple efficiency (η1) 




Rational efficiency (η2) 




Utility efficiency (η3) 





Summary of batch versus continuous wet granulation based tablet manufacturing 






η1 η2 η3 η1 η2 η3 
α-1 DISPENSING 98.8 96.1 69.8 98.8 96.1 70.0 
α-2 GRANULATION 69.7 60.3 23.8 94.3 85.2 61.3 
α-3 MIXING 99.3 98.6 52.9 99.8 99.0 78.4 
α-4 COMPRESSION 95.3 87.9 61.1 99.4 91.8 93.2 
α-5 COATING 66.4 62.4 10.6 66.8 62.9 10.6 
α-6 PACKAGING 98.7 97.8 41.9 98.7 97.8 42.2 
TOTAL PROCESS LEVEL 78.6 71.7 24.4 86.5 79.9 32.8 
 
Annex A4: Resource efficiency TRAMACET® production (related to Chapter 4) 
Summary of batch versus continuous wet granulation based tablet manufacturing 










α-1 DISPENSING 0.2 0.1 2.6 
α-2 GRANULATION 6.1 0.8 86.6 
α-3 MIXING 0.1 0.0 68.3 
α-4 COMPRESSION 0.6 0.1 88.6 
α-5 COATING 6.4 6.3 1.8 
α-6 PACKAGING 0.6 0.6 1.8 
TOTAL PROCESS 
LEVEL 
14.0 8.0 43.1 
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Annex A5: Stakeholder Survey (related to Chapter 6) 
Project Introduetion 
Within the framewerk of sustainable development of pharmaceuticals in healthcare systems, there is 
an emerging need towards streamlining and harmonization in termsof sustainability 
assessments of global supply mechanisms. 
As part of the European Platform on Life Cycle Assessment (EPLCA), the European 
Commission's Joint Research Centre (JRC) kicked-off a project in 2015 on reviewing the state of 
the art of sustainability assessments used in pharmaceutical and healthcare systems. The three 
main objectives through reviewing scientific literature, gathering feedback through surveys and 
expert interviews are: 
- Reporting state of the art LCI and LCIA methods used in pharmaceutical production and in 
evaluating environmental sustainability of current healthcare systems. 
- Evaluation of the possible construction of a so-called node in the Life Cycle Data Network 
(LCDN) to enhance collaboration in (corporale) sustainability assessments; the construction of a Life 
Cycle Database tor pharma + healthcare 
- Evaluation of the EC Production Environmental Footprinting (PEF) methad and identification 
of necessary requirements towards Product Environmental Fooiprint Category Rules (PEFCR). 
This Survey intends to gather expert opinions on above mentioned topics and the application of 
LCA in general on pharmaceutical produels in healthcare pathways. For this, The Commission 
reaches out to a variety of stakeholders including private industrial companies, NGOs, researchers, 
policy makers, etc. 
Confidentiality 
Your answers will be processed and aggregated by the project team. All data obtained trom 
participants will be kepi confidential and will only be reported in an aggregate format (by reporting 
only combined results and never reporting individual ones). While we will not attribute specific 
comments to particular individuals or companies, we would like to show our appreciation tor your 
input by acknowledging your participation as a stakeholder in the final report, if you approve. 
Questions and feedback 
lf you have questions regarding the project, you may contact: 
• Wouter De Soete at Wouter.DeSoete@UGent.be 
• Sirnone Fazio at Simone.Fazio@jrc.ec.europa.eu 
• Jo Dewulf at Jo.Dewulf@jrc.ec.europa.eu 
• David Pennington at David.Pennington@jrc.ec.europa.eu 
• lngrida Hiunni at lngrida.Hiunni@ec.europa.eu 
• European Platform on Life Cycle Assessment 
• Forum tor Sustainability through Life Cycle lnnovation 
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B lntroductionary Questions 
8.1 What is the name of your organisation? 
8 .2 What type of organization are you representing? 
Ö Private Organisation 
Ö Policy/Governmental (research) body/NGO 
0 University/Research lnstitution 
0 Sector or Trade Association/Consortium 
0 Consumer (Hospita! , Pharmacy, Patient, Doctors, etc.) 
0 Other 
8.3 Other: 
8.4 What is your role in the organisation? 
8.5 In which Member State or country are you based? 
C Use of LCA 
C.1 What are the main drivers tor your organisation to perferm Life Cycle Assessments (LCA)? 
C.2 For what applications do you u se LCA? 
!Cl Process optimisation (re-design) 
!Cl Sustainability reporting 
!Cl Product development 
!Cl 828 communication 
!Cl 82C communication 
!Cl Hotspot determination 
!Cl Other: 
Annex A5: Stakeholder Survey (related to Chapter 6) 
C.3 Other: 
C.4 To assess the environmental sustainability of pharmaceutical products: 
El A product group approach is sufficient 
El A product-specific approach is favourable 





El UK NHS Carbon Foetprint Guidance 
El Other: 
C.6 Other: 
C.7 What midpoint impact categories do you evaluate? 
El Climate change (e.g. through Carbon Foetprint indicator) 
El Fossi l fuel consumption 
El Human toxicity 
El Water consumption 
El Other: 
C.8 Other: 
C.9 Do you evaluate endpoint categories? lf so, which ones? 
El Human Health (e.g. through DALY indicator) 
El Ecosystem species (e.g. through species*year indicator) 
El Natural resources (e.g. through surplus cost indicator) 
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C.1 0 To construct the Life Cycle lnventory (LCI), I use the following data sources: 
El Bill of Materials 
EJ MSDS files 
El Batch Production Reports 
El Equipment manuals 




C.12 What LCA approach is typically used in your organisation? 
El Full-blown CtC or CtG LCA 
El Streamlined LCA (e.g. focusing on Hotspots) 
El Depends on the application (please explain): 
C.13 Depends on the application: 
D User experience and methodological challenges 
D.1 What type of system boundaries are applied? 
El Gate-to-Gate (GtG) 
El Cradle-to-Gate (CtG) 
El Cradle-to-Cradle (CtC) 
D.2 lf CtC, how do you assess pharmaceuticals or pharmaceutical metabolites in the environment (e. 
g. waste water)? 
D.3 To your opinion, is there a need to expand system boundaries and take into account healthcare 
services related toa pharmaceutical product (e.g. doctor visits, hospitalisation, ... ) and likewise 
shift Functional Units trom physical atributes (e.g. 1 kg API, 1 tablet, .. . ) to the service oftered to 




Annex A5: Stakeholder Survey (related to Chapter 6) 
D.4 Please elaborate: 
D.S What do you perceive as the biggest hurdle in LCAs on Pharmaceuticals? 
0 828 communications to obtain primary data trom suppliers 
0 Lack of Life Cycle Data 
~ Confidentiality in data sharing 
0 Lack of integration of process design tools and LCA tools 
0 Lack of harmonisation of LCA methodelogies in serving different markets 
D.6 Do you think the lack of LCA data on chemica! building bleeks, solvents and pharmaceuticals is a 
crucial aspect that should be tackled? 
0 Yes 
0 No 
D.7 lf so, are you familiar with the Life Cycle Data Netwerk (LCDN)? 
~ Yes 
0 No 
0 I have heard of it 
Note: The Life Cycle Data Netwerk (LCDN) was launched in Brussels on 6th February 2014 by 
Vladimir Sucha, Directer General of DG JRC, and Alan Seatter, Deputy Directer General of DG 
Environment. Through entry-level requirements, the Netwerk allows for flexibi lity while facilitating the 
availability of coherent and quality assured life cycle data trom different organisations. The Netwerk 
is a non-centralised web-based infrastructure that ensures life cycle data can be easily accessed via 
searches, filtering, and sorting. The datasets in the Netwerk come globally trom any data developer 
/owner, e.g. industry, national LCA projects, research groups, and consultants. 
More intermation on the Life Cycle Data Netwerk: Click here 
To browse datasets: Clickhere 
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0.8 To your opinion, could the establishment of an LCA database on pharmaceuticals and chemica! 
building blocks (respecting confidentiality of data providers) be a preterred salution to overcome 
the issue of LCA data unavailability? 
ö Yes 
ö No 
0.9 Do you think the lack of harmonisation of LCA methodologies in serving different markets is a 
crucial aspect that should be tackled? 
Ö Yes 
0 No 
0.10 lf so, are you familiar with the Product Environmental Foetprint method (PEF)? 
Ö Yes 
Ö No 
0 I have heard of it 
Annex A5: Stakeholder Survey (related to Chapter 6) 
Note: DG Environment has worked tagether with the European Commissicn's Joint Research Centre 
(JRC lES) and other European Commission services towards the development of a harmonised 
methodology tor the calculation of the environmental tootprint of products (including carbon). 
This methodology has been developed building on the International Reference Life Cycle Data 
System (ILCD) Handbook as wellas other existing methodological standards and guidance 
documents (ISO 14040-44, PAS 2050, BP X30, WRI/WBCSD GHG protocol, Sustainability 
Consortium, ISO 14025, Ecological Footprint, etc). 
The final methodology was published as an Annex to the Commission Recommendation on the use 
of common methods to measure and communicate the life cycle environmental performance of 
products and organisations. 
This version was developed taking into account the results of 2011 roadtest , the results of the 
invited expert consultatien and of a consultatien between Commission services. 
Product Environmental Footprint Category Rules aim at providing detailed technica! guidance on how 
to conduct a product environmental tootprint study. PEFCRs complement general methodological 
guidance tor environmental tootprint by providing further specificatien at the product level. PEFCRs 
will increase reproducibility and consistency in product environmental tootprint studies. 
For more information: Clickhere 
D.11 To your opinion, could the establishment of a Product Environmental Footprint Category Rule 
tor pharmaceutical products be a preterred salution to come to a harmonised LCA 
methodology? lf not, where do you see bottlenecks or what key aspects should be present in a 
harmonised methad tor LCAs on pharmaceutical products? 
0 Yes 
0 No 
D.12 lf not, where do you see bottlenecks or what key aspects should be present in a harmonised 
methad tor LCAs on pharmaceutical products? 
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Correlation models of cumulative resource consumption at overall industrial level 





= 3.575 + 0.269 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡) − 0.693
∗ 𝐿𝑂𝐺(𝑀𝑜𝑙𝑎𝑟 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦) + 0.550 ∗ 𝐿𝑂𝐺(Δ𝑡) − 0.201 ∗ 𝐿𝑂𝐺(Δ𝑇)




= 3.766 + 0.264 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡) − 0.685








= 4.280 + 0.266 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡) − 0.709




= 4.946 + 0.543 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡) − 0.770
∗ 𝐿𝑂𝐺(𝑀𝑜𝑙𝑎𝑟 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦) 
 
γE 
𝐿𝑂𝐺(𝐶𝐸𝐸𝑁𝐸𝐸) = 5.032 + 0.648 ∗ 𝐿𝑂𝐺(𝑂𝑟𝑔𝑎𝑛𝑖𝑐 𝑆𝑜𝑙𝑣𝑒𝑛𝑡)    
 
A7: Calculating and Reporting Greenhouse Gas 
Emissions for Pharmaceutical Products (related 
to Chapter 8) 
285 
Annex A6: Multiple Regression Models (related to Chapter 8) 
286 
• Public Health 
England 




This document describes a number of possible approaches to calculating the eradie to gate greenhouse gas 
(GHG) emissions tromthema nufacture of pharmaceutical s, w ith particular focus on small molecule 
pharmaceuticals in tablet form. 
Organisations may wish to calculate t he GHG emissions of pharmaceuticals tobetter understand and reduce 
these emissions over time. Additionally, the Sustainable Development Unit (SDU) is seeking trom 
manufacturers more representative pharmaceutical specific GHG data to inform updates to the NHS Carbon 
Foetprint and demonstrate success against the 10% GHG reduction target set for 2015. The most recent study 
can be found here: http://www.sduhealth.org.uk/documents/publ ications/HCS Carbon Foetprint vS Jan 2014.pdf 
Data submitted to the SDU to be incorporated into the NHS Carbon Foetprint should preferably include eradie 
to gateanderadie to grave GHG emissions of the product (as supplied), per do se and per active ingredient. 
When providing pharmaceutica l data to the SDU it is preterred that the following hierarchy is used noting the 
approach taken, scope of what is included (eg eradie to gate, tablet and packaging, API only) and year that the 





Specific appraisa l of a pharmaceut ica l productusinga recognised standard . 
Hybrid appraisa l of a pharmaceutical product using specific API data and genericdata for 
the remainder of t he pharmaceutical (eg excipients, packaging, etc). 
Streamlined appraisal using a calculation tor the API based on chemistry and generic dat a 
tor the remainder of the pharmaceutical. 
Estimate of GHG emissions for a pharmaceutica l product using generic categorisation. 
Levell: Specific GHG Appraisal of a Pharmaceutical Product 
The preterred approach is tor organisations to conduct a eradie togate/grave GHG appraisa l of a 
pharmaceutical using product specific manufacturing data. Relevant standards should be applied when 
conducting t he GHG appraisal in order of preference: 
a) Use the GHG Sector Guidance for Pharmaceuticals and Medica! Devices. 
b) Use a non-sector specific GHG standard such as GHG Protocol Product Standard, PAS 2050 or ISO 
14067. 
Note t hat this approach can betaken for all pharmaceuticals, not just for small molecule pharmaceuticals in 
tablet form. The level of accuracy of a study employing this approach is considered to be high. 
Level2: Hybrid GHG Appraisal of a Pharmaceutical Product (Using API Specific Data) 
lf a specific study of a pharmaceutical product cannot be completed the next level of appraisa l involves using 
active pharmaceutica l ingredient (API) specific manufacturing data and combin ing these data with estimates 
for other manufacturing data (eg excipients, packaging, etc) . The follow ing stepsca n be taken: 
a) Collect specific API manufacturing data and calculate GHG emissions using the guiding principles in a 
recognised standard. 
b) lf the API is not manufactured by the pharmaceutical product supplier, ask the API manufacturer 
whether they have ca lculated GHG emissions of the specific API (typically expressed in kg C02e I kg of 
API). 
I Sustainable Development Unit 
Worl n< h NHS. 1bl1 He, I n and S 1al C r 'Y' 
c) lf data are available and the pharmaceutical is in tablet form then include t he API va lue into the ABPI 
ca rbon tootprint tooi. 
d) lf data are available and the pharmaceutical is not in tablet form then report only the GHG emissions 
of the API, noting the difference in scope. 
Level 3: Streamlined GHG Appraisal of a Pharmaceutical Product (Using API Chemistry) 
lf GHG data for API ma nufacture are not available from the supplier this can be estimated by collecting data 
for three key manufacturing variables basedon API chemistry. The following stepscan be taken: 
a) Collect information on quantity of organic solvents, molar efficiency and duration of synthesis steps 
used in API ma nufacture and apply the approach in the artiele titled " Environmental Susta inability 
Assessments of Pharmaceuticals: An Emerging Need for Simplification in Life Cycle Assessments" to 
ca lculate the API GHG emissions. 
• The formula to calculate GHG emission fora single synthesis step is: LOG( CFsynthesis step) = 
-0.32 + 0.258 * LOG(Organic Solvent)- 0.907 * LOG(Molar Efficiency)+ 0.3 3 * LOG(llt) 
• The GHG emissions of the API canthen be calculated by adding together the GHG emissions 
of each synthesis step multiplied by a conversion factor based on how much of the synthesis 
step output is required to produce the final API : 
C FAPJ = :Ef=t Conversion factor( i) * C Fsynthesis step(i) 
• Where: n = Number of synthesis steps 
CFAPJ = Carbon footprint (GHG emissions) from API production (kg C02e I mol) 
Converion factor = Input moles ofsynthesis step required to produce API (mol/mol) 
Output mol es of fin al API 
CFsynthesis step = Carbon footprint from production of a synthesis step (kg C02e I mol) 
Organic Solvent = Total net consumption of organic solvents in a synthesis step (L/mol) 
M olar Efficiency = Output mol es of product from ~ sy~thesis step (mol/mol) 
Input moles of product ofraw matenals ma synthes1s step 
tJ.t = Time duration of a synthesis step per mole output (s/mol) 
b) lf the pharmaceutical is in tablet form then include the API value into the ABP I carbon tootprint tooi. 
c) lf data are available and the pharmaceutical is not in tab let form t hen report only the GHG emissions 
of the API, noting the difference in scope. 
Level 4: GHG Estimate of a Pharmaceutical Product 
lf specific API data cannot be provided nor ca lculated then estimates may be used that are available in t he 
ABPI tooi using the following approach: 
a) For small molecule pharmaceuticals in tablet form, use the ABP I carbon tootprint tooi and select the 
most appropriate estimate of API manufacture (either by entering chirality and number of synthesis 
steps or choosing a low, average or high estimate). 
b) For other pharmaceuticals ca lculate a GHG estimate using other approach, noting t he method 
employed . 
Useful References 
• GHG Sector Gu idance for Pharmaceuticals and Medica l Devices: 
http://www.ghgprotocol.org/feature/pharmaceut ical-and-medical-device-sect or-guidance-product -
l ife-cycle-accou nti ng. 
• Environmental Sustainability Assessments of Pharmaceuticals: An Emerging Need for Simplification in 
Life Cycle Assessments: htt p://pubs.acs.org/doi/abs/10.1021/es502562d 
• ABP I Blister Park Carbon Footprint Tooi: http://www.abpi.org.uk/our-
work/mandi/Pages/sustainability.aspx 
I Sustainable Development Unit 
Work n• he NHS 'ubl• He. I h nd S 1a1 C. re sy" 
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Example Application ofthe Pharmaceutical GHG Formula 
The formula presented in this document was developed by the research group EnVOC of the Department of 
Sustainable Organic Chemistry and Technology at Ghent University in collaboration w ith Janssen 
Pharmaceutica NV (2014). 
Production data on 40 Active Pharmaceutical lngredient (API) synthesis steps was used todetermine the most 
relevant process parameters concerning the emission profile of a synthesis step. As an indicator for the 
performance of a synthesis step, the IPCClOOa Carbon Footprint (CF) Life Cycle Impact Assessment (LCIA) 
method was used. A statistica! backwards stepwise linear elimination procedure was applied on the primary 
parameters, with the correlated CF of the synthesis step as the response variable. A set of three parameters 
was determined which contained the largest predictive power: Organic Solvent Use (L/mole), Molar Efficiency 
(%), and Total Time Required (s/mole). The moles mentioned in the parameters are the intermediate or final 
products that result from a synthesis step. Using these parameters, a linear regression model was created. For 
a single synthesis step, the CF/mole can be calculated as in Equation 1: 
LOG(CF) = - 0.320 + 0.258 * LOG(Or9anic Solvent)- 0.907 
* LOG(Molar Efficiency)+ 0.330 * LOG(fJt) 
(1) 
For API production routes that conta in more than one synthesis step, the yield of each synthesis step has to be 
taken into account . The yield is defined as the total moles of intermediate or final product obtained from the 
synthesis step divided by the theoretica! maximum of moles obtainable from the synthesis step. The yield 
enables the ca lculation of a conversion factor for each synthesis step. As, due to the yield being less than 
100%, proportionally more moles of intermediate from the first synthesis step w ill be required to produce 1 
mole of end product. 
Fora hypotheticallinear production route with three steps, the yields and conversion factors are as follows: 
Yield 
CF (kg C02-eq/mole) 
Conversion factor 
Synthesis step A 
40% 
3.0 
(1/0.8)/0.6 = 2.08 
Synthesis step B 
60% 
9.0 
1/0.8 = 1.25 




In order to calculate the total CF/mole product of a production route, the formula has to be applied as in 
Equation 2: 
CFAPI = evA* CFA +CVB* CFs + CVc * CFc (2) 
CFAPJ = 2.08 * 3.0 + 1.25 * 9.0 + 1 * 7.5 = 25.0 k9 C02 eqfmole API 
With CFAPI as the Carbon Footprint of the complete production route, CV A as the conversion factor of synthesis 
step A and CFA as the Carbon Footprint of synthesis step A. Parameters for synthesis steps B and C are 
analogue. Note that CFA has undergone an inverse LOG transformation from the LOG(CF) that is the response 
variabie f rom Equation 1. 
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